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Abstract
Introduction
Low dose-rate brachytherapy is an accepted treatment for early prostate cancer in the 
UK. This thesis reports studies of clinical outcome from this treatment in a UK 
centre.
Patients and Methods
Prospective observational study in three areas o f outcome for patients undergoing low 
dose-rate (LDR) seed brachytherapy implants:
i. Quality o f life questionnaires were used to prospectively assess toxicity of  
3 LDR brachytherapy treatments: monotherapy+/- androgen deprivation+/- 
external beam radiotherapy in a longitudinal study.
ii. Post-implant catheter use was correlated with preoperative variables 
(prostate volume, androgen deprivation, urodynamic obstruction status and 
IPSS score) and treatment indices (Prostate D90, Urethral DIO, D25, and 
D50).
iii. Bicalutamide and goserelin for pre-brachytherapy prostate volume 
reduction.
Results
General health related quality o f life was ‘a little’ to ‘moderately’ decreased 6weeks 
after brachytherapy, but unchanged by clinically significant amounts >9 months after 
any brachytherapy treatment. Permanent problematic urinary incontinence (<4%) and 
significant bother from use of incontinence aids (<3%) were rare after any 
brachytherapy subtype. Urinary problems, principally frequency and urgent 
micturition worsened after brachytherapy with peak ‘very much’ worsened symptoms
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at 6-weeks post treatment and improvements to ‘a little’ worse than baseline at 1-2 
years. Sexual function declined significantly in potent men with partners who 
underwent brachytherapy. By 2 years post brachytherapy, almost half o f men who 
were potent before brachytherapy as monotherapy started using phosphodiesterase 
inhibitors (e.g. Viagra®). Despite this medication, at least 47% reported moderate- 
severe erectile dysfunction.
Postoperative need for catheterisation was predicted by elevated prostate volume 
(>35cc), raised IPSS score (>7 vs. <7), and urodynamic obstruction (vs. equivocal or 
unobstructed patients). Bicalutamide produced smaller reductions in prostate volume 
than Goserelin (-8 vs. -26% reduction in volume).
Conclusions
Clinically significant changes in HRQOL were present at >12m but they were of 
small magnitude except for sexual side effects which continued to be common and 
marked.
Use of an IPSS score, prostate volume and urodynamic assessment may improve 
selection o f patients for brachytherapy. Bicalutamide is superior to goserelin for 
prostate cytoreduction prior to brachytherapy.
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Chapter 1 
Scope of Thesis
Chapter 1.0
Chapter 1.0 - Scope of Thesis
I became interested in prostate cancer whilst working in Bristol as a junior doctor in 
the urology department in the year 2000. Prostate cancer is a common disease in the 
UK. In the small community hospital in which I undertook clinics, local audit (1998- 
2000) identified that almost half o f men diagnosed with prostate cancer presented 
with evidence o f metastasis. The only management option for these men was 
hormonal therapy with palliative chemotherapy or radiotherapy if  this treatment 
failed. Prognosis of men diagnosed with skeletal metastasis remains poor. In this 
environment, the early detection and radical curative treatment o f prostate cancer 
seems a very desirable aim.
The incidence o f prostate cancer has more than doubled from 1990 to 2000 as a result 
of the introduction o f the prostate specific antigen (PSA) blood test and more 
widespread use o f transrectal ultrasound and needle biopsy, in order to pick up men 
before their prostate cancer has metastasised. Despite this, mortality is unchanged. 
This raises questions about the value o f an increased level o f case-finding activity.
Thus far attempts to distinguish men at high risk o f morbidity and mortality from a 
diagnosis o f early (or organ confined) prostate cancer (EPC) from the group o f  
patients who have clinically indolent EPC that will not progress to symptomatic local 
invasion or metastasis have been unreliable. Many men with EPC choose to undergo 
radical ablative treatment with external beam radiotherapy (EBRT), radical 
prostatectomy operation (RP) or more recently brachytherapy (BXT), which may be 
delivered using high dose rate (temporary implant) or low dose-rate rate (permanent
Chapter 1.0
implant) radiotherapy sources. All o f these treatments have toxicity and information 
on this is important for men choosing treatment.
Although one randomised trial has shown a benefit in terms o f survival from RP when 
compared to conservative treatment, none of the currently accepted methods o f giving 
radiotherapy have been compared to conservative treatment in randomised trials. 
Recruitment o f men to randomised trials has been difficult with many men diagnosed 
with EPC unwilling to accept randomisation. Observational studies have suggested 
that the more modem methods of giving BXT and EBRT are equivalent to RP in 
terms o f recurrence free survival. Previous reports of various strategies for delivering 
low dose-rate rate (LDR) brachytherapy have included the implantation o f radioactive 
seeds alone, with the addition of androgen deprivation ‘hormonobrachytherapy’ 
(HBXT), or as a combined treatment with brachytherapy given as a radiotherapy 
boost to the prostate after treatment of the pelvis with external beam radiotherapy 
(BXTC).
This thesis describes the outcome o f treatment with three subtypes o f LDR 
brachytherapy treatment in a non-experimental design. A full appreciation o f the 
structure and function of the prostate, PSA, epidemiology o f prostate cancer, methods 
of screening and diagnostic options and current evidence for their efficacy would be 
outside the scope o f this thesis. However to give a context for the studies described, 
an overview o f these topics is given in chapter 2.1-2.4. A more detailed description o f  
LDR brachytherapy is included in chapter 2.5 in order to understand the current place 
of brachytherapy in the treatment of prostate cancer and why HBXT or BXTC may be 
considered. An introduction to radiotherapy (chapter 2.7) is included in order to allow
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the non-radiation oncologist reader to understand the development and the described 
practice o f LDR brachytherapy in the prostate.
This thesis focuses specifically on the area o f LDR brachytherapy and its application 
in the treatment of organ confined prostate cancer in three main areas:
(i) Description o f the toxicity and Health Related Quality o f Life (HRQOL) 
following brachytherapy in a contemporary UK practice
(ii) The preoperative evaluation o f clinical measures including urodynamics 
which may guide suitability for brachytherapy treatment by allowing the 
prediction of patients at high risk of urinary retention
(iii) The changes in prostate volume observed after androgen deprivation in the 
pre-brachytherapy patient
The aims o f the work performed in each area are described in the aims and objectives 
(chapter 3.0). As the patients were all recruited from a cohort o f men undergoing 
brachytherapy at a single centre, the first chapter o f the methods (chapter 4.0) 
describes the standard protocols that were in place for men who underwent each form 
of LDR brachytherapy treatment.
The introduction includes a systematic review (chapter 2.9) of the available work on 
(HRQOL) after LDR brachytherapy and work comparing LDR brachytherapy to other 
treatment options for EPC (but not on studies primarily describing the outcome o f  
other modalities without comparison to LDR brachytherapy). This allowed selection 
of questionnaires suitable for the HRQOL study (chapter 4.1). A longitudinal 
observational study o f quality of life after BXT was performed as described in
Chapter 1.0
methods (chapter 4.1), results (chapter 5.1) and the discussion (chapter 6.1). 
Assessment of the psychometric properties in the relatively new PR25 questionnaire 
was performed (chapter 5.0 and 6.0) and the effects of various forms of analysis 
assessed when dealing with missing data in the HRQOL study (chapter 5.1).
The work describing the use o f urodynamic assessment in predicting urinary retention 
after brachytherapy is described in the methods section (chapter 4.2), results (chapter
5.2) and discussion (chapter 6.2). The utility o f androgen deprivation in 
brachytherapy is described in chapter 2.5. The change in prostate volume study is 
found in the methods (chapter 4.3), results (chapter 5.3) and the discussion (chapter
6.3).
The discussion comments on each of the projects before examining the implications 
of the completed work for clinical practice and possible recommendations for future 
work (chapter 7.1-7.2) in developing clinical trials assessing the outcome o f treatment 
for EPC with particular reference to trials involving LDR brachytherapy.
Chapter 2 
Overview of early prostate cancer and
brachytherapy
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Chapter 2.0 - Structure and function of the prostate and PSA
The normal healthy adult prostate weighs 18 g; measures 3 cm in length, 4 cm in 
width, and 2 cm in depth; and is traversed by the prostatic urethra (1). The 
appearances o f the normal prostate are illustrated in figure 1 (below). Although the 
prostate is ovoid it is anatomically referred to as having anterior, posterior and lateral 
surfaces. The base is the surface o f the prostate that is continuous with the bladder 
and lies superiorly if  the man is standing in the anatomical position (but if the prostate 
is removed by the pathologist it tends to be the flattest surface o f the prostate that is 
generally used as the base during sectioning prior to pathological analysis). Similarly 
the apex of the prostate is the inferior part o f the gland in the anatomical position 
figure 2 (p27) where the prostate narrows and the apex would be the peak only in a 
pathological specimen rotated to rest on the prostate base.
Figure 1. Midline sagital section through supine human male pelvis: reproduced 
from Hinman (2).
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The diagram is drawn with the left side most caudal and the right most cephalad. In 
this position prostate apex is to the left and base to the right adjacent to bladder.
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Figure 2. Schematic midline sagital section o f prostate (traced from Figure 1).
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Prostate rotated to show its position A: With the body supine (Left caudal, Right 
Cephalad), B: With the body standing in an erect position and C: W ith the prostate 
rotated to sit on its base (right) for pathological dissection.
The prostate is closely related to other structures in the male pelvis. Principally (in 
the anatomical position, Figure 2 drawing B) these are the bladder superiorly, the 
anterior pelvic bones (pubic symphysis) where it is anchored by the puboprostatic 
ligaments, with the endopelvic fascia laterally and the rectum posteriorly (allowing 
digital examination o f the prostate). The seminal vesicles lie cephalad to the prostate. 
The pelvic floor muscles are found at the lateral surfaces o f the prostate. At the apex 
o f the prostate the striated urethral sphincter (voluntary continence muscle o f the 
male) is in continuity with the prostate. Thus the surgical excision o f the prostate 
gland has always meant that there is a significant risk o f damage to the striated 
sphincter and hence incontinence.
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The cavemosal nerves run along the postero-lateral surface o f the prostate. They are 
crucially important as they supply both parasympathetic and sympathetic fibres to the 
corpora of the penis which are solely responsible for erection.
When the removal o f the prostate is desired to control organ confined prostate cancer 
these nerve bundles are often injured or excised. Nerve sparing radical prostatectomy 
implies that the neurovascular bundles are left in situ whilst the rest o f the prostate is 
removed. In reality, the visible neurovascular bundles are simply the largest branches 
of a nerve plexus running along the postero-lateral surface of the prostate. Smaller 
nerves are also present, which run in the lateral prostatic fascia and have been referred 
to as the ‘Veil o f Aphrodite’ in recent surgical literature. Preservation o f these in 
addition to standard nerve sparing is postulated to preserve potency after radical 
prostatectomy (although this has not been studied in any randomised studies) (3).
Figure 3. Histopathological slide (right) and schematic drawing (left) showing the 
anatomy of a transverse section through the prostate. Reproduced: Walsh et al (4).
/  L a ie r s t  p e lv ic  fa s  c ia
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The anatomy o f the prostate has also been described in terms o f the different 
functional zones (McNeaTs zones) (5). Initially this may seem an unnecessary 
complication that does not bear an obvious relationship to the gross anatomy o f the 
prostate. However, because McNeaTs classification o f zonal anatomy is based around 
the histopathology (and hence the embryological origins) o f the prostate, it represents 
the functions of the different areas o f the prostate better than a purely macroscopic 
anatomical classification.
In embryological terms, the prostate develops under the control of foetal androgens 
(principally dihydrotestosterone [DHT] from the testis) from buds o f mesodermal and 
endodermal tissue (6). An absent androgen receptor, (the binding site o f the hormone 
DHT) in the Testicular Feminization Syndrome, results in non-development of the 
prostate.
These buds of tissue form in five pairs (either side o f the midline) from the urogenital 
sinus. These buds then invade the mesenchyme to form the fused prostate. The top 
pairs o f urogenital sinus buds form the inner aspect of the prostate and may be of 
mesodermal origin in contrast to the more caudal buds, which become the outer aspect 
of the prostate and are believed to originate from the endoderm. The outer part o f the 
prostate becomes the thicker outer layer of the true prostate. The more central 
portions which are o f mesodermal origin form first into the urethra and then develop 
into the mucosal and sub-mucosal prostate as well as the ejaculatory ducts and the 
prostatic utricle (6). The seminal vesicles form from the mesonephric (Wolffian) duct 
and it has been suggested that the central zone of the prostate is also derived from the 
mesonephric duct. The sites o f the zones within the structure o f the prostate are 
illustrated in figure 4.
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Figure 4. McNeal’s zonal anatomy o f the prostate. Reproduced from McNeal et al 
1988 (5). Orientated with body supine.
Transition zone
Central zone
Anterior fibromuscular stroma
Peripheratzone
McNeal’s zones differ in their composition o f glandular and stromal tissue. In the 
young adult the glandular tissue is divided into 25% in the transition zone, 5-10% in 
the central zone and 65-70% in the peripheral zone (5). This bears some relationship 
to the distribution o f prostate cancer in the prostate with 68% occurring in the 
peripheral zone (nearest the rectum), 24% in the transition zone and 8% in the central 
zone. Little glandular tissue or cancer is found in the anterior fibro-muscular zone.
It therefore appears that there is an imprecise relationship between amount o f  
glandular tissue in the zones described and cancer frequency. This led McNeal to 
suggest that it was the fact that central zone glands are structurally and 
immunohistochemically distinct from the exocrine glands o f the rest o f the prostate 
that led to the low rates of cancer originating in the central zone. He postulated that 
the separate embryological origin of these cells (possibly from a remnant o f the 
Wolffian duct) led to the low incidence of prostate cancer in the central zone.
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Function of the prostate gland
The main functions o f the prostate are exocrine secretion and mechanical activity 
during the process o f ejaculation. 70% of the mass o f the prostate is made up of 
glandular elements (1), with the rest being composed o f fibromuscular stroma. The 
prostate gland secretes a clear or milky alkaline fluid into the urethra during the 
emission phase o f male sexual function. Prostatic secretions make up approximately 
10-30% of the ejaculate with the rest being produced by the seminal vesicles. The 
prostatic secretions contain the enzymes acid phosphatase and prostate-specific 
antigen. They also contain zinc and citric acid.
The prostate secretions become mixed with the sperm produced by the testes and 
transported to the urethra in the vas deferens and the fluid from the seminal vesicles to 
become ejaculated semen. Semen is then ejaculated by contractions o f the smooth 
muscle o f the prostate gland and urethra.
Prostate Specific Antigen
Prostate Specific Antigen (PSA) is secreted by the glandular elements o f the prostate. 
It is one o f a family o f associated proteins termed the human kallikreins (hK). PSA is 
also known as hK3. PSA is a serine protease inhibitor uniquely found in the prostate 
epithelium which is important in the lysis o f seminogelin. This effect on seminogelin 
is important in the liquefaction o f the ejaculate to allow sperm to be released from the 
ejaculate and ascend in the female genital tract after intercourse.
PSA was first identified by Albin in 1970, and as it is produced only by prostate 
tissue, it was initially considered as a potential forensic marker for legal cases where it
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was critical to know whether intercourse with ejaculation had taken place. It is found 
in mg/ml quantities in the ejaculate. Later it was discovered that PSA was detectable 
in serum samples at levels o f ng/ml. It is found in serum as both a free molecule and 
complexed with endogenous protease inhibitors (such as alpha 2 -macroglobulin and 
alpha 1 -antichymotrypsin). PSA has a half life o f 2-3 days following radical 
prostatectomy, although the free form is cleared after 2-3 hours by renal excretion and 
it seems that the complexed form is more slowly excreted.
PSA secretion by prostate epithelium is closely related to the exposure o f the prostate 
epithelial cell to androgens which bind to and activate the androgen receptor. PSA 
staining o f prostate cells increases at age 0-6 months and over the age of 10 years 
when it is known that a surge in testosterone levels occurs in boys,
PSA levels in the serum are related both to expression of PSA by prostate epithelial 
cells and to changes in the architecture of these cells. Inflammation, physical trauma 
such as prostate biopsy, benign hypertrophy and prostate cancer have been shown to 
increase levels o f PSA in the serum. It is thought that these various processes 
contribute to raised levels in the serum by either:
1. Disruption of prostatic architecture due to cancer or inflammation. This allows 
the PSA to diffuse more easily into the extra-cellular fluid of the prostate 
gland and from there into the circulation.
2. Changes in the number o f cells secreting PSA
3. Changes in the level o f PSA expression per cell (due to increased gene 
transcription)
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Thus changes to each o f these processes can lower serum PSA. This has been shown 
to happen after treating prostatitis with antibiotics (reducing inflammation), partial or 
complete surgical resection o f the prostate (reducing cell numbers) and reducing PSA 
expression (by reducing levels o f highly active dihydrotestosterone (DHT) with a drug 
such as Finasteride, which inhibits DHT production from the precursor hormone 
testosterone). PSA has been used as a guide to prostate cancer risk with higher levels 
triggering referral for prostate biopsy. The use of PSA as a screening tool for prostate 
cancer is discussed further in section 2.4.
Chapter 2.1 - Prostate cancer definition, development and grading
The United States National Cancer Institute defines cancer as a group o f diseases 
caused by abnormal cells that divide without control. These cells may invade other 
tissues, either by direct growth into adjacent tissue (invasion) or by migration o f cells 
to distant sites (metastasis) (7). The unregulated growth is caused by a series of 
acquired or inherited mutations to DNA within cells, damaging genetic information 
that defines the cell functions and removing normal control o f cell division.
It is usual before treatment to confirm a clinical suspicion o f prostate cancer with 
biopsy specimens, which are submitted for histological analysis. Prostatic 
intraepithelial neoplasia (PIN) and invasive prostate cancer are diagnosed by looking 
at the cellular architecture o f prostate biopsies under light microscopy (Figure 5) (8). 
The degree o f cellular dysplasia differentiates these conditions from benign 
abnormalities o f the prostate.
Figure 5. Carcinogenesis from prostatic intraepithelial neoplasia to micro-invasive 
carcinoma reproduced from Bostwick et al 1989 (8)
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Prostatic intraepithelial neoplasia
Whilst mild dysplasia is not generally thought to be a clinically important finding on 
prostate biopsy, high grade (moderate-severe) PIN is thought to be a pre-cancerous 
lesion that may coexist with or predate invasive prostate cancer. 85% of men with 
high grade PIN on a first prostate biopsy have co-existent prostate cancer (9, 10). In 
addition, retrospective studies identified first-biopsy high grade PIN as a significant 
predictor o f future prostate cancer (11). Interestingly the predictive value of high 
grade PIN is now decreasing, probably as a result o f increasingly few missed cancers 
due to a greater number of biopsy cores being taken in the modem era (11).
The reticular collagen layer, which forms an anchoring site for of the epithelial tissue, 
is referred to as the basement membrane. The differentiation o f PIN from cancer is 
based on the critical event of invasion o f the basal membrane (12). This may be 
observed on simple light microscopy with haematoxylin and eosin staining (for large 
cancers) or it may require more complex immunohistochemical techniques to stain the 
keratin-rich basement membrane (Alpha-methacyl-CoA-Racemase (13), High 
Molecular Weight Cytokeratin Antibody (13) and p63 Basal Cell Nuclear Stain (14) 
may be combined to give clearer information on cellular breach o f the basement 
membrane).
Grading prostate cancer
The light microscopy grading system described by Donald Gleason in 1977 (15, 16) 
remains the histopathological benchmark by which all prostate cancers are assessed 
and has the advantage of having predictive value for both stage o f disease at 
presentation and prognosis following conservative (17) or radical treatment.
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Once prostate cancer is identified on the biopsy (by invasion o f the basement 
membrane) the two most prevalent areas are assigned a score based on their 
appearance on light microscopy (see figure 6). Scores based on macroscopic tissue 
architecture change range from 1 (Closely packed uniform glands) to 5 (Solid nests o f 
cells, no glandular architecture, may show necrosis). The scores are then expressed as 
a sum (i.e. Gleason (3+4) =  7). Thus the range o f Gleason scores is 2-10
F igure 6. Gleason grading o f prostate cancer reproduced from Gleason et al 1977 (16).
Gleason scores o f <6 have been found to be unreliable on the small biopsy specimens 
available from modem core biopsies leading to recommendations that scores <6 are 
not assigned to needle core biopsy but only to those specimens from radical 
prostatectomy and TURP on which Gleason’s work was originally done (18).
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Chapter 2.2 - Prostate cancer epidemiology, genetics and prevention 
of prostate cancer
Prostate cancer was the commonest cancer in UK men in 2003, with 31,900 new 
cases. In 2005, 10,000 UK prostate cancer deaths were recorded, which accounted 
for 13% o f all male cancer deaths(19). Prostate cancer was second only to lung cancer 
as a cause o f cancer death in men for the first time in 2000 and Parkin et al (20) 
estimated in 2001 that by 2016, prostate cancer will be the most commonly diagnosed 
cancer in men worldwide.
The incidence o f prostate cancer is rising in the UK and the rest o f the developed 
western world. Steep increases from 1990-2001 have been followed by a plateau in 
incidence (figure 7). These rises followed the widespread introduction o f the serum 
prostate specific antigen (PSA) assay into UK practice.
Figure 7. Age standardised incidence o f and mortality from prostate cancer, Great 
Britain 1975-2004 reproduced from Cancer Research UK(19).
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PSA testing led to more men receiving prostate biopsies to detect early prostate 
cancer, however even in the 1980’s, increased levels o f prostate surgery and better 
histopathological analysis had started to result in increased numbers o f men being 
diagnosed with prostate cancer. The increased use o f PSA screening and an 
increased level of surgical intervention for urinary symptoms in apparently benign 
prostate disease may have brought to light a previously undiagnosed cohort o f patients 
who would not have presented clinically with prostate cancer during their lifetime.
Mortality rates from prostate cancer have not increased as much as would have been 
expected if  the rise in prostate cancer detection truly represented a greater incidence 
of the disease. As a much larger number o f the prevalent (but undiagnosed) cases 
were picked up from the population and ‘ad hoc’ screening reached a new, steady but 
increased level o f activity, the incidence rates have stabilised. This pattern of a 
transient rise in incidence followed by a plateau as the number o f undetected prevalent 
cases in the population is reduced following mass screening have also been 
demonstrated in the USA. The fact that US prostate cancer mortality has remained 
relatively static (at 3.6%) despite large increases in incidence may support the 
hypothesis that many o f the additional cases detected by either formal screening or 
widespread case finding with serum PSA may be of clinically indolent disease which 
was never destined to cause mortality(21). With increases in the diagnostic 
sensitivity and diagnostic activity, the USA lifetime risk o f being clinically diagnosed 
with prostate cancer (currently 16.5%) has risen a long way towards the 50% of 50 
year old men in the USA who have microscopic evidence o f prostate cancer at post­
mortem for other causes of death. In the USA healthcare economy proactive case 
finding or screening o f healthy populations has the potential to detect clinically less 
relevant or even insignificant disease (22).
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Risk factors for prostate cancer
The most significant risk factors for prostate cancer are older age, family history and 
ethnicity (Afro-Caribbean descent). A study in Michigan, USA suggested that the 
majority o f American men will develop prostate cancer if  they live long enough 
(Table 1)(23). 75% of men who died over the age o f 85 had detectable prostate 
cancer on careful histopathological analysis o f the prostate at post mortem.
Table 1. Histological prevalence o f prostate cancer in patients at post-mortem (23-25).
Age Prevalence of Prostate Cancer on Post Mortem (%)
30-39 27-29
40-49 32-34
50-60 50-55
70-80 64
>85 75
Genetic risk factors for prostate cancer
Different countries report large variation in prostate cancer incidence (Figure 8, p40), 
which may be related to a number of factors other than genetics. The influence of 
genetic polymorphism in populations is difficult to separate from environmental 
exposures and exposure to other carcinogens. Ethnicity seems to be an important risk 
factor especially in African-Americans with an incidence of 137/100,000/year 
(approximately double the rate in the UK as a whole) (26) and reduced incidence in 
Asian men. Although reported rates of cancer are lower in developing countries due 
to shorter life expectancy and less accurate registries, prostate cancer is the 
commonest cancer in Nigerian men where life expectancy at birth is 47 years 
compared with 86 years for 2007 in the UK (27).
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Figure 8. Age-standardised (world) incidence and mortality, prostate cancer, selected 
countries, 2002 estimates. Reproduced from Cancer Research UK(19).
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Familial prostate cancer
Familial cancers have been described in a number o f sites and familial clustering for 
prostrate cancer was first described in the 1960’s (28). Little was understood o f the 
inheritance o f prostate cancer until work on other tumours illustrated the possible 
mechanism for inherited prostate cancer. Knudson’s classic work on the rare eye 
tumour retinoblastoma led to the ‘two hit hypothesis’ for development o f cancers in 
genetically predisposed family members (29). Knudson proposed that tumour 
suppressor genes (TSG) existed and could predispose the host to cancer if  they failed 
to function. Tumour suppressor genes normally restrain cell growth. W hen m issing 
or inactivated by mutation, they allow cells to grow in an uncontrolled manner (with 
changes to the cell cycle, apoptosis or proliferation). Knudson proposed that in 
families with a congenital mutation o f the TSG inherited from one parent (the first hit) 
that cancer developed when a spontaneous mutation o f the second copy o f the TSG
■  Incidence
■  Mortality
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occurred. Healthy individuals with two functional TSG’s would be less likely to 
develop cancer, as the probability o f two spontaneous mutations at the same genetic 
locus would be less. This hypothesis was confirmed in 1993 when germ-line 
mutations in the retinoblastoma gene (RB) were detected in families affected by 
hereditary retinoblastoma (30).
Studies o f mono and dizygotic twins in Sweden, Denmark and Finland revealed a 
strong heritable element (42%) for prostate cancer (31). Prostate cancer proband 
concordance was the most highest o f all the studied cancers and this has been 
confirmed in studies in the USA (32).
Additional work had correlated familial risk o f prostate cancer with risk o f other 
tumours. The female members of families with hereditary prostate cancer are twice as 
likely to be diagnosed with breast cancer (33, 34) and likewise prostate cancer is 
more frequently detected in men from familial breast cancer families (35, 36).
A number o f mechanisms have been used to investigate the genetic risk factors for 
prostate cancer and the variation in the techniques used may explain the different 
findings reported in the published literature. The accepted criteria defined by the 
Johns Hopkins group (37) identified familial prostate cancer in 3-5% of families as 
follows:
1. 3 or more first degree relatives (father, son)
2. 3 successive generations of either the maternal or paternal lineages, and/or
3. At least 2 relatives affected at age 55 years or younger.
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The Hopkins criteria may however exclude families with some types o f hereditary 
susceptibility to prostate cancer (with mutations in autosomal dominant susceptibility 
genes). It is currently accepted that genetic susceptibility accounts for 5-10% of 
prostate cancers (38, 39).
From a practical point of view it has been estimated that a man with a second degree 
relative with prostate cancer has a relative risk (RR) of 1.7 (95%CI 1.0-2.9) for 
developing prostate cancer compared with a man without a family history of prostate 
cancer (40). A man with a first degree relative has a RR of 2.0 (95%CI 1.2-3.3) 
compared to a man with no family history and a man with both a first and second 
degree relative has a RR of 8.8 (95%CI 2.8-28.1) of developing prostate cancer.
Locating a Locus for the Prostate Cancer Gene(s)
The recognition that prostate cancer clusters within families has led many 
investigators to collect information from families with numerous diagnosed cases in 
an attempt to identify susceptibility genes using linkage studies. Linkage studies are 
a gene hunting technique looking at patterns of disease in families with clusters o f  
prostate cancer. They attempt to locate a disease-causing gene by identifying genetic 
markers o f known chromosomal location that are co-inherited with the trait o f interest. 
The strength of linkage between a known genotype and the cancer phenotype is 
expressed as a Lod (or log o f odds) score, which calculates the probability o f a 
particular pedigree o f phenotypic disease arising randomly or by genetic linkage. In 
practice, linkage is declared if  the Lod score is equal to or greater than 3 (i.e. the 
likelihood o f observing the result if  the two loci are not linked is less than 1 in 1000, 
the same p<0.001 value used by some statisticians). On the other hand, linkage can be 
completely excluded if  the Lod score is below -2.
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This work however has been problematic and a review o f genome wide linkage 
searches including a total o f 4,600 cases o f prostate cancer from 1,293 families found 
that no chromosomal region was reported as significant (Lod >3) by more than one 
study (41). Only one locus corresponded to a peak previously suggested by another 
research group. Some researchers have therefore concluded that differences in 
populations (with varying but often high incidence o f non-familial disease), enrolment 
criteria (definitions o f familial disease), as well as the nature o f the genetically 
complex nature o f the disease might account for the lack o f consistency between 
linkage studies (41). These problems may be compounded by PSA screening picking 
up high levels o f sporadic disease due to familial screening activity after one family 
member is diagnosed, much o f which might represent disease unlikely ever to present 
with symptoms.
A full examination o f candidate genes in prostate cancer is outside the scope o f this 
thesis. It is likely that the search for prostate cancer genes will be refined further in 
the future but it has not as yet formed a major part o f clinical practice outside of 
centres where linkage studies are currently being performed. The major clinical 
implications have been a recommendation for PSA screening in patients who fulfil the 
Hopkins criteria at 5 years below the age o f diagnosis o f the youngest affected relative 
(37).
Environmental risk factors and prevention of prostate cancer
It has been suggested that ‘western’ diets rich in fat, meat and dairy products lead to 
an increased risk of clinically diagnosed prostate cancer (26). Dietary phyto- 
oestrogens from foods such as soybeans may also have an effect on very early 
prostate cancer growth from microscopic disease to levels where it may present with
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symptoms. This might help to explain the low incidence of clinically diagnosed 
prostate cancer in Asian countries (Figure 8, p40) despite similar incidence o f latent 
cancers in post-mortem studies (42).
Interest in the role o f other chemo-preventative agents such as selenium, vitamin E, 
lycopene (found in tomato products) and drugs which prevent the conversion of  
testosterone to its active form dihydrotestosterone by inhibiting the enzyme 5-Alpha 
Reductase in the prostate (5ARI) e.g. finasteride (Proscar®) and dutasteride 
(Avodart®) are increasing.
The recent Prostate Cancer Prevention Trial (PCPT) with 9060 analysed patients was 
a randomised controlled trial o f finasteride compared with placebo in men who had a 
normal PSA and digital rectal examination at randomisation. Patients in the study had 
a further biopsy if their PSA increased significantly during the study and all remaining 
patients had a biopsy irrespective of PSA after completion o f seven years of 
treatment. The PCPT study was terminated early due to a significant decrease in the 
incidence of new cancers diagnosed in the finasteride group. An absolute increase in 
the number of high grade (Gleason Grade > 7) cancers diagnosed was found in the 
finasteride group compared with placebo (43).
Questions have arisen about whether it is possible that the higher incidence o f high- 
grade cancer could be due to the effects o f androgen deprivation. This is thought not 
to be the case (particularly since patients on the drug for longer periods did not have a 
greater risk than those who had a biopsy after only a short period on the drug).
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Alternative explanations include:
1. Higher sampling rates (due to taking the same number o f biopsy cores in a 
prostate that has been reduced in volume due to atrophy of the glandular 
prostate elements as an effect of androgen deprivation) (44).
2. The effects of androgen deprivation on the appearance of prostate cancer cells. 
Gleason’s work was done in patients who had not experienced androgen 
deprivation and hence Gleason grading may be inaccurate in the setting of 
chronic DHT deprivation (44).
The concerns about induction o f high-grade cancer have meant that a widespread 
strategy of preventative finasteride has not been adopted. Further trials including 
REDUCE (Reduction by Dutasteride in prostate Cancer Events) may give us a clearer 
picture than that available from the PCPT as to whether the 5ARI class o f drug may 
have an indication in this role (45).
The SELECT trial (SELenium and vitamin E Cancer prevention Trial), which is being 
run by the National Institutes for Health in the USA, closed to accrual in 2004. It has 
recruited 35,534 participants and aims to assess the role o f Selenium and Vitamin E in 
the prevention o f prostate cancer (45).
It remains to be seen whether chemo-preventative agents are effective in reducing 
cancer mortality or morbidity. It is therefore likely that the current high incidence o f  
prostate cancer and prostate cancer death will continue to present a significant 
problem in the UK’s ageing population unless effective treatment or prevention 
strategies are implemented.
Chapter 2.3 - Prostate cancer screening, staging and prognosis
There is controversy about the most effective methods o f reducing morbidity and 
mortality from prostate cancer in the UK. To my knowledge, only one randomised 
controlled trial has shown a small (5% at 10 years) survival advantage to radical 
prostatectomy over watchful waiting (46). No other contemporary treatments have 
been compared to one another in an experimental setting. No RCTs have been 
published comparing outcome in screened populations (as opposed to men with more 
advanced and sometimes symptomatic disease which presents clinically).
The efficacy of treatment may be difficult to prove not necessarily because of limited 
effectiveness o f the available treatments in curing prostate cancer, but because of high 
levels o f co-morbidity in elderly men who are currently most often diagnosed with 
prostate cancer. This means that end points such as 10 year metastasis free or clinical 
recurrence free survival may be overshadowed by the impact o f mortality from non­
cancer causes. The long lead time o f early disease from a positive prostate biopsy to 
metastasis or cancer death means that men often die with, rather than of, prostate 
cancer (47) . Large studies o f low risk disease will therefore be required to describe 
any treatment effects.
Current estimates are that around 16% of men who have prostate cancer detected by 
screening would gain years of life or avoid morbidity by being cured o f prostate 
cancer (48).
These estimates may make prostate cancer seem less o f a priority compared with other 
conditions, however with a rising population life expectancy (male life expectancy in
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the UK is increasing by about 3 years at birth every 10 years (49)) and better 
treatment for co-morbid conditions, prostate cancer seems destined to have a greater 
impact both in terms of both years and quality o f life lost.
Screening
The principles o f screening were identified by Wilson and Jungner (50) in 1968. 
They are reproduced in Table 2. Prostate cancer screening either using serum PSA 
levels, digital rectal examination (DRE) or both fails several o f these criteria at the 
current time. New tests such as polymerase chain reaction to detect prostate cancer- 
specific genes in cells shed in voided urine have not yet been shown to be better than 
PSA as screening tools (51, 52)
Table 2. Disease screening criteria according to Wilson and Jungner (50)
1. The condition being screened for should be an important health problem
2. The natural history should be well understood
3. There should be a detectable early stage
4. Treatment at an early stage should be o f greater benefit than at a later stage
5. There should be a suitable test for the early stage
6. The test should be acceptable
7. Intervals for repeating the test should be determined
8. There should be adequate health service provision for the extra clinical 
workload resulting from the screen
9. The risks should be less than the benefits
lO.The costs should be balanced against the benefits
Although prostate cancer is common and may be serious its natural history is not 
adequately understood to predict on an individual level which patients will require 
radical treatment to prevent morbidity or mortality from prostate cancer. Although 
the use o f PSA screening allows us to identify a group o f patients at increased risk of  
a prostate biopsy set showing evidence o f prostate cancer (53) it is raised in many 
benign conditions including prostatitis and benign prostate enlargement (BPE) and
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using a cut-off of 4pg/L misses the detection of up to 36.5% of cancers (54). Prostate 
cancer is relatively common at all levels o f PSA. When biopsies were done in healthy 
60-90 year old American men with a PSA< 4pg/L at the end o f the Prostate Cancer 
Prevention Trial, (described in Chapter 2.2 p44) these showed that 15.2% had prostate 
cancer. Decreasing levels o f prevalence for positive biopsy were noted with lower 
levels o f PSA but even men with PSA <0.5pg/L had a positive biopsy rate o f 6.6%.
Although more complex strategies based on using age and prostate volume may make 
the chance o f missing a patient with histological evidence o f prostate cancer on biopsy 
smaller, there is as yet no evidence that they increase the detection o f ‘clinically 
significant’ cancers which would contribute to morbidity or mortality within the 
patients lifetime.
Screening for prostate cancer has generally involved the combination o f a PSA blood 
test and digital rectal examination to detect patients with increased risk o f prostate 
cancer. Since these tests both have inadequate sensitivity and specificity the diagnosis 
must be confirmed by prostate biopsies and these are generally acquired using a 
transrectal ultrasound guided approach. Biopsy is not always acceptable to patients, 
has a significant false negative rate and may produce morbidity in terms o f  
haematuria, urinary infection, pain, urinary retention and rarely systemic sepsis.
However, it is certain that ad-hoc screening for prostate cancer has become 
increasingly common in the UK(55) due mainly to a lack of centralised guidance on 
PSA testing and pressure from patients at an individual and group level. This increase 
in activity has produced an increase in the number o f cancers detected (56) and hence
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an increase in men presenting for treatment. The number o f men with few symptoms 
and early stage disease (i.e. organ confined prostate cancer) who are presenting to 
urologists and oncologists is also therefore likely to increase.
Whilst it has been argued that routine screening for breast cancer was started before 
there was evidence that breast cancer screening fulfilled the Wilson/Jungner criteria 
(57, 58), it is unlikely that governments will be willing to fund screening until these 
criteria are fulfilled for prostate cancer.
Staging and prognosis
Prostate cancer may be diagnosed at a variety o f stages, localised to within the 
prostate (Early Prostate Cancer, EPC), locally advanced disease (which has invaded 
the prostate capsule but not metastasised), or disease which has metastasised to lymph 
nodes, bone or other sites. Early prostate cancer makes up approximately 57% of the 
prostate cancers currently detected in the UK compared with 31% with locally 
advanced disease and 12% with metastatic disease (59).
Prostate cancer staging in the UK is most commonly classified according to the TNM 
2002/Version 6) staging system (60) (Table 3, p50) which classifies tumours using 
clinical examination, imaging and biochemical tests to determine their extent once 
cancer has been confirmed by biopsy.
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Table 3. TNM 2002 Clinical Staging for Prostate Cancer (60, 61)
Primary Tumour Regional Lymph Distant Metastasis
Nodes
Tx 1° Tumour Cannot Be Assessed Nx Regional LN 
not assessed
M
X
Distant metastasis 
cannot be 
assessed
1 T0
No evidence of 1° Tumour NO No regional 
LN metastasis
M
0
No distant 
metastasis
T1 Clinically unapparent tumour not palpable or N1 Regional LN M Distantvisible on imaging Metastasis 1 Metastasis
Tla Found in <5% of TURP chips
Tib Found in >5% of TURP chips
T ic Identified on needle biopsy
T2 Tumour confined within prostate
T2a Tumour involves < Vi o f one lobe
T2b Tumour involves > Vi o f one lobe
T2c Tumour involves both lobes
T3 Tumour extends through prostate capsule
T3a Extracapsular extension on 1 or both sides
T3b Tumour invades seminal vesicles
T4 Tumour is fixed or invades adjacent 
structures: bladder neck, external sphincter, 
rectum, levator muscles
Prostate cancer progression may be from local growth which may result in invasion of 
peri-prostatic structures (urethra, bladder, ureter or rectum), or by metastasis usually 
to bone. The prognosis will depend upon the stage of disease at presentation and the 
cancer’s ability to progress.
Clinically detected prostate cancer metastatic to bone in the era when the palliative 
effects of castration were unknown was a rapidly lethal disease (62) and even with 
androgen deprivation (where LHRH analogues are used to reduce serum testosterone 
and anti-androgens are used to inhibit activation o f the androgen receptor) 59% of  
patients died within 18 months (63). Established metastasis to local lymph nodes
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(LN) are associated with a 46% risk of death at 22 months-post diagnosis (64) 
compared with only a 10% risk o f progression in lymph node negative patients .
Thus accurate staging o f disease is essential. In the PSA era it has become easier to 
identify those patients at low risk o f metastatic disease. In untreated men a PSA 
below 10 is associated with a risk o f bone metastasis o f 0.5%(65) and providing the 
disease is localised and low grade (<T2b, Gleason score<7) then the risk o f pelvic 
lymph node metastasis is <1% (66).
The stage o f the primary tumour also has prognostic value. Capsular penetration and 
seminal vesicle involvement are predictive of occult lymph node metastasis (67, 68) 
and this affects PSA-recurrence-free-survival after radical surgery (69) even if  the 
primary tumour is completely resected. Accurate staging o f local disease using 
clinical, biochemical or imaging methods to predict capsular penetration is however 
not currently possible. Predictive tables have been prepared that aim to determine the 
probability of capsular penetration, seminal vesicle or lymph node involvement based 
on clinical stage (TNM), serum PSA and pathological grade (Gleason sum)(70). 
Although these nomograms such as Partin’s tables (70) have helped to predict the 
stage of prostate cancer without the need for surgical resection, they only allow risk 
estimation rather than confirmation o f a definitive stage for any individual patient.
Identifying patients with disease that has already progressed will have a strong impact 
on prognosis; however prognosis will also depend on the biological potential o f the 
tumour to progress. Growth rate and metastatic potential are the biological features 
that determine progression. Both macroscopic (tumour volume, regional lymph node
Chapter 2.3
status) and microscopic (Gleason Score, Perineural Invasion, Presence o f coexisting 
high grade Prostatic Intraepithelial Neoplasia) have been shown to correlate with 
biological potential (15, 71-73) and other predictive markers have been sought but not 
' routinely adopted into clinical use. These markers have been used to describe various 
risk groupings for Early Prostate Cancer. These are outlined in table 4 (below).
Table 4. Early prostate cancer: Risk group classification systems
Group Low risk Intermediate risk High risk
Zelefsky et al (74) 
(Memorial 
Sloan-Kettering, NY  
Classification)
PSA < 10  ng/ml 
Gleason score 2-6  
Stage Tl-T2b
PSA > 1 0  ng/ml 
Gleason score > 7 
Stage> T2b
2 or 3 o f the 
intermediate risk 
factors
Stock, Stone(75) 
(Mount Sinai, NY)
PSA < 10 ng/ml 
Gleason score 2-6  
Stage Tl-T2a
PSA 10.1-20 ng/ml 
Gleason score 7 
Stage T2b
2 or 3 o f the 
intermediate risk 
factors and/or PSA 
> 20 ng/ml and/or 
Gleason score 8-10  
and/or Stage > T2c
D ’Amico et al(16) 
(Harvard MS)
PSA < 10 ng/ml 
Gleason score 2-6  
Stage Tl-T2a
PSA 10.1-20 ng/ml 
Gleason score 7 
Stage T2b
PSA > 2 0  ng/ml 
and/or Gleason 
score 8-10 and/or 
Stage > T2c
The assumption o f the current therapeutic strategy o f radical surgical resection, 
irradiation or cryoablation o f the prostate is that untreated localised disease will 
eventually result in either local progression or distant metastasis (figure 9, p53) and 
hence ultimately morbidity and death and those local therapies may remove or delay 
the risk o f local and metastatic disease progression. This assumption is currently 
supported by a single randomised study o f radical prostatectomy compared with 
watchful waiting in clinically palpable disease (46). Whilst this is powerful evidence 
that the process o f metastasis and cancer death can be halted by local ablative 
treatment further studies will be required to determine the size of the treatment effect
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in men presenting with the earlier stage prostate cancer being diagnosed in the PSA 
screening era.
Figure 9. Possible patterns o f prostate cancer progression -  Reproduced from 
Whitmore et al (47).
Prostate Cancer Morbidity and 
Prostate Cancer Death
Localized
Disease
Lymph Node Skeletal
Metastasis
iV
Metastasis
Capsular
Penetration
Locally
Advanced
Disease
This thesis will concentrate on disease which is or is thought to be confined to the 
prostate, which will be referred to as early prostate cancer (EPC). The aim of 
treatment for EPC is to prevent progression from early disease to metastatic or 
locally advanced disease with symptoms within the patient’s lifetime or as a 
cause of a shortened lifespan.
Although ideally patients might aim for cure o f their disease, it might be acceptable to 
confine treatment and its complications to those patients who are likely to have 
progression of their early disease within their lifetime. We are not yet able to reliably 
identify this group of patients because although the Gleason grade o f the prostate 
cancer, TNM stage and PSA allow us to estimate risk in populations the finding o f  
Tow-risk’ prostate cancer does not exclude an aggressive clinical course for the 
individual.
Chapter 2.4 - Treatment options and outcomes in early prostate cancer
Once prostate cancer is detected, patients and their physicians have to make choices 
about treatment. The options include immediate radical treatment, immediate medical 
treatment without curative intent or observation o f the progress o f the disease with the 
intent of intervening with either radical treatment if  the disease is considered to be 
aggressive (active monitoring, AM) or palliative treatments if the disease becomes 
symptomatic (watchful waiting, WW).
Established potentially curative treatment options include:
Radical Prostatectomy (RP) open, laparoscopic or robot assisted laparoscopic route 
External Beam Radiotherapy (EBRT)
Low Dose-Rate Brachytherapy (BXT)
Low Dose-Rate Brachytherapy combined with External Beam Radiotherapy (BXTC) 
High Dose-Rate Brachytherapy Monotherapy (HDR BXT)
High Dose-Rate Brachytherapy with External Beam Radiotherapy (HDR BXTC) 
Cryotherapy/Total CryoAblation o f the Prostate (TCAP)
High Intensity Focussed Ultrasound (HIFU)
Medical treatment options for early prostate cancer (currently there are no 
curative treatments available) include:
Hormonal treatment = Androgen Deprivation (AD)
-  Lutenising Hormone Releasing Hormone (LHRH) agonists e.g. Goserelin
-  Lutenising Hormone Releasing Hormone (LHRH) antagonists
e.g. Abarelix, Ganerelix (Limited use currently -  histamine related toxicity)
-  Androgen receptor antagonists Non-Steroidal e.g. Bicalutamide
Steroidal e.g. Cyproterone Acetate
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Novel/uncommonly used treatments
Proton beam irradiation 
Growth factor antagonists 
Immunotherapy & vaccines
Chemotherapy (Chemotherapy is standard treatment for metastatic prostate cancer but 
has been investigated in only a few studies o f EPC usually in combination with 
ablative treatment for high risk EPC)
Observational studies of the natural history of untreated early prostate cancer
Prostate cancer can be a relatively indolent disease. Three groups over the last decade 
have reported on large cohorts o f men followed up for 15-20 years after a diagnosis of 
early prostate cancer (77-79) with many more studies o f shorter follow up. 
Johansson et al reported on 223 Swedish men with at least 15 year follow-up who 
received no initial treatment and only AD on clinical disease progression. They 
reported an 81% survival at 15 years (95% Cl 72-89%) (77). Adolfsson et al in a 
separate study o f men who had no radical treatment for EPC based at a different 
institution in Sweden reported 20 year outcomes from a cohort o f 119 men with EPC 
diagnosed between 1978-1982 (79). Adoffsson reported an 85% (95%CI 77-93%) 
disease-specific survival rate at median 24 year follow-up with 43% of men free from 
a need to start AD at 10 years.
Albertsen et al describe outcome for a cohort o f 223 men who again were clinically 
diagnosed with prostate cancer in the pre-PSA era in the USA (diagnosed in 1977- 
1984) and who received no radical treatment (78). They report a 29% disease-specific 
mortality from early prostate cancer at a median of 24 years follow-up (patients who 
received AD immediately or on disease progression were included in the analysis as
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well as untreated patients). Albertsen also reported the prostate cancer mortality rates 
for differing Gleason grade of cancer and these were markedly different for men with 
the highest Gleason sum 8-10 cancers (66%) compared with the lowest, least 
histologically aggressive cancers Gleason sum 2-4 (7%).
Although all of these studies had the potential for selection bias due to the described 
patients actively opting not to undergo radical treatment, which may reflect their 
physician’s impression that they had high risk co-morbidities or low risk prostate 
cancer, the benefit o f a cure from EPC may be limited in some men with limited life 
expectancy. More recent analyses by Parker et al (80) based on the Albertsen data 
attempted to adjust for the possible lead-time bias o f patients with PSA/DRE screen- 
detected prostate cancer and the estimated effect o f radical treatment on disease. This 
study suggested that for men at the lowest risk o f dying in the Albertsen study (aged 
55-59), with cancer with the lowest risk (Gleason grade <7), that disease-specific 
survival benefit of radical treatment would be in the range 0-2%. It will be interesting 
to see if  these estimates prove accurate as it may be possible to pursue follow-up 
without immediate treatment in quite large cohorts o f men with prostate cancer and a 
low risk of disease progression without increasing morbidity and mortality.
Active monitoring/surveillance is follow-up using PSA and repeat prostate biopsy 
without intervention until there are biochemical (increasing PSA) or histological 
(worsening biopsy results) suggestions o f disease progression. Progression triggers 
radical cancer treatment if  the disease is still localised (81, 82) or palliative treatment 
if  required. These strategies are currently being investigated and protocols for safe 
observation o f prostate cancer with long term (>10 year) outcomes are not as yet 
available (81, 82).
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Summary of evidence from randomised trials of treatment for early prostate 
cancer
Despite the evidence that favourable risk (Gleason grade <7) prostate cancer may be a 
relatively indolent disease, few randomised trials assessing radical treatment options 
for early (localised) prostate cancer (EPC) have included a no immediate treatment 
arm or compared accepted treatments such as brachytherapy and surgery to each 
other. Most studies have addressed modifications to a technique o f surgery or 
adjuvant treatment with hormones combined with radiotherapy or surgery.
This lack o f control data is partly explained by difficulties in randomisation with 
several studies including the MRC PR06 in 1994-1996 (comparing RP vs. EBRT vs. 
No Immediate Treatment) and the SPIRIT (Surgical Prostatectomy vs. Interstitial 
Radiation Intervention Trial (ACOSOG Z0070), comparing low dose-rate 
brachytherapy to radical prostatectomy) in 2004 closing due to difficulty with 
recruitment. Reports from these studies suggested that patients were unwilling to 
accept the uncertainty o f random allocation o f quite different treatments. Only 3-5% 
of men who were approached were willing to accept randomisation, and even when 
(in the SPIRIT study) specific patient information groups were run this only achieved 
a maximum recruitment o f 12.9% of approached patients.
Newer studies, such as ProtecT (table 5, p58) aim to overcome this problem by 
recruiting and educating patients before achieving a screening-based diagnosis. 
Although this was more effective with 70% of patients randomised to Radical 
Prostatectomy(RP), External Beam Radiotherapy (EBRT) or Active Monitoring of 
PSA (AM) the costs of screening-based studies are substantial as only 1-2% of 
patients will be diagnosed within the life o f such a study (83) (ProtecT approximate
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budget = £10 million) and such studies introduce significant lead-time bias which may 
potentially dilute the size o f any treatment effect.
Table 5. Current randomised controlled trials assessing oncological outcome after 
primary ablative/radical treatment for organ confined (<TNM T3) early prostate 
cancer (not including studies where intervention is a modification o f same radical 
therapy)
STUDY NAME FULL TITLE DESIGN
PIVOT Prostate Cancer Intervention 
Verses Observation Trial
RP vs. WW for TNM stage Tla- 
T2c disease
Opened 1999 and aimed to recruit 
1050 patients over 7 years with 
planned 15 year follow-up. Now 
closed to recruitment.
ProtecT Prostate Testing for Cancer and 
Treatment (ProtecT)
Screen detection of prostate cancer 
with patients randomised to 
treatment with EBRT, RP or AM
Calgary RCT of EBRT vs. 
Cryotherapy for Localised 
Prostate Cancer
A Randomised Controlled Trial 
Comparing External Beam 
Radiation and Cryoablation in 
Localised Prostate Cancer
68-73 Gy Radiotherapy with 
neoadjuvant androgen deprivation 
vs. Cryotherapy for localised 
prostate cancer (84)
BRACHYTHERAPY STUDIES
STUDY NAME FULL TITLE DESIGN
RTOG 0232 
(Pilot POO 19)
Interstitial Brachytherapy With or 
Without Extemal-Beam Radiation 
Therapy in Treating Patients With 
Prostate Cancer
Phase III RCT comparing BXTC 
with BXT alone for intermediate 
risk EPC
NCT00241384 Low Dose Supplemental External 
Radiation With Pd-103 vs. Pd-103 
Alone for Prostate Cancer
RCT comparing 20 Gy 
supplemental external beam 
radiotherapy to seed implant alone 
in localised prostate cancer
Trials described above are currently recruiting or awaiting reporting and compare
radical treatments to each other or no treatment (A greater number of trials which 
are not listed compare the effectiveness of adjuvant treatments in groups of 
patients receiving identical radical therapy, e.g. androgen- 
deprivation/chemotherapy plus radical treatment or ways of delivering 
radiotherapy e.g. fractionation schedules, dose escalation and reduction trials). 
Database Search (http://www.controlled-trials.com 28/5/2007, Includes: International 
Standard Controlled Trial Number Register, United States National Institutes o f  
Health Randomised Trials Register (clinicaltrials.gov), Medical Research Council 
Register, UK Clinical Trials Gateway, NHS Trusts Clinical Trials Register, NHS 
Health Technology Assessment Program Register and the Wellcome Trust Register -  
621 Studies of Prostate Cancer Identified, o f which 5 are identified above).
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An exhaustive review of the relative efficacy o f all o f the commonly used radical 
treatments for early prostate cancer is outside the scope o f this thesis. However recent 
systematic or high quality reviews (85-87) o f the relative efficacy o f treatments found 
Cochrane level 4 evidence (poor quality cohort and case-control studies) for the 
relative efficacy o f radical treatments for EPC (e.g. brachytherapy, radical 
prostatectomy or conformal external beam radiotherapy to >64 Gy) with level lb  
(Individual RCT with narrow Cl) evidence confirming a significant survival 
advantage with radical prostatectomy over delayed hormone therapy at progression in 
the study by Holmberg et al (46, 83).
The Holmberg study was a landmark randomised controlled trial o f 695 men treated 
with radical open prostatectomy versus watchful waiting with hormonal manipulation 
if  required (which recruited before PSA screening started in Sweden). It showed that 
with a median follow-up o f 8.2 years there was a survival advantage to radical 
prostatectomy (46, 88) of approximately 5% compared to watchful waiting with 
delayed hormone therapy at progression (mortality RP-27% vs. WW-32%). There 
was also a reduction in the risk o f developing metastatic disease by almost half (15 vs. 
25%) with a reduction in cancer-specific mortality o f 5.3%.
This trial was the first to demonstrate the expected reduction in all cause mortality 
following radical treatment of localised disease. The outcome o f radical treatment in 
men with PSA screen-detected EPC, who are less likely to have micro-metastatic 
disease than this population are unknown, but it is likely that the differences would 
demonstrate a longer lead time before becoming clear.
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A further randomised study comparing EBRT (55Gy in 20 fractions) to 35.75 Gy in 
13 fractions plus a 17Gy HDR brachytherapy boost in 2 x 8.5 Gy fractions separated 
by 24 hours was performed in the UK in patients with clinical stage T1-T3 disease 
(89) . 220 patients were randomised equally between the two treatments and the HDR 
brachytherapy groups showed a decreased risk o f biochemical failure compared to the 
EBRT group. In addition this group reported reduced toxicity for the HDR-BXTC 
group compared with EBRT in terms of total FACT-P score and rectal discharge on 
RTOG scoring at 12 weeks post treatment although there appeared to be no 
differences in late toxicity. The total delivered doses in the external beam 
radiotherapy arm are low by contemporary standards and hence this study may not 
give a final answer as to whether HDR-BXTC should replace EBRT. However this 
work is encouraging and further work comparing HDR to contemporary (higher dose) 
intensely modulated radiotherapy is warranted.
A single analysis combining 3 multi-centre international randomised studies on the 
use of Bicalutamide (Casodex®) as monotherapy for the treatment o f EPC has led to 
licences for its use in this role being revoked in the UK, USA and Europe (90).
The subset o f current trials identified in table 5 which include a no radical treatment 
arm (p58) compare patients randomised to radical treatment and either PSA 
monitoring (active monitoring) with treatment only in the event o f rapid PSA rises or 
watchful waiting with hormonal therapy instituted only in the event o f clinical 
progression. The department o f Health in the UK is processing a bid to fund a study 
of outcome following Brachytherapy or Radical Prostatectomy for early prostate 
cancer (SABRE -  Surgery Against Brachytherapy; Randomised Evaluation).
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Summary of evidence from non-randomised comparative studies of radical 
therapy in early prostate cancer
Although the evidence is o f poor quality (Cochrane level 4) it is generally agreed that 
cohort studies and institutional series (selected large volume comparative studies 
summarised in table 6, p62) have suggested equivalent efficacy in terms of 
biochemical cancer control for RP, modem three-dimensional conformal EBRT (to 
>72 Gy) and prostate LDR-BXT in the treatment o f EPC at least in the short term 
(<10 years) (85, 91-93). These studies have all produced biochemical cure rates of 
around 80% for low risk disease treated with any o f the modalities with at least 5- 
years of follow-up.
Although the studies outlined have not included randomisation it is hoped that the 
results o f studies currently recruiting will confirm the efficacy o f the currently 
available prostate cancer treatments and define their place in therapy particularly in 
comparison to active surveillance for early prostate cancer.
Other studies to define the place o f increasingly available new modalities such as 
HDR-Brachytherapy monotherapy and high intensity focussed ultrasound and 
compare them with the described modalities will also be required.
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Chapter 2.4
Treatment selection in early prostate cancer
Available (Cochrane level 4) evidence for the relative efficacy o f radical treatments 
summarised in this chapter does not show evidence that any one o f the radical 
treatment modalities are superior in terms of PSA recurrence free survival or overall 
survival, although there is some evidence that EBRT to a total dose of <72 Gy 
produces inferior PSA recurrence free survival (95-98).
Treatment selection may depend on other criteria until further evidence on efficacy is 
available. These may include the patient’s characteristics including his cancer grade 
and stage, habitus and comorbidity, the advice o f his doctors and his own ideas on 
treatment. Access to the various treatments may be limited by providers (in the UK, 
NHS provision and in the USA, this treatment may not be covered by all health 
insurers). As a result of the lack o f clear superiority o f any one modality, medical 
professionals from different disciplines may give conflicting recommendations as to 
the optimum form of radical treatment for EPC (96, 99, 100).
Currently brachytherapy, radical prostatectomy and external beam radiotherapy are 
widely used in the UK and patients are often asked to make their own decisions on 
which treatment to accept. UK consultants often advise younger men to undergo 
surgery however there is little evidence that radiotherapy is inferior to surgery in 
younger men especially when modem techniques are used to achieve high radiation 
doses to the prostate.
Carefully conducted quality o f life research may help to identify which treatments 
have the best symptomatic outcome for eligible patients. This is particularly
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important given the excellent survival rates after any form of radical treatment for 
EPC. It is likely that in the future much o f the decision making may be based on 
identifying which treatments offer the best quality o f life to particular subgroups of 
patients as well as identifying which treatment offers the optimal form of prostate 
cancer disease control.
Current UK practice in treatment of early prostate cancer
The number o f men treated for prostate cancer by . different modalities in the UK is 
unknown and other than incidence and death rates no nationally collected information 
is available. The British Association o f Urological Surgeons (BAUS) has attempted 
to collect a minimum dataset for urological cancers but this is incomplete covering 
only about 60% of prostate cancers when the project started in 1999 (59) and this had 
declined to about 50% of the nationally recorded incidence figure in 2003. The NHS 
currently lacks the resources to collect reliable information on treatment and outcome 
at a national level.
The last published postal survey of UK consultant urologists revealed that an 
estimated 1417 radical prostatectomy operations were performed in 1999/2000 (101) 
and a repeat survey has not been performed since. Hospital episode statistics which 
are based on the coded summary o f discharges from hospitals in the UK, estimate that 
around 2043 radical prostatectomy operations per year were performed in 1998-2004 
(102).
Analysis o f the BAUS minimum dataset (approximately half o f the national dataset) 
from January to December 2005 (103) reveals that 5551 dataset patients were
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diagnosed with organ confined disease in 2005. Radical surgery was used as a 
curative treatment in 1296 men and radiation therapy in 1701 patients (59). 
According to the BAUS registry only 176 men received brachytherapy in 2005.
Even if  these figures were duplicated in the approximately 50% of the population who 
are not covered by the BAUS registry, they suggest an underestimate as commercial 
brachytherapy suppliers estimate (based on sales and Department o f Health 
Communications) that 1068 implants were performed in 2005 with estimates rising to 
1203 implants in 2006 and 1490 in 2007. Analysis o f the results of this £9-12 million 
per year spend on brachytherapy (based on £8500 per case reimbursed by primary 
care trusts and private insurers) is clearly desirable.
It is likely that > 10,000 patients in the UK each year are diagnosed with organ 
confined disease and that >7000 patients per year currently receive radical treatment. 
This number will probably remain stable in the short -  medium term as incidence o f  
the disease appears stable and access to radical treatment may be improving. 
However the impact o f active monitoring o f prostate cancer may impact on these 
figures.
Chapter 2.5 - Brachytherapy for prostate cancer: history and 
current practice
Discovery of ionising radiation
Henri Becquerel discovered natural ionising radiation in 1896(104) when he described 
a series o f experiments on photographic film (separated from natural light by metal 
foil) which, when exposed to radiation from uranium, developed dark spots without 
exposure to light. In 1898 Marie and Pierre Curie extracted Polonium (104) (named 
after Poland where Marie Curie was bom) and Radium from naturally occurring 
pitchblende ore. Pierre Curie studied the properties o f the radioactive elements 
isolated by his wife including strapping radium rods to his skin, which produced a 
bum, which eventually matured into a grey scar. The Curies received a Nobel Prize 
for physics shared with Becquerel for their discovery o f radiation and later Marie 
Curie received an individual Nobel for Chemistry on the merits of her work to purify 
the new elements Polonium and Radium.
History of brachytherapy
Danlos made the first attempts at radiotherapy in 1901 in the St.Louis Hospital in 
Paris when he inserted a tube containing radium into a tumour and found that 
radiotherapy caused the tumour to regress. This was both the first medical use of 
radiotherapy and the start of brachytherapy. Brachytherapy is derived from the Greek 
word brachios meaning ‘short’ and describes the key concept that in brachytherapy 
the radiation source is introduced only a short distance from the tumour (in an existing 
body cavity) or inserted into the tumour, usually with a needle (as opposed to external 
beam radiotherapy where the source might be further away). The Curie centre in
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Paris continued to pioneer brachytherapy and was paralleled by centres in the USA 
including the Memorial Hospital in New York (forerunner o f the Memorial Sloan 
Kettering Cancer Centre).
Pasteau and Degrais experimented with radium for the treatment o f prostate cancer 
using a transurethral radium pellet and experimental radium needles (105). By 1917, 
Barringer had inserted radium needles transperineally into the prostate, guided by a 
finger in the rectum. Unsurprisingly (given the lack o f any available measure o f the 
radiation dose given to the prostate) these treatments were not effective, but 
researchers continued their efforts having observed the effects o f radiation on normal 
and cancerous tissues.
Surgeons continued to attempt after-loading in advanced cancers where they believed 
that they could not resect the tumour completely. Isotopes with better activity for
1QO zn i^r O'}
treatment of tumours, including Gold, Cobalt, Iodine, and Phosphorus, were 
developed in the Ohio state university and used for medical implantation. These were 
more suitable than Radium, which has a very long half-life (1602 years for the most 
stable isotope Radium) which makes it less useful for permanent implantation.
1 ORIn 1952, Flocks injected radioactive Gold solution in prostatic cancer during open
iL
operation. Initial problems with brachytherapy in the first half o f the 20 century 
caused by issues with source placement and isotope availability (with higher than 
ideal energy delivery) suggested that brachytherapy might have limited use in prostate 
cancer.
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12;>Iodine (12:>I) is a radioactive isotope o f iodine which is encased in titanium ‘seeds’
125to perform brachytherapy. “ I is a low dose-rate source o f radiation that emits 
gamma rays with a half life o f around 60 days. Gamma radiation is characterized by 
high frequency and high-energy particles with a relatively short wavelength and hence 
an ability to produce a relatively high dose within a small field, making it ideal for 
brachytherapy.
Five years after they were first produced in 1967, W hitmore et al described retropubic
p r
Iodine seed implantation through an open operation with pelvic lymph node 
dissection (106). He aimed to control localized disease with a combination o f 
brachytherapy and pelvic lymphadenectomy (Figure 10). More recently seeds 
containing 13'Caesium  and 10jPalladium have been commercially produced and these 
are in clinical use in some centres for prostate brachytherapy.
Figure 10. Transabdominal brachytherapy implant according to W hitmore et al (106)
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Unfortunately the advances in technology in terms o f producing seeds with 
reproducible doses o f radio-isotopes were not accompanied by advances in seed 
delivery techniques such that many o f the 1970’s implants (e.g. figure 11, below) had 
such poor dose distribution that cure was infrequent.
Figure 11. X-ray o f patient after transabdominal brachytherapy implant and 
lymphadenectomy showing surgical clips from lymphadenectomy and seeds from 
brachytherapy
Surgical Clips 
Iodine Seeds
In 1983 Prof Hans Holm working at the University o f Copenhagen in Denmark 
described interstitial seed brachytherapy using a template and combined transverse 
and longitudinal trans-rectal ultrasound imaging. This was the beginning o f the 
current renaissance o f brachytherapy in the treatment o f localized prostate cancer. 
The 1980s saw the possibilities o f more accurate source placement (107, 108) evolve 
with widespread reports o f successful brachytherapy treatment at a variety o f sites. 
Prostate cancer was treated using ultrasound and CT imaging to improve the accuracy 
o f source placement.
• 1Q9High dose rate (HDR) brachytherapy where Iridium sources are used to deliver 
large doses o f radiotherapy per fraction at a high dose rate either as monotherapy or in
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combination with a course of external beam radiotherapy was also developed in the 
1980s and 1990s (109). HDR brachytherapy involves using pre-placed catheters, 
which are inserted percutaneously into the prostate to deliver 1-3 fractions o f high 
dose rate brachytherapy. The use of a remote after-loading device allows the sources 
to dwell at varying times along the course o f the catheter to optimise dose 
distributions. Dose rate is the amount o f radiation delivered per unit time in Gyh'1. 
The American Association o f Physicists in Medicine (AAPM) define high dose-rate 
treatment as >12Gyh'1, low dose rate treatment as <0.5Gyh'1 with the intervening 
category described as medium dose-rate treatment (110).
HDR brachytherapy has potential advantages in locally advanced prostate cancer 
where delivering dose (to a planned treatment volume) outside the prostate capsule 
may be required for successful treatment. There are also theoretical radiobiological 
advantages to giving large doses per treatment fraction (see explanation o f the a/p 
ratio in prostate cancer p84-86).
Delivery of low dose-rate brachytherapy - use of hormones and external beam 
radiotherapy in combined brachytherapy treatments
Low dose-rate Brachytherapy (BXT) has been used as treatment for localised prostate 
cancer with a variety o f treatment plans. Treatment plans have included:
i. BXT as monotherapy
ii. BXT combined with neoadjuvant androgen deprivation (HBXT)
iii. BXT combined with androgen deprivation and external beam radiotherapy
(BXTC)
iv. BXT with EBRT but without androgen deprivation
- 7 0 -
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In 1999 a USA based patterns of care survey of 51 facilities, reviewed the case notes 
of 36,496 men treated with radiotherapy for prostate cancer (111). This included 
13,293 men who received some form of prostate brachytherapy and o f these 90% had 
LDR treatment. 46% had BXT, with 54% having some form of external beam 
radiotherapy in addition to their implant, and 40% received AD treatment. Clearly all 
of the options described above make up part o f contemporary practice in the USA and 
it is likely that practice patterns in the UK are similar although I was not able to find 
evidence o f any nationally collated data.
Androgen deprivation for prognostic benefit
The place o f neoadjuvant and adjuvant androgen deprivation combined with BXT is 
unclear due to a lack o f studies with an experimental design. However interest has 
been stimulated following observations o f a synergistic effect on the treatment of 
localised(112) and locally advanced (113-115) prostate cancer using external beam 
radiotherapy. Three non-experimental studies are discussed which illustrate the lack 
of agreement on the prognostic benefit o f neoadjuvant AD before brachytherapy in 
the current literature.
Two non-randomised studies from the same centre have suggested that there might be 
a benefit in terms o f PSA relapse free survival associated with the use o f androgen 
deprivation prior to a BXT implant in intermediate risk disease (75, 116), however 
both studies had significant methodological flaws. These flaws included shorter 
follow-up in the hormone treated group which can radically affect the results of  
studies that use the American Society o f Therapeutic Radiology and Oncology
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(ASTRO) definition o f failure (three PSA rises after a post-treatment PSA nadir) by 
underestimating failure where follow-up is short. In addition patients who received 
implants with good dosimetric results (Dose to 90% of the prostate [D90] >140 Gy) 
did not benefit from androgen deprivation (75, 116). This suggests that the effects of 
neoadjuvant AD may be to reduce the frequency o f diagnosing early treatment failure 
in series with short follow-up where good dosimety was not always achieved.
Potters et al showed no benefit from the addition o f AD in a series o f 1,449 patients 
who underwent brachytherapy implant +/- EBRT +/- AD. In this non-experimental 
study they used multivariate analysis and demonstrated no benefit to AD in any risk 
group with median follow up o f 6.8years (maximum follow up 12 years) (117).
Although the American Brachytherapy Society guidelines have not been revised since 
1999, their recommendation was for androgen deprivation only to reduce prostate 
volume before implantation and not for prognostic reasons in high risk disease (118) . 
This remains consistent with the published conflicting evidence o f no definite benefit.
Neoadjuvant androgen for cytoreduction before brachytherapy
In larger prostates access to the anterior part o f the prostate gland may be difficult 
due to the pubic-arch preventing placement o f needles into the anterior gland and this 
may prevent an implant being undertaken (119). Such pubic arch interference may be 
prevented in larger prostates by using AD to shrink the prostate (cytoreduction).
The best agent for cytoreduction of the prostate before brachytherapy has not been 
investigated by experimental studies. Lutenising hormone-releasing hormone
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(LHRH) analogues are the standard treatment for cytoreduction prior to prostate 
brachytherapy with typical reductions in prostate volume o f 32-35%(120, 121). 
Larger reductions may occur in patients with larger initial prostate volumes (122).
LHRH analogues have a significant adverse event rate including hot flushes, night 
sweats, loss o f libido, gynaecomastia and may be associated with impotence rates 
during treatment of 80-100% (123-125). Bicalutamide 150mg as monotherapy has 
equivalent efficacy (no significant difference in all cause mortality or disease 
progression) to medical or surgical castration in locally advanced non-metastatic 
prostate cancer at a mean follow-up of 6.3 years (126). Bicalutamide as adjuvant 
treatment after external beam radiotherapy compared with placebo for locally 
advanced disease has been shown in 305 patients followed up for a median of 5.3 
years in the Casodex® early prostate cancer research study to be associated with a 
hazard ratio o f clinical disease progression o f 0.58 (95% Cl 0.41-0.84; P=0.003)(127). 
However, differences have been seen in the efficacy o f bicalutamide in managing 
patients with metastatic disease at presentation where a hazard ratio o f death o f 1.3 
was associated with bicalutamide as opposed to medical (LHRH analogue) or surgical 
castration.
Bicalutamide is well tolerated with gynaecomastia and breast tenderness the main side 
effects of treatment(128) . Studies on the quality o f life o f patients with metastatic 
and locally advanced prostate cancer comparing Bicalutamide at the 150mg dose to 
castration (orchiectomy or Goserelin) demonstrated a significant advantage in favour 
of bicalutamide in the physical capacity and sexual interest subscales (129). Although 
the sexual function assessment was hampered in this questionnaire study by a poor
Chapter 2.5
response rate to the sexual function subscales, an impotence rate o f 8% has been 
reported in a physician-assessed study (128). Bicalutamide (Casodex) has been 
advocated as adjuvant treatment for patients treated with curative intent using external 
beam radiotherapy (EBRT) or BXT (130) and reduces prostate volume in benign 
disease (131). Bicalutamide may be an alternative to LHRH analogue treatment for 
prostate volume reduction before brachytherapy.
External beam radiotherapy
In the era before intensely modulated radiotherapy (IMRT) and 3-dimensional 
conformal radiotherapy were widely available, brachytherapy combined with external 
beam radiotherapy was considered as one means o f giving high dose conformal 
radiotherapy to the prostate in patients where radiotherapy treatment o f the pelvis was 
thought to be desirable. The rationale for giving combined brachytherapy and EBRT 
is now justified by two arguments.
The first argument may have more relevance to the practice o f brachytherapy before 
the current era. During the technological evolution of brachytherapy when dosimety 
at the time o f implant or based on post-operative computed tomography (CT) scan 
was less advanced or not attempted, accurate seed placement within the prostate was 
difficult to verify. In situations where seed placement is suboptimal an area of  
prostate tissue receiving an inadequate dose o f radiation can occur. Giving external 
beam radiotherapy with brachytherapy increases the radiation dose to the prostate and 
may be used ‘fill in’ any under-dosed areas o f prostate by the so called ‘spackle 
effect’ described in the USA literature (132). Some authors who adopted 
brachytherapy early with poor results have advocated brachytherapy only as part of
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combination treatment with external beam pelvic irradiation (133). In the current era 
when CT scanning is routinely performed to confirm the quality o f the implant the 
routine use o f external beam radiotherapy for this indication is perhaps less important.
The second argument advanced by institutions that use combined EBRT and 
brachytherapy even although they report good dosimetric results from their BXT 
implants is that the role o f external beam radiotherapy may to be useful in treating 
prostate cancer outside the prostate capsule. The tissues close to the prostate may be 
locally invaded by undetectable microscopic deposits of cells as the disease spreads 
through the capsule (134). It is also possible that combined EBRT and BXT may 
improve results by treating micrometastasis to lymph nodes within the pelvis(134).
To my knowledge there is no definite evidence from studies with experimental 
designs that EBRT improves the results o f brachytherapy in patients who have good 
dosimetry but it has frequently been prescribed in the management o f high and 
intermediate risk prostate cancer because o f relatively poor results from early 
brachytherapy in these groups (135). Current American Brachytherapy Society 
Guidelines (produced in 1999) recommend BXT monotherapy only in patients with 
TNM stage Tl-2a disease, serum PSA<10 and Gleason sum <6 tumours with EBRT 
and brachytherapy boost for all higher risk tumours. Recently 2 institutions with good 
reported dosimety for BXT as monotherapy have reported excellent PSA recurrence 
free survival in intermediate-high risk EPC with both BXT monotherapy (136, 137) 
and with combined EBRT + BXT treatment (134, 138).
Chapter 2.5
The degree of benefit will be explored by studies currently randomising patients to 
BXT +/- EBRT (in the USA based Radiation Therapy and Oncology Group protocol 
RTOG0232 and protocol NCT00241384 at the Schiffer Cancer Centre, West Virginia, 
USA, which are both recruiting intermediate risk patients).
Androgen deprivation with external beam radiotherapy and brachytherapy
The assumption that androgen deprivation given as neoadjuvant/adjuvant treatment 
alongside BXT and EBRT treatment (BXTC) is mostly extrapolated from literature on 
EBRT where addition o f AD to standard EBRT is known to be beneficial in localised 
(112) and locally advanced (113-115) prostate cancer.
In brachytherapy no experimental studies have compared BXT plus EBRT with or 
without androgen deprivation and I could find no evidence that experimental studies 
are planned. Two studies from two centres illustrate the conflicting outcomes from 
high risk patients in whom AD was either given or omitted.
Potters et al described a matched pair analysis o f 263 patients who received AD with 
cytoreductive intent or no AD prior to BXT or BXT plus EBRT. High risk men who 
underwent BXT plus EBRT did not benefit from AD (in terms o f improvement in 
PSA recurrence-free survival) (139). Merrick et al followed 204 patients with high 
risk prostate cancer treated with good quality iodine or palladium implants (mean D90 
110-120 Gy in each group) as a boost after 45 Gy EBRT and with or without 
androgen deprivation (non-randomised) with a median follow-up o f 7 years. This 
group did not show a cancer-specific survival benefit to either <6m or longer
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treatment but biochemical failure was less common in patients who underwent 
treatment with HBXT (140).
The place of combination brachytherapy (BXTC) compared with implant or EBRT 
plus implant is unclear but is clearly part o f practice in the USA (111).
Chapter 2.6 - Urological issues in patient selection for brachytherapy
LDR-seed brachytherapy is suitable for the treatment o f organ confined prostate 
cancer. It is not a treatment without toxicity. Several prospective studies have 
identified urinary toxicity, principally storage and voiding lower urinary tract 
symptoms (LUTS) and acute urinary retention (AUR) as common events (chapter 2.9, 
table 11, p i04). Although clinically significant symptoms seem to be self limiting 
(141, 142) in the majority o f patients reported in the current literature they may result 
in protracted LUTS or catheter use. Incontinence rates o f between 20 and 40% have 
been reported when BXT is combined with TURP to relieve longstanding LUTS 
(143-147).
Previous studies have suggested that the risk o f AUR, and hence o f bladder outflow 
surgery when retention does not spontaneously resolve, is related to pre-treatment 
International Prostate Symptom Score (IPSS) (146). Although treatment o f urinary 
symptoms with alpha-blockers such as Tamsulosin reduces symptoms post-treatment 
(in terms of IPSS) randomised studies have not identified a reduction in rates o f AUR 
(148).
Patients undergoing rigorous pre-treatment selection (with IPSS <9 in 74% of  
patients treated with BXT) have been reported to have rates of acute urinary retention 
as low as 5% with only half o f these patients eventually requiring surgery to relieve 
retention or intractable lower urinary tract symptoms (LUTS) (146). However other 
centres in America and Europe have not achieved such low rates o f AUR with a 
typical incidence of 7-15% (149-151).
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A summary o f previously reported prognostic factors for acute urinary retention is 
presented in table 8 (p82). Predictive factors were considered by the European 
Association o f Urologists (EAU), European Society for Therapeutic Radiology and 
Oncology (ESTRO) and the European Organisation for Research and Treatment of 
Cancer (EORTC). The EAU/ESTRO/EORTC group issued guidelines (Table 7, 
below) for selection and treatment o f patients (152) recommending preoperative 
patient evaluation with IPSS score and urodynamic studies, recording maximum flow 
rate and post-void urine volume. Although the use of the IPSS to select patients is 
evidence-based (144, 146) the guidance on functional assessment o f voiding was 
unreferenced and may be less useful.
Table 7. EAU/ESTRO Guidelines for selection and treatment of patients suitable for 
LDR-Brachytherapy (152)_____ _______________ _______________________________
Brachytherapy Outcome
Recommended 
/Do Well
Optional
/Fair Investigational 
/Do Poorly
Presenting PSA (ng/ml) <10 10-20 >20
Gleason Sum 5-6 7 8-10
TNM Stage Tlc-T2a T2b-T2c T3
IPSS 0-8 9-19 >20
Prostate Volume (cc) <40 40-60 >60
Q-max (ml/s) >15 15-10 <10
Post-Void Residual Urine 
Volume (ml)
>200
Previous TURP +
IPSS scores may be employed as a screening tool to assess symptom burden however 
they are a qualitative measure of LUTS and correlate poorly with degree of 
urodynamic obstruction since they are not designed to quantify bladder outflow 
obstruction or diagnose detrusor instability (153).
Uroflowometry is also a useful screening test which may help to rule out bladder 
outflow obstruction (BOO) particularly when flow rates are normal or supranormal.
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However there are significant limitations with the technique. Voided urine volumes 
above 150ml are required to give a clinically useful trace and acquiring this data is 
dependent on patients arriving in outpatient clinics able to void (154). There is also a 
subset o f patients who despite normal uroflowometry have significant BOO and 
compensate for this by greatly increasing the intravesical pressure either using a 
voluntary increase in intra-abdominal pressure or due to involuntary increase in 
pressure generated by the detrusor muscle o f the bladder wall (154).
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Chapter 2.7 -Radiotherapy: terms, measurement and mode 
of action
Measurement of radiotherapy and dose units
Louis Harold Gray was the inventor o f many of the concepts o f modem radiobiology. 
His name is given to the standard (SI) unit for absorbed dose, specific energy and 
kerma (kinetic energy in matter). 1 Gray is the dose o f energy absorbed by a 
homogeneously distributed material of mass 1 Kg when exposed to ionising radiation 
bearing 1 joule o f energy. Therefore 1 Gray (Gy) = 1 J/Kg (Older nomenclature 
described Rads, lGy = 100 Rad).
The Sievert (Sv) is the SI (International System) unit of dose equivalent radiation, 
named after Rolf Sievert (a Swedish medical physicist)(165). It attempts to recognise 
that the biological effects o f radiation as opposed to its physical properties which are 
measured in Gray (Gy). Sieverts are still measured in J/Kg hence the different 
eponymous SI units. The Sievert is derived by multiplying the dose in Gy by a 
(dimensionless) radiation weighting factor rW. The rW is the product o f two 
constants. The quality constant Q, depends upon the type o f radiation delivered and 
the mode o f delivery. The other constant N  depends on the type o f tissue irradiated 
with highly radiosensitive tissues, for example gonadal tissue or bone marrow, having 
higher N values than less sensitive tissues such as bone.
The dose equivalent (measured in Sieverts, Sv) is used to give an idea o f the relative 
exposure to radiation necessary to perform a variety o f medical procedures including 
both diagnostic and therapeutic radiology/radiotherapy. The natural background 
effective dose varies considerably (depending on environmental exposure to differing 
levels of cosmic radiation and natural radioactivity (in the UK Radon gas is an
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example o f radioactivity that significantly affects background radiation dose) but 
typically is around 2.4 mSv/year.
Other units o f radiation measurement are the Bequerel (Bq) which is the SI unit for 
radioactivity; defined as one radioactive disintegration/second. Derived from this is 
the Curie (Ci), which was originally the radioactivity o f one gram of radium. More 
recently the Curie has been redefined as 3.7x1010 Bq as a standardisation to cope with 
the differing activity o f radium’s different isotopes. This is relevant as seed activity is 
described in milli-Curies mCi.
Basic radiobiology
The delivery of ionising radiation to cells has a variety o f effects. The physical phase 
consists o f interactions between the charged particles o f the ionising radiation and the 
atoms from which the tissue is composed. These particles can cause ejection o f  
orbital electrons from the atoms making up a cell (ionisation) or raising o f excitement 
levels within the atoms or molecules (excitation) (166). These instant reactions to 
ionising radiotherapy are termed the physical phase.
The physical phase is followed by the chemical phase, which is the period in which 
damaged atoms and molecules react with other surrounding material. These reactions 
frequently result in breaks in the bonds that bind atoms together as molecules. The 
broken molecules or ‘free radicals’ are destabilised by the effects o f ionising 
radiation and then tend to undergo further reaction with other surrounding molecules 
in order to reach a state o f electronic charge equilibrium. In fact, free radicals are so 
unstable that they generally complete their initial series of reactions within one 
millisecond o f the delivery o f the radiation.
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The last and least predictable phase o f the effect o f ionising radiation on cells is 
termed the biological phase. This is the effect of the radiation that happens after the 
initial reaction of the free radicals with the cell. It includes enzymatic reactions to 
repair damage to the critical structures o f the cell (particularly the DNA). The effect 
of a lesion to the cell’s DNA depends on number o f factors and the majority o f lesions 
would be repaired prior to the next cellular mitosis. Lesions to DNA would cause cell 
death if  a particular cellular function was prevented, for instance, by a block in the 
DNA coding relating to expression of a protein or to the structure o f the protein 
required for cell survival. For proteins that are not needed often in a cell’s life cycle 
or for low-level DNA damage more than one mitosis may occur before cell death.
The responses of tissues to radiation are complex with no well defined tolerance dose 
or tumoricidal dose available. Curves describing the populations o f cells being 
destroyed have however been produced with survival ranges o f 0-100% vs. radiation 
dose. The linear quadratic model is a means o f modelling the effects o f radiation on 
populations o f cells. It is an equation that is used to model the cell survival curves.
The Linear Quadratic formula for cell survival is:
P(survival)=exp(-aD-pD2)
Where: P=probability of cell survival
D=radiation dose
t
a (in Gy' )and p (in Gy' ) are constants for defining any effect o f radiation in a tissue 
(e.g. cell death in prostate cancer cells or telangectasia in skin). For functional tissues 
such as the prostate in vitro, biochemical failure (detectable and rising levels o f PSA 
in serum samples above 2ng/ml (167)) has been used to produce recurrence-free
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survival curves and these are then used to give an estimate of the a/p ratio (in Gy) for 
prostate cancer by considering data from various fractionation schedules (168) .
Early and Late Radiation Effects
Side effects o f radiotherapy have traditionally been described as early effects and late 
effects. Early effects arise from the effects of ionizing radiation on the stem cells of 
normal tissues (166). Stem cells are semi-differentiated cells that are able to divide 
indefinitely to provide a pool o f cells to replace those lost due to apoptosis 
(programmed cell death), disease or trauma. Death o f significant stem cell 
populations can cause breakdown o f skin, mucosal membranes, the intestines and 
myelosuppression of the haematopoietic system. Thus the onset o f early symptoms 
corresponds to the lifespan of the differentiated cells and their rate o f replacement 
from the stem cell population. In treatments such as external beam radiotherapy 
where single doses (fractions) o f a planned course o f radiotherapy are given at 
separations o f days or weeks, early reactions are more common when there is a short 
period between fractions.
Late effects o f radiation are defined as those occurring at >90 days post treatment and 
may occur years after radiotherapy (166). They may include fibrosis and 
telangectasia o f the skin, lung fibrosis, bone necrosis and even spinal cord or nerve 
damage. Late reactions are typically permanent and often affect slowly dividing 
tissues. Whilst different late reactions have differing patterns, it is true in general that 
for fractionated treatments increased dose per fraction seems to increase the incidence 
of many known late effects.
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An increased number o f tumours are described in radiated tissues than in those of 
patients of similar ages who have not been irradiated. This probably reflects 
inactivation o f critical genes such as tumour suppressor genes by radiation-mediated 
DNA damage.
The a/p ratio is different for different tissue types with typical early reacting tissues 
such as skin having high a/p ratio (Desquamation a/p=9.1-12.5 Gy, atrophy of healthy 
testis a/p=12-13 Gy) whereas late reacting tissues have much lower a/p ratio (Lumbar 
spinal cord a/p=2.3-4.9 Gy).
Prostate cancer is thought to have a relatively low a/p ratio of 2-5Gy (168, 169) . 
This means that large doses per fraction may be advantageous in terms o f cancer 
control although proof o f this from randomised trials such as the Conventional or 
Hypo-fractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer 
(CHHIP) trial is awaited (170).
Chapter 2.8 - Quality of life and symptom measurement in early 
prostate cancer
The World Health Organisation (WHO) defined health as ‘a state o f complete 
physical, mental and social well-being, and not merely an absence o f disease’ in 1946. 
Since then interest has been increasing in collecting data which attempts to measure a 
variety o f symptoms and increasingly the more holistic construct of quality o f life.
How is quality of life defined ?
Quality o f life is an ill-defined concept o f wellness. In order to measure wellness in 
studies o f medical treatment outcome it has been necessary to try to define it more 
completely as different individuals describe wellness in differing ways (171). For 
some individuals feelings of wellness might be defined by external events such as 
success o f a football team for an ardent fan whereas others might have feel that their 
quality o f life was poor without access to time with their family.
The World Health Organisation Quality o f Life Group defined quality o f life as ‘an 
individual’s perception of their position in life in the context o f the culture and value 
systems in which they live and in relation to their goal, expectations and standards and 
concerns. It is a broad ranging concept affected in a complex way by a person’s 
physical health, psychological state, level of independence, social relationships and 
their relationships to salient features of their environment’ (172).
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Quality o f life measurement in the setting of health studies is usually defined in a 
much narrower context. Health studies have asked a number o f questions o f patients 
which attempt to cover a variety o f outcomes. These might include; feelings o f  
general health, ability to function physically and perform tasks, the presence or 
absence o f various symptoms relevant to specific disease processes and functional 
questions on levels o f physical, emotional, role, sexual and cognitive functioning 
(173).
Questionnaires have usually been used to determine patient reported outcomes. This 
has helped remedy problems with under-reporting o f toxicity after treatment when 
health professionals record the answers to symptom indices (patients and physicians 
report very different outcomes even in studies where the same question is 
administered to both) (174) and helps with blinding of health professionals to study 
outcome.
Due to the diverse nature of these possible areas o f study and the differing ways in 
which questionnaires attempt to handle them it is critically important at the design 
stage o f the research project that a clear research question is identified. Given that 
most questionnaires target specific areas o f the spectrum of issues which may affect a 
patients ‘quality o f life’ the research question should ideally state explicitly which 
areas o f quality of life are to be addressed and not merely that the study will report on 
‘quality o f life’ after an intervention.
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What do quality of life questionnaires measure?
Evolution o f questionnaires (or instruments) for measuring quality o f life has been 
rapid. A range o f instruments now exist which attempt to reflect the effect o f illness 
and treatment on the patient. Instruments range from simple symptom indices like the 
International Prostate Symptom Score (IPSS) to measure urinary symptoms which 
reflect only the severity of a limited range o f symptoms to general instruments such as 
the RAND Short Form-36 (SF36) which are designed to measure the more complete 
construct o f health related quality o f life (HRQOL).
Most instruments which attempt to measure HRQOL include measures o f both 
objective functioning and subjective wellbeing. Levels o f function can be assessed 
against current ‘gold standards’ such as observed physical performance in order to 
determine their utility. Subjective wellbeing raises different challenges and may be 
heavily influenced by psychological factors unrelated to physical performance status 
or to changes in patients criteria for appraising wellbeing (175).
Objective functioning domains in HRQOL questionnaires usually include questions, 
which assess physical performance. Hence they are prone to report reduced health 
related quality of life with increasing age. They also mostly include self assessment 
of cognition.
Wellbeing and ‘emotional function’ are areas subjectively assessed areas o f HRQOL 
which are more difficult to assess against a gold standard as there are few alternatives 
to patient reported measures.
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Most HRQOL questionnaires do not report a total quality o f life index number made 
up o f several domains. Rather they report each domain separately (domains are 
usually a summary score made up of related questions) and end with a single 
‘wellness’ question to sum up the impact o f these on the individual.
In clinical practice the use o f questionnaires is unlikely to ever become routine due to 
time constraints. However in a research setting they are invaluable as they add an 
objective and patient-centred assessment of outcome from treatment. Questionnaire 
selection has a significant impact on the ability o f a study to answer a research 
question. A number o f factors which are reproduced in Table 9 (below) must be 
satisfied when assessing appropriateness of questionnaire selection.
Table 9. Properties required o f measures used for HRQOL research. Reproduced 
from Higginson & Carr (176).
Property
Required
Method of Assessment
Does the measure cover aspects that are clinically relevant to patients, 
their families and to healthcare professionals ? (Face Validity)
Are the domains appropriate, important and sufficient for the setting or 
types o f patients being studied? (Content Validity)
Validity Does the measure correlate with a gold standard or superior measure? 
(Criterion Validity). If this is not known because a gold standard does 
not exist then an alternative question is whether the measure produces 
results which correlate with a theory, e.g. for a measure o f weakness does 
this correlate to advanced stage disease or poor exercise tolerance
Appropriateness Is the measure short/long enough for completion in the planned setting
and Is the format and language suitable for the intended setting?
acceptability Has it been used successfully in this or similar settings?
Reliability
Does the measure produce the same results when repeated in an 
unchanged population?
Includes inter- (and intra-) observer variability, test-retest reliability and 
internal consistency (a test o f whether questions in a subscale correlate 
with one another)
Responsiveness Can the measure detect clinically meaningful changes in the measured domain?
Interpretability Do the results from using the measure have clinical relevance?
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Conduct of HRQOL Studies
HRQOL literature has in the past suffered from methodological weakness. These 
have at times resulted from the use o f questionnaires without the necessary properties 
for the required study. Frequently HRQOL studies have been added as an 
afterthought to prospective research on prostate cancer outcomes such as biochemical 
disease free survival or all cause survival.
Clearly when HRQOL measures are used to compare treatments a prospective 
approach which includes baseline HRQOL assessment adds valuable information and 
helps to confirm that patients were comparable prior to treatment. Repeated 
administration o f the instrument in a longitudinal study design will be necessary to 
give the best understanding o f the patient’s experience o f symptoms over time. If 
retrospective study designs are used then recall bias, where patients report symptoms 
less accurately than in studies where the questionnaires are administered in a 
contemporary setting, may be a significant problem (177-179).
It is also clear that late toxicity may occur following either radiotherapy or surgery 
after the first year and although this is rarely severe, inadequate follow-up or cross 
sectional studies with assessment at variable time intervals may mask significant 
toxicity.
Despite the obvious advantages of randomised clinical trials in terms o f avoiding 
allocation bias practical difficulties have limited recruitment o f prostate cancer 
patients into this type of study.
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Currently only a single study has collected HRQOL data from patients randomised 
between surgery and radiotherapy. Akakura et al (180)randomised 95 men to 
treatment with RP and adjuvant endocrine therapy (stilboestrol or LHRH analogue) 
vs. EBRT and adjuvant endocrine therapy and showed no significant difference in 
biochemical or clinical progression, all cause or prostate cancer-specific survival at 10 
year follow-up. Unfortunately the HRQOL element o f this study(181) was typical of  
the ‘afterthought approach’ o f much o f the published HRQOL research. It reported 
HRQOL assessment o f the 46 surviving patients 3-8 years post randomisation, none 
of whom completed a baseline questionnaire. It used a validated questionnaire (the 
EORTC GU questionnaire which has now been superseded by the EORTC 25 item 
prostate cancer questionnaire (PR25) for reporting prostate cancer morbidity). This 
study although small suggested that surgical patients had greater risk o f incontinence 
but that EBRT patients had more difficulty with urination and haematuria. The study 
also reported that RP patients had greater psychological distress and worse social 
activity and functional status scores which the authors attributed to the effects of  
urinary incontinence in Japanese men.
It was also disappointing to see that the first study (182) to achieve recruitment of  
patients randomised to RP or watchful waiting (a major achievement in itself) gave 
suboptimal quality of life data due to the omission o f a baseline questionnaire, use of 
an non-validated instrument and a lack o f control data in age matched men with the 
chosen instrument.
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Despite the lack o f evidence from studies comparing HRQOL in patients randomly 
allocated to radical treatment in EPC; increasing evidence from well followed cohorts, 
studied with prospective longitudinal designs is becoming available and most o f the 
studies which are currently recruiting (RTOG 0232 and ProtecT), comprise some 
form of HRQOL assessment.
Although recommendations from the American Brachytherapy Society for reporting 
HRQOL and symptoms following BXT are available(183) there is currently no 
consensus as to the most accurate method of reporting toxicity in studies comparing 
BXT to RP or EBRT.
It is important that validated questionnaires, which attempt to reflect changes in those 
symptoms most relevant to patients, are adopted in all future studies to gain the 
maximum information from these costly studies in which recruitment still remains a 
significant obstacle. It may also be important to include questionnaires which score 
the bother that symptoms cause to patients so that if  new urinary symptoms emerge 
with the development o f new treatments that these are measurable at least in a global 
bother of symptoms question. Data may be lost if  exhaustive and overly specific 
symptom scales are used in isolation e.g. using the International Prostate Symptom 
Score (IPSS) to measure symptoms in radical prostatectomy indicates a consistent 
improvement in symptoms after surgery as the scale fails to include questions on 
incontinence and hence misses clinically significant toxicity (184, 185).
It is also important to recognise the differences between cohorts of patients compared 
in most o f the currently available literature and avoid direct comparisons between
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groups of patients in non-randomised studies. Such reports may be significantly 
confounded due to selection criteria for men currently deemed suitable for treatment 
using the different modalities. Even more important to resist is the temptation to 
directly compare patient and physician reported end-points which are often 
significantly different (174).
How is quality of life assessed in prostate cancer?
Selection o f an appropriate quality of life measure is determined by the characteristics 
of the study group (literacy, language, tolerance to questioning about study areas e.g. 
sexual history), the outcome o f interest and the way you wish to measure it. It may be 
useful to have a portfolio o f questionnaires available to study outcomes o f particular 
interest within trials. Particular research questions may also necessitate the 
development of new questionnaires.
The preparation of a new HRQOL instrument requires extensive testing to determine 
its reliability, validity and clinical significance. The psychometric validation process 
is unfamiliar to many clinicians; however it is essential that the questionnaires chosen 
for and reported in, HRQOL studies are validated, ideally within the group being 
investigated.
Face validity (relevance to clinically significant outcomes reported by patients) and 
content validity (assessment o f the importance and appropriateness of the reported 
domains) are often assessed by expert opinion. Criterion validity (a measure o f  
correlation with a gold standard) is sometimes reported. Where a questionnaire is
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used to measure mobility it might be possible to correlate score with time to walk a 
set difference, this is generally regarded as unfeasible in QOL research particularly 
when related to general health related quality o f life.
Although attempts have been made to compare measures of erectile function using 
pharmacological testing to measure penile tumescence this is not equivalent to 
erectile/sexual function and hence it is unsurprising that only loose correlations have 
been observed (186). During a recent structured literature review o f erectile function 
outcome reporting after radical prostatectomy rates of complete erectile failure ranged 
from 26-100% for the same treatment and led the American Urological Association’s 
guideline panel to state that until consensus is achieved on reporting erectile 
dysfunction in clinical trials the figures will remain relatively unhelpful (187). 
Likewise questionnaires on lower urinary tract symptoms may correlate poorly with 
objective measures o f good function such as normal flow rate but not all patients with 
a reduced flow rate would have bothersome urinary symptoms (153).
Even when appropriately valid measures have been identified the selection o f the 
most appropriate measure for any clinical trial may be determined by practical factors 
such as brevity and available translations.
Questionnaires commonly used to assess outcome after radical treatment in previously 
published studies for prostate cancer are outlined in table 10 (p96). A suggested 
portfolio o f questionnaires was developed and published by a consensus panel 
(including radiation oncologist, urologist, HRQOL expert and gastroenterologist) and 
is outlined in the discussion and appendix VIII (p332) (188).
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Table 10. Common questionnaires in prostate cancer HRQOL research.
Heath Related Quality o f Life (HRQOL), Cancer-specific Quality o f Life (CSQOL), Prostate Cancer- 
specific Quality o f Life (PCSQOL), Symptom Index (SI), Short Form 36 (SF36), Functional 
Assessment o f Cancer Therapies-General (FACT-G), FACT-Prostate (FACT-P), European 
Organisation for Research and Treatment o f Cancer Quality o f life Questionnaire (EORTC QLQC30), 
EORTC Prostate-25 (EORTC PR25), University of California Los Angeles-Prostate Cancer Index 
(UCLA-PCI), Expanded Prostate cancer Index Composite (EPIC), International Prostate Symptom 
Score (IPSS), International Index o f Erectile Function (KEF). Items refers to number of questions 
asked.
1 Name Type Items | Assesses | Advantages Disadvantages
RAND
SF36
(SF 12/8)
HRQOL 36 HRQOL Benchmark, well 
validated questionnaire 
for assessment o f general 
heath related QOL. 
Available in 44 
languages.
Insensitive in EPC, doesn’t 
attempt to measure disease- 
specific items.
Shortened by removing questions 
which correlate strongly with 
each other to SF 12 then to SF 8 
to increase compliance
FACT-G CSQOL 34 CSQOL Well validated instrument 
applied to cancers in 
general
No disease-specific items. 
Usually paired with disease- 
specific subscale (FACT-P)
EORTC 
QLQ C30
CSQOL 30 CSQOL Well validated instrument 
widely used in oncology 
trials. Validated in most 
European languages.
Like FACT usually paired with a 
disease-specific module (PR25)
FACT-P PCSQOL 13 Weight 
Loss, Role, 
ED, LUTS
Brief, designed to work 
with FACT-G and scored 
as a total with FACT-G
Assessment o f LUTS but not 
urinary incontinence. May be 
insensitive to change in EPC
EORTC
PR25
PCSQOL 25 ED, Bowel,
Urinary and
toxicity
from
androgen
deprivation
More comprehensive, 
suitable for assessment of 
localised and metastatic 
disease. Suitable for 
assessment o f patients 
post surgery, BXT or 
EBRT
Newer questionnaire still 
awaiting publication o f validation 
studies
UCLA-
PCI
PCSQOL 20 Urinary, 
sexual and 
bowel
function and 
bother
Comprehensive 0 Often paired with SF36 to assess 
assessment o f common | HRQOL. Lack of brevity may 
side effects following RP I decrease return rates. Urinary 
and EBRT I function assesses solely
I incontinence and does not include 
I irritative LUTS
EPIC 
(EPIC 26)
PCSQOL 50 ED, Bowel,
Urinary
function and
toxicity
from
androgen
deprivation
Designed to compare 
results o f treating early 
disease with BXT, EBRT 
orRP. Expanded version 
of UCLA-PCI
Validated in the USA only, lack 
of brevity limits clinical use. 
Does not assess HRQOL so 
usually paired with SF12 or 
SF36. Heavy weighting towards 
LUTS vs. incontinence. 
Shortened by removing questions 
which correlate strongly with 
each other to EPIC 26 to increase 
compliance
IPSS SI 8 LUTS Well validated index of 
LUTS, familiar to 
urologists
Not exhaustive (doesn’t assess 
incontinence, haematuria or 
dysuria)
IIEF
IIEF-5
SI 15 ED Well validated, familiar, 
available in abbreviated 
form (sexual health index 
for men, comprises five 
erectile subscales of IIEF)
Concentrates on function and 
doesn’t assess effect o f ED on 
HRQOL. Only validated in 
sexually active patients with 
female partner
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Chapter 2.9 - A systematic review of quality of life following low 
dose-rate brachytherapy and studies describing direct comparisons 
with other radical treatment options for early prostate cancer
Search strategy and selection criteria
Modem techniques for brachytherapy have evolved over the last 15 years. Prior to 
this dose inhomogeneity and lack o f quality assurance made reports o f outcome 
unrepresentative o f the modem technique. Systematic literature review spanned 
1990-2007 (Date o f final search, August 1st 2007) using Medline, the Bath 
Information and Data Services Database (BIDS), the Cochrane Collaboration, 
EMBASE and Cinahl. The Search terms: “Brachytherapy” and “Prostate Cancer” or 
“Prostate Neoplasm” were merged with “Quality o f Life” or “Symptoms” or 
“Questionnaire”. Studies which reported quality o f life or questionnaire reported 
health outcomes following LDR brachytherapy (BXT) or comparing LDR BXT to 
other treatment options were included. Review articles were reviewed for secondary 
references but are not discussed further in this review. The recent review o f the 
literature by the National Institute for Clinical Excellence was also hand searched 
(86).
The search results are outlined in figure 12 (p98). 22 studies have compared LDR 
Brachytherapy with other treatments; 15 o f them were published by 5 centres (4 in the 
USA and 1 in Japan). 12 Studies used longitudinal designs with baseline assessments 
of symptoms and the majority o f these studies (n=9) utilised the UCLA-PCI 
questionnaire popularised by Litwin’s group, which has no domains to assess non­
leakage urinary symptoms (although often the IPSS was co-administered). Thus 
further high quality studies may still contribute useful data.
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Figure 12. Search strategy for systematic review of HRQOL and symptomatic 
outcome after treatment with LDR-prostate brachytherapy
Dates of Publication 1992-2007 Last 15 years (n=202)
Human, Male, Studies reported in English (n=185)
Above Search with Limits as Below:
Table 8: Comparisons between LDR Brachytherapy and Other Treatments
(n=22)
Description of Selected Papers (n=54)
Table 7: Short and Long Term Toxicity of Brachytherapy
Uncontrolled Series of Brachytherapy patients describing HRQOL (n=13) 
Uncontrolled Series of Brachytherapy patients describing symptoms (n=19)
Hand Search of Papers (review papers used only for secondary 
references). Excluded: Papers without any data on Low-Dose Rate 
Brachytherapy and papers dealing only with questionnaire 
development but without any clinical data
Papers Describing Outcome of 
Questionnaire Symptom Scales (n= 19)
Papers Describing HRQOL (n= 35)
Search of Medline, BIDS, Cochrane Library, EMBASE and Cinahl
Prostate Cancer” or “Prostate Neoplasm” and “Quality of Life” or 
“Symptoms” or “Questionnaire” and “Brachytherapy” (225)
Date: August 1st 2007, Number of Papers Available in Brackets
Quality of Life” (n=92,205), “Symptoms” (n=5,732, 590), 
Questionnaire” (n=233,246), “Brachytherapy” (n=12,750) 
“Prostate Cancer/Prostate Neoplasm” (n=34,700),
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What changes in quality of life are observed after brachytherapy?
Most men in the USA are not symptomatic before treatment for EPC and hence 
HRQOL questionnaires have difficulty in separating age matched controls from 
prostate cancer patients (189). Consensus from the American Brachytherapy Society 
(183) has identified urinary, bowel and sexual morbidity as areas most commonly 
affected after treatment with prostate brachytherapy and recommends prospective 
reporting of toxicity in these areas using validated questionnaires. The effects of 
treatment may depend greatly on patient selection (age, pre-treatment potency, pre­
treatment urinary symptoms, prostate volume etc) and whether BXT comprises seed 
monotherapy, or includes neo-adjuvant androgen deprivation or short course EBRT 
(see chapter 2.5). Indeed some studies report LDR and HDR brachytherapy together 
(190) or group all patients who have received ‘pelvic irradiation’ i.e. BXT of any type 
or EBRT together (191). Many questionnaire studies concentrated only on one area 
of toxicity. Table 11 is therefore divided up by type of symptom reported after LDR- 
Seed Brachytherapy. Table 12 contains comparisons between brachytherapy and 
other modalities.
Acute Morbidity
Acute morbidity might be defined as toxicity experienced by the patient within the 
first year post-implant. Acute morbidity is likely to result from a combination o f  
radiation effects and local trauma due to needle placement and usually resolves with 
conservative treatment.
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Although a statistically significant decrease in HRQOL at 1 month post treatment has 
been demonstrated following BXT as monotherapy using the Functional Assessment 
of Cancer Therapy-General (FACT-G) instrument in a study with longitudinal design 
(192, 193), the changes at >3 months were not statistically significant suggesting that 
the effects o f BXT on HRQOL are short-lived. This has been confirmed in a 
longitudinal studies (190) by Litwin et al in America using the SF36 although a 
French group led by Buron et al (194) using the EORTC QLQ-C30 reported a 
deterioration in general HRQOL following brachytherapy o f ‘a little’ clinical 
magnitude up to 24m.
When the Functional Assessment o f Cancer Therapy-Prostate (FACT-P) module was 
used to assess HRQOL by Lee et al (192), statistically significant differences were 
detected at up to 3-months. This correlated with clinically significant changes in IPSS 
(>3 points(195)) which persisted for 3 months post-implant. However Lee et al (192, 
193) and other investigators (196) have shown using the IPSS that urinary function 
within the first year does not return to baseline although the changes are not clinically 
significant at > 3 months.
Incontinence is relatively rare following BXT with 1% incidence o f new pad use 1 
year post-treatment in patients from a longitudinal study treated with seeds alone 
(197). Sexual function deterioration following brachytherapy has been reported in a 
variety of studies in varying ways. Using the international index o f erectile function 
(a questionnaire designed initially to measure fine changes in sexual performance in 
order to assess the efficacy o f drugs such as the Phosphodiesterase inhibitor 
Sildenafil,Viagra®) as a measure o f potency gives potency preservation rates of 
around 50% at 3 years with possible later deterioration (see late morbidity).
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Late morbidity
Cross sectional studies o f patients following BXT have revealed a variable incidence 
of late toxicity which was more prevalent in older studies(198) when case selection 
and treatment planning to minimise radiation dose to critical structures (urethra, 
rectum) prior to BXT was evolving.
In cross-sectional studies it is difficult to assess the impact o f treatment on a 
population which is known to report a significant prevalence o f incontinence (33%), 
rectal symptoms (33%) and erectile dysfunction [ED] (60%) in the absence of a 
prostate cancer diagnosis (199). Much of the late morbidity in the past may have been 
due to prolonged urinary symptoms that have resulted in a need for TURP leading to 
increased risk o f incontinence (198). In early series it may not have been recognised 
that a generous TURP following BXT results in physician-reported incontinence rates 
of up to 40% (143-147). Since this complication has been recognised and a protocol 
of conservative management o f lower urinary tract symptoms(LUTS) within the first 
year followed by minimal resection where necessary adopted, most physician- 
reported series (142, 196) report incontinence rates o f <1% following contemporary 
brachytherapy.
Recent cross sectional series demonstrate no significant difference in IPSS or the 
Expanded Prostate cancer Index Composite (EPIC) urinary subscales between BXT 
patients at a mean o f 5.5 years post BXT and age matched controls with early prostate 
cancer (200). Improved late morbidity is likely to be due to a combination of 
improved case selection (patients with smaller prostate glands and fewer urinary 
symptoms) and realisation o f the importance o f minimising urethral radiation dose 
and avoiding post-implant TURP.
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Later longitudinal studies by Litwin et al using the UCLA-PCI to assess ‘urinary 
control’ seem to suggest that post-brachytherapy continence returns to baseline in at 
least 90% o f patients at 2 years post treatment (190). A longitudinal French study 
showed by Buron et al 12.5% of men who underwent brachytherapy reported new 
urinary incontinence based on replies to the EORTC PR25 questionnaire (194). These 
are relatively sensitive measures (radical prostatectomy was reported to be associated 
with a 68.5% deteriorated rate in the Buron study (194) with a 70% deteriorated 
continence rate reported by Litwin’s group (190). Clearly there are a significant 
number of patients reporting ‘incontinence’ o f urine who do not wear an incontinence 
aid such as a pad. It may be more appropriate to report % affected by severe 
incontinence or % affected by bother related to the use of an incontinence aid. To 
date this information has not been specifically reported.
Late onset urinary symptoms have been assessed in a longitudinal study by Miller et 
al (2 cross sectional assessments at 1.75 and 6.2 years post treatment with no 
baseline). This study showed a consistent improvement at 6.2 years from paired 
earlier post-treatment (1.75 years) reporting o f urinary frequency, urinary pain and 
haematuria (201). These symptoms were however at a significantly higher level at 
both assessments than those observed in an age matched cohort o f healthy controls 
who were followed up with questionnaires at baseline and 4.5 years later.
Some series report subsequent further deterioration in IIEF score to 39% potent at 6 
years although these measures are highly dependent on the patient attempting 
intercourse regularly which is not confirmed in the study and where the mean age o f  
participant at 2nd (6 year assessment) was 69. Frequency o f intercourse attempts may 
be significantly affected by a 6 year age increase. Little control data is available to
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suggest how many patients in such a cohort we would expect to become impotent 
without BXT however one study by Miller et al (201) reports a 10% increase (from 
19% to 29%) in reporting of poor/no ability to get erection over during a 4.5 year 
period o f observation in age matched men without a history o f prostate cancer. The 
same study reported a similar increase in erectile failure among brachytherapy 
patients o f 11% over a 4 year period (between years 2 and 6 o f follow-up).
Hormones and EBRT in combined brachytherapy treatments
Cross sectional HRQOL studies have suggested that the androgen deprivation cohort 
of patients had worse sexual function and sexual bother than patients treated with 
BXT alone(202). In the absence o f RCT evidence these studies add weight to the 
suggestion in a physician reported study o f sexual function by Potters et al (203) that 
androgen deprivation prior to BXT may have long term effects on potency although 
there are studies which suggest short course androgen deprivation does not affect long 
term potency (204).
Patients receiving EBRT combination therapy have been compared with cohorts of 
patients receiving seeds alone in studies using cross sectional (205) and longitudinal 
(197) designs. Although most patients with more aggressive disease received 
androgen deprivation, these studies suggested that combination therapy produced 
significantly worse physical and emotional domain scores on the SF36, worse urinary 
function and bother and worse sexual and bowel bother on the University of 
California Los Angeles -  Prostate Cancer Index (UCLA-PCI) when compared with 
BXT alone.
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Table 11. Patient reported complications following prostate brachytherapy and impact 
on QOL.
Morbidity Incidence
Mean 
Duration of 
Symptoms
Impact On HRQOL Ref.
Increased
LUTS 80-95%
6-24 months
Symptoms assessed with IPSS tend to peak at 
4-8 weeks and result in decreased HRQOL 
for up to 3 months(192,193). Kleinberg et al 
describe typical changes of increased 
Nocturia (80%), dysuria (48%) and 
frequency (71%) with a modified 
(unvalidated) RTOG scale.
(192, 193, 
196,206)
Urinary
retention 12% 2 weeks
Postal questionnaire. Similar figures from 
recent reviews(158, 207) suggest that for 
urinary retention requiring catheterisation 
physician reporting is acceptable. HRQOL 
impact not separately assessed in 
questionnaires but probably normalised by 3- 
months in line with urinary bother(192, 193).
(208)
Urinary
Incontinence 1-2%
Reported at 
12 months 
FU
Several cross sectional studies and one 
prospective longitudinal study(197) using 
UCLA PCI report highly variable prevalence 
(See table 12).
(197)
Impotence
Potency Preserved 
(HEF-5>13) in 
51% at 3 and 
39% at 6 years
Permanent
2 reports from longitudinal study (which 
included patients treated with EBRT) have 
prospectively reported using a validated 
symptom index (IIEF-5) and baseline 
potency was not assessed with IIEF. If the 
higher scores achieved following treatment 
with sildenafil (Viagra™) where necessary 
are used then the 6 year impotence rate was 
8%.
(209, 210)
Potency Preserved 
(IIEF-EF >11) 
50-80% 3 years
2 separate studies show 80-50% potency 
preservation after treatment at 3 years but a 5 
point mean change in IIEF-EF domain score 
is about half the change expected if  men with 
moderate degree ED stopped Sildenafil.
(204,211)
Rectal
Bleeding/
diarrhoea
12% Deteriorated
X-sectional 
study with 
mean FU of 
66 months
No longitudinal studies available using 
validated SI or HRQOL measure and 
American Brachytherapy Society guidelines 
have not suggested a patient completed 
questionnaire. Several cross-sectional 
studies report bowel function and bother to 
be more prevalent than in age matched 
controls but await prospective confirmation 
see comparative studies (Also see Table 12)
(212)
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What are the differences between patients treated with brachytherapy and other 
modalities?
The currently published evidence has not yet convincingly answered the question o f  
which therapy produces the least toxicity for patients, not least because patients 
choosing treatment with different modalities tend to experience different toxicities, 
the significance o f which may be weighted differently by different men. In addition 
those series where baseline morbidity was clearly reported tended to show significant 
heterogeneity o f function at baseline (often associated with much older men 
undergoing EBRT and BXT). Statistical modelling adjusts poorly for this as the 
baseline function/HRQOL is usually the factor most closely related to long term 
outcome and explains up to 40% of variance in multivariate analysis(213).
Table 12. (p i07) summarises the current HRQOL literature comparing curative 
treatment in EPC. It is clear that all o f the current treatment modalities have some 
adverse effects on either sexual, urinary or bowel function and that some patients find 
these symptoms bothersome. It is also clear that the majority o f men report normal or 
near normal general HRQOL both in the first year following modem radical 
treatments and at further follow-up (191) and that some improvement in long term 
HRQOL (Emotional fimction/Role Function may result from treatment (214)).
Although a lack of detail in reporting baseline function and a lack o f studies with 
randomised designs have produced a somewhat confusing picture the trends in studies 
to date suggest that BXT patients, particularly when androgen deprivation has not 
been used, have better sexual function than patients who received either EBRT or RP.
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Incontinence is greatest following RP in most o f the reported literature. The UCLA- 
PCI only reports urinary incontinence (not voiding or urgency symptoms) in the 
urinary function subscale but also includes a more holistic urinary bother subscale 
which may explain an apparent paradox where men report more incontinence 
following RP but similar levels o f urinary bother. This is not because incontinence is 
not bothersome but due to the prevalence o f storage or voiding symptoms following 
BXT or EBRT, which are bothersome to patients, but not scored in the urinary 
function subscale o f the UCLA-PCI.
Bowel function (diarrhoea) is reported to be worse in most o f the studies comparing 
BXT to radical prostatectomy but several o f these have not separated BXT patients 
from patients treated with a combination o f BXT and external beam radiotherapy 
which adds morbidity in most o f the domains o f the UCLA-PCI. For those studies 
where a percentage o f men affected is defined, effect size is frequently unavailable. 
For those studies describing a mean effect size number of men adversely affected is 
often omitted.
Table 12. Studies comparing HRQOL following radical treatment for early prostate cancer. Radical 
Prostatectomy (RP), Laparoscopic Radical Prostatectomy (LRP), External Beam Radiotherapy 
(EBRT), Watchful Waiting (WW), Brachytherapy monotherapy (BXT), Brachytherapy combined with
| Study Design Groups | Instrument | Summary & Comments
Litwin et al 
(189)
JAMA 1995
Cross
Sectional
(No
baseline)
RP
EBRT
WW
Controls
UCLA PCI 
SF36
1 N=528. USA. Worse sexual and urinary function 
reported by radical prostatectomy patients did not 
translate into worse bother scores. Patients who 
received EBRT had worse bowel function but were 
no more bothered. No significant changes in general 
| HRQOL were demonstrated.
Brandeis, 
Litwin et al 
(205)
J.Urol
2000
Cross
Sectional
(No
baseline)
RP
BXT
BXTC
Controls
UCLA PCI 
SF36
1 N=122. USA. Questionnaire administered at variable 
length of follow-up (mean 7.5 months). No 
difference in HRQOL between groups. BXT and 
BXTC groups analysed separately. Urinary function 
was best in controls, then in BXT patients and worst 
following RP or BXTC. Bowel function was 
equivalent in all groups except the BXTC group 
which had worse bowel function. Sexual function 
was best preserved in the BXT group followed by 
equivalent scores in the RP and BXTC groups.
Krupski, 
Theodorescu 
e ta l(  215) 
Urology 2000
1 Cross 
Sectional 
(No 
1 baseline)
RP
BXT
BXTC
FACT G 
IPSS
+2 unvalidated 
questionnaires
N=242. USA. Questionnaire administered at variable 
period of follow-up Similar FACT G scores within 
group. IPSS score lower after RP than BXT/C but 
other scores unvalidated and hard to interpret.
Davis,
Schellhammer 
et al (216) 
J.Urol 2001
Cross
Sectional
(No
baseline)
RP
EBRT
BXT
Controls
UCLA PCI
SF36
TAG
Life/Family
N=633. USA. Variable length o f follow-up (mean 22- 
37 months), which was significantly different 
between treatment groups. Controls had best urinaiy, 
bowel and sexual function. BXT patients had more 
LUTS assessed using the IPSS but better sexual and 
urinary function as assessed by the UCLA-PCI than 
RP patients and EBRT was associated with worse 
bowel and better urinary and sexual function than RP.
Lee e ta l(  192)
IJROBP
2001
Prospective
Longitudinal
Non-
Randomised
RP
EBRT
BXT
FACT-P
IPSS
N=90. USA. Small, well designed study comparing 
the major treatments with a longitudinal design. Both 
RP and BXT produced decrease in FACT P scores at 
1 and 3 months post implant with largest reductions 
in the RP group. Significant improvement occurred 
by 3 months and by 1 year scores had returned to 
baseline in all groups. EBRT had less marked 
changes in HRQOL using the FACT P however the 
follow-up period o f 1 year would tend to favour 
outcome with EBRT as late morbidity was not 
assessed.
Fulmer, 
Theodorescu 
e ta l(  197) 
Cancer 2001
Prospective
Longitudinal
Non-
Randomised
RP
BXT
BXTC
Selected 
elements of 
UCLA PCI 
IPSS
N=212. USA. Shortened UCLA PCI at several 
periods of follow-up (max 18/12). All BXT/BXTC 
patients had AD. RP patients had best baseline 
sexual function, sexual bother and urinary function 
followed by BXT then BXTC. RP patients had the 
worst postoperative urinary function (leakage) but 
were no more bothered than other patients, perhaps 
because o f irritative symptoms in the BXT and 
BXTC patients. RP patients initially had worse 
sexual function and sexual bother scores but these 
became comparable to BXTC patients at 18 months. 
RP patients were the group with the lowest % chance 
o f returning to baseline erectile function or urinary 
control at all points o f follow-up.
- 107-
Chapter 2.9
Table 12. Studies comparing HRQOL following radical treatment for early prostate cancer. Radical 
Prostatectomy (RP), Laparoscopic Radical Prostatectomy (LRP), External Beam Radiotherapy 
(EBRT), Watchful Waiting (WW), Brachytherapy monotherapy (BXT), Brachytherapy combined with 
external beam radiotherapy (BXTC), Androgen Deprivation (AD); Pelvic Irradiation of any sort (PI)
Study Design | Groups Instrument | Summary & Comments
Wei,
Litwin,
et al
(217) .
JCO
2002
Cross 
Sectional 
(No baseline)
RP
EBRT
BXT
N= 902
Age
Match
Controls
N=112
SF36
FACT-P
EPIC
1 N=1014. USA Study hampered by administration of 
questionnaire at variable time post-therapy and lack of 
baseline questionnaire. No information on AD therapy 
given. HRQOL not different between primary treatment 
groups however greater urinary bother sexual, bother and 
bowel bother reported by BXT patients than EBRT or RP 
patients (pO.001). All groups were inferior to age 
matched controls in all domains (p<0.001).
Penson et 
al(191) 
JCO 
2003
Cross
Sectional
2-years
post treatment
(Retrospective
baseline)
WW
AD
RP
PI
SF36
PCI
N=2036. USA. Assessed HRQOL and PCSQOL 2 years 
post treatment. ‘Baseline’ questionnaire not administered 
at a fixed point in follow-up. HRQOL not significantly 
different 2 years post treatment independent of primary 
treatment. RP or AD associated with lower % chance of 
erections sufficient for intercourse than WW or PI 
although RP and PI had the best sexual function pre­
treatment. Baseline potency WW 58%, AD 57%, PI 65%, 
RP 61% compared with 2 year potency WW43%, AD 
30.5%, PI, 44.5%, RP 19.7%. RP had a 21.5% chance of  
resulting in frequent urinary leakage or no control 
compared with 1.9%, 3.3% and 4.7% for AD, PI and 
WW respectively. Bowel function was not separately 
reported.
Talcott et 
al (213) 
JCO 
2003
Prospective
Longitudinal
Study
EBRT
RP
BT
SF36
Talcott
Symptom
index(218)
N=417. USA. 24m follow-up. Difficulty with 
interpretation o f data due to validated but not widely used 
symptom scales. Significant differences in baseline 
function between groups (urinary function problems in 
RP>EBRT>BXT and ED in EBRT>BXT>RP). Baseline 
urinary incontinence (1% daily leak) and rectal function 
similar in all groups. Baseline function alone best 
predicts outcome in each area except for sexual 
dysfunction where RP predicted worse outcome than the 
rest o f the cohort. In the RP group incontinence was 
much worse than after EBRT or BXT. 24m Urinary 
obstruction/irritation resulted in minor decrease after RP 
compared with no change after EBRT and a minor 
increase after brachytherapy. ED was worst after RP and 
EBRT (but baseline ED was least in RP group) and 
slightly less prevalent in the BXT group (RP outcomes 
better with nerve sparing but still worse than 
EBRT/BXT).
Downs et 
al (219) 
JUrol 
2003
Prospective
Longitudinal
Study
EBRT
BXT
BXTC
RP
SF36 and 
UCLA-PCI
N=419. USA. Men from the CAPSURE (Cancer o f the 
Prostate Strategic Urologic Research Endeavour) 
database (BXT n=93, RP n=327). Patients treated with 
BXT or RP did not differ greatly in general HRQOL after 
treatment. Both treatment groups showed transient 
impairment in general domains with scores approaching 
baseline at 18 to 24 months. Patients treated with BXT 
had significantly higher urinary function scores at 0 to 6 
months post treatment than patients treated with RP. 
Urinary bother scores at 0 to 6 months after treatment 
were not significantly different between patients treated 
with BXT or RP. Both treatment groups had decreases in 
sexual function that did riot return to pre-treatment levels.
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Table 12. Studies comparing HRQOL following radical treatment for early prostate cancer. 
Radical Prostatectomy (RP), Laparoscopic Radical Prostatectomy (LRP), Robotic Radical 
Prostatectomy (RRP), External Beam Radiotherapy (EBRT), Watchful Waiting (WW), Brachytherapy 
monotherapy (BXT), Brachytherapy combined with external beam radiotherapy(BXTC), Androgen 
Deprivation (AD); Pelvic Irradiation of any sort (PI)
Study Design Groups Instrument Summary & Comments
Bradley, 
Theodorescu 
et al 
(220)
BJUi 2004
Cross
Sectional
BXT
BXTC
RP
FACT-G
IPSS
N=214. USA. Poor quality study which attempted to 
control statistically for the different time points o f cross 
sectional survey between groups . Unreliable findings. 
Initially better sexual outcomes after BXT did not 
persist. BXT produced worse IPSS scores. FACT did 
not identify quality o f life differences by group.
Litwin et al 
(221)
JUrol 2004
Prospective
Longitudinal
Study
EBRT
BXT/BXTC
RP
Bowel 
Function 
Scales of 
UCLA-PCI
N=1584. USA. Men from the CAPSURE database. 
Bowel function and bother worse after EBRT and to a 
lesser extent BXT than RP but BXT not analysed 
separately from BXTC.
Borchers 
e ta l (214) 
BJUi 
2004
Prospective
Longitudinal
Study
BXT
RP
EORTC 
QLQ C30
ICS Male SF
Kelly (faecal 
Incontinence)
N= 132. Germany. Small study o f 38 RP with nerve 
sparing (NS), 42 RP and 52 BXT patients. No AD use 
mentioned. Much older patients for RP and BXT (>6 
years) than NS-RP. Outcomes were reported at 1 year. 
Incontinence was RP>NS-RP>BXT. Non-bothersome 
stool incontinence was RP=NSRP<BXT. Sexual 
Function was RP>NS-RP»BXT. Emotional function 
improved by all treatments.
Speight 
et al (222) 
IJROBP 
2004
Prospective
Longitudinal
Study
EBRT
BXTC
HBXT
BXT
Sexual 
Function 
Scales of 
UCLA PCI
N= 992. USA. Men CAPSURE recruited with follow- 
up to 2 years. Validated but not optimum questionnaire 
for assessment o f sexual function and bother. BXT 
Patients reported better function and the least change in 
function of any group. Patients receiving BXTC 
reported the greatest decline in function and EBRT 
patients also reported significant decline. Function 
scores associated with HBXT were initially lower than 
in patients with BXT; however by 1 year no statistically 
significant difference in function o f bother were noted.
Soderdahl 
Schellhammer 
etal(223) 
J.Endourol 
2005
Prospective
Longitudinal
Study
LRP
RP
BXT
SF36
UCLA-PCI
IPSS
N=240. USA. patients evenly distributed between 
treatments with 12m follow-up. Younger patients 
(mean 8 years) in the LRP/RP group. SF36 domains 
deteriorated after treatment but returned to baseline 
levels with no difference by treatment at 12m. By 12m 
the RP and LRP patients reported worse sexual function 
and bother and worse urinary function but similar levels 
of urinary bother to BXT patients. Poor completion 
rates (as low as 50% of patients for RP and BXT) and 
suboptimal choice o f questionnaires limit the 
information from this study.
Ball,
Schellhammer 
e ta l (224)
J.Endourology
2006
Prospective
Longitudinal
Study
Baseline and 
1,3,6,9,12, 
18,24,36m 
post
treatment
BXT
Cryotherapy
RP:
Open-
Surgeiy
LRP
Da-Vinci
RRP
UCLA-PCI
IPSS
NO HRQOL
N=719. USA. Significant age differences described 
(Surgical groups median 59,61,60, BXT=67, Cryo=72). 
Results processed in two groups to cope with age 
disparities (G1 surgeiy, G2 BXT/Cryo) limiting 
generalisability.
Group 1: Sexual Function Better with RRP>LRP=ORP 
(p=0.03), other domains similar 
Group 2: Sexual function better after Brachytherapy 
than cryotherapy (63% vs. 18% returned to baseline 
scores). Early (<6m) overall urinary function better 
after BXT than Cryotherapy (p0.05). IPSS scores 
worse at 3m after BXT than cryotherapy.
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Table 12. Studies comparing HRQOL following radical treatment for early prostate cancer. 
Radical Prostatectomy (RP), Laparoscopic Radical Prostatectomy (LRP), External Beam Radiotherapy 
(EBRT), Watchful Waiting (WW), Brachytherapy monotherapy (BXT), Brachytherapy combined with 
external beam radiotherapy(BXTC), Androgen Deprivation (AD); Pelvic Irradiation of any sort (PI)
Study Design Groups Instrument Summary & Comments
Miller et al 
(201)
Later follow- 
up of patients 
described by 
Wei, Litwin et 
al (217)
JCO 2005
Cross
Sectional
(No
baseline)
RP N=488
EBRT
N=114
BXT N=65
Age Match 
Controls
SF12
FACT-P
EPIC
USA. N=709 Survivors of the Wei study able to 
consent, Returned questionnaire with equal response 
rate by group. Age distribution still an issue (older 
patients EBRT and BXT) and obviously highly selected 
group undergoing BXT (almost 7x greater number of 
RRP done at institute suggests that if  patients were fit 
for RRP then this was the delivered treatment). 
HRQOL not different between primary treatment 
groups however greater urinary bother sexual, bother | 
and bowel bother reported by BXT patients than EBRT 
or RP patients (pO.OOl). All groups were inferior to 
age matched controls in all domains (pO.OOl). Urinary 
irritative, urinary incontinence, bowel and sexual 
function as assessed by EPIC all worst for BXT even 
when adjusted for age and length o f follow-up but this 
as the authors admit is likely to reflect patient selection. 
Improvement rather than the expected deterioration in 
post BXT sexual function suggests AD was commonly 
still active at first assessment.
Namiki et al 
(225)
Urology 2006
Prospective
Longitudinal
Study
Baseline and 
1,3,6, 12m 
post­
treatment
BXT
Open-RP
SF-36
UCLA-PCI
IPSS
N=137. Japanese. RP significantly lower scores in 
several domains of the SF-36 at 1 month (P <0.05), 
self-limiting within 6 months. BXT patients - no 
significant changes in any general HRQOL domain to 
12m. RP lower post-treatment urinary function score, 
which reflected leakage, than the BT group. However, 
the BT patients experienced a significantly delayed 
recovery of the urinary bother score. Data from IPSS 
Score showed adverse effects from BT on voiding 
symptoms for the initial 6 months after treatment. No 
differences in bowel symptoms. RP associated with 
worse sexual function than BT, although nerve-sparing 
surgery minimized the difference
Kakehi et al 
(226)
J.Urol
2007
Cross
Sectional
(No
baseline)
RP
EBRT
BXT
AD & WW
EPIC N=460. Japanese Group. Main focus is validation of  
EPIC in Japan.Variable follow-up and lack of baseline. 
Bowel domain scores worst after EBRT. Worse 
urinary function scores for RP with <lyear vs. >1 year 
follow up and similar worse scores in a group o f  
patients who underwent brachytherapy <1 year vs. >1 
year ago.
Frank et al 
(227)
Authors from 
Davis et al 
2001 paper
J.Urol 2007
Cross
Sectional
(No
Baseline)
RP
EBRT
BXT
EPIC N=625 (of 960 treated patients in USA) completed the 
survey after treatment in 1998-2000. No AD was used. 
Significant mean age discrepancy; RP: 61, BXT:64, 
EBRT:68. Different lengths of follow-up; RP:4 years, 
BXT:3.5 years, EBRT:4.7 years. EBRT worse bowel 
function (p<0.0001) and both EBRT and BXT worse 
bowel bother than RP (p<0.0001). Urinaiy 
Incontinence worst after RP (p<0.001) than other 
treatments. Urinary incontinence worse than control 
after EBRT but not BXT. Urinaiy function better after 
EBRT than RP (but not BXT) pO.OOl). BXT and 
EBRT worse urinary irritation (p<0.01) than RP. BXT 
had better sexual function than RP and EBRT (P<0.01). 
Urinary and sexual bother similar between 3 modalities 
but worse bother than control group (p<0.01).
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Table 12. Studies comparing HRQOL following radical treatment for early prostate cancer. Radical 
Prostatectomy (RP), Laparoscopic Radical Prostatectomy (LRP), External Beam Radiotherapy 
(EBRT), Watchful Waiting (WW), LDR-Brachytherapy monotherapy (BXT), LDR-Brachytherapy 
combined with external beam radiotherapy (BXTC), Androgen Deprivation (AD), Pelvic Irradiation of  
any sort (PI), HDR-Brachytherapy combined with external beam radiotherapy(HDR-BXTC)
Study Design Groups Instrument Summary & Comments
Buron et al 
(194)
IJROBP
2007
Prospective
Longitudinal
Multicentre
Study
Non-
Randomised
Baseline, 
end of 
treatment 
and 2, 6, 12, 
18, 24m post 
treatment
RP N=127 
BXT N=308
EORTC
QLQ-C30
EORTC
PR25
IPSS
collected and 
reported in 
discussion 
but no 
figures given.
N=435. Multi-centre French study. RP: open surgery 
(86%) Lap.RP (14%). Nerve sparing of patients 
undergoing RP not recorded. Patients receiving androgen 
deprivation not separately analysed but AD given with 
43.5% BXT and only 6.3% of RP treatments.
Quality o f life at the end of hospital treatment favoured 
BXT (moderate-severe differences in HRQOL) in all items 1 
o f QLQ-C30 other than nausea, diarrhoea and financial J 
problems. J
By >6 months post-treatment, changes had reversed with 
changes of ‘a little’ clinical significance in the general 
HRQOL domain only, in favour o f RP. Relationship to 
questionnaire responses unclear as the paper only shows 
change in score which does not allow the reader to assess 
baseline scores or comment on floor/ceiling effects. These 
are said to be significant in the discussion but no figures 
are reported.
EORTC scaling guidelines for PR25 not followed and 
individual questions reported at the discretion of the 
reporting team with only % of men deteriorating given (no 
magnitude of deterioration given). Urinaiy incontinence 
and erectile dysfunction more common after RP than BXT 
at all FU, however other urinaiy symptoms including 
urinary pain, urinary frequency and faecal symptoms 
(incontinence and bleeding) were more common after 
brachytherapy.
Litwin et al 
(190)
Cancer
2007
Prospective
Longitudinal
Study
Baseline and 
1,2,4,8,12, 
24m post­
treatment
RP N=307 
EBRTN=78
Combined
Analysis
LDRBXTor
HDR-BXTC
+/-AD
N=90
SF36
UCLA-PCI
IPSS
N= 475. USA. Recent trial with high rates o f cavemosal 
nerve sparing to the RP group (80% bilateral, 10% 
unilateral, 9.1% Non-nerve sparing).
Mean age was 60 ys for RP; 68 for BXT and 71 for EBRT 
with highest rates of diabetes and cardiovascular disease 
after BXT. Mixed treatment delivered to BXT group 
makes interpretation o f the results difficult.
Return to baseline defined as within 10% of baseline 
score. No significant differences in return to baseline 
scores by treatment for general HRQOL.
For Sexual function return to baseline function occurred to 
a greater degree for EBRT>BXT>RP. For urinary control 
EBRT=BXT >RP. For IPSS Score BXT worse than RP & 
EBRT. For Bowel function RP>EBRT=BXT. Sexual and 
Urinary bother similar by treatment but BXT and EBRT 
report more bowel bother.
Similarity of EBRT and BXT outcome explained by 
not separating HDR-BXTC from LDR-BXT.
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Patients’ expectations of toxicity from a particular form of therapy will have a 
powerful effect on their acceptance both o f the treatment at the time o f selection and 
of any side effects should they occur. It is unsurprising that patients are reasonably 
accepting o f the complications that they have been warned to expect. Acceptance, or 
the development o f coping strategies for decreased function, might be reasons for a 
general decrease in symptom bother scores (when these are reported separately) which 
seems to occur with studies where longer follow-up is reported. Regression to the 
mean might represent an alternative explanation.
This acceptance does not mean that the acute toxicity o f treatments is equal nor 
equally acceptable to all men. The popularity of BXT is evidence that a significant 
number o f men will choose the perceived lower risks o f impotence and incontinence 
which seem to be associated with this procedure at the expense o f an increase in their 
lower urinary tract symptoms(LUTS) in the first year following treatment. This trade 
off as to the bother o f incontinence or impotence vs. the bother o f LUTS is a highly 
personal matter and may be different for different men.
It is unknown whether the views o f men who have chosen a specific therapy because 
they believe that they would be most able to live with the toxicity o f that type of 
treatment can safely be generalised to other groups o f patients. In particular some 
patients might feel that increased LUTS or risk o f incontinence would be 
unacceptable despite a more favourable toxicity profile in other areas o f function.
Although randomised studies are therefore essential to allow us to better advise 
patients only 1 in 20 patients agreed to be randomised in a pilot study o f RP vs. EBRT
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following the failure o f the MRC PR06 study (228). Reports by the SPIRIT trialists, 
(prior to closure of SPIRIT for failure to recruit) that approximately 1 in 30 patients 
approached have accepted randomization, mean that those men who are willing to 
accept randomisation may not be representative o f the prostate cancer population in 
general.
Chapter 3 
Aims and objectives
Chapter 3.0 - Aims and objectives
The aims o f this study are to obtain knowledge and understanding o f the clinical outcomes of LDR 
brachytherapy for prostate cancer; to optimise selection o f patients and to obtain insight into which 
regime o f androgen deprivation before brachytherapy is most suitable for reducing prostate volume. 
To this end, the following objectives were set:
1. To investigate patient reported health-related quality o f life before and after brachytherapy 
for prostate cancer
2. To identify patient characteristics predictive o f the risk of urinary retention from 
brachytherapy
3. To determine the association between different pre-operative cytoreductive androgen 
deprivation regimes and prostate volume.
The first objective was investigated in a longitudinal study o f prostate cancer patients’ self-reported 
HRQOL before treatment and during the two years thereafter. This was called the prostate cancer 
symptom study (PCSS). The methods relating to the clinical management protocols o f the men 
undergoing brachytherapy in all three o f the described studies is covered in chapter 4.0. 
Questionnaire selection and validation and further details o f the design of the PCSS are covered in 
chapter 4.1. The results o f the PR25 questionnaire validation study are presented in chapter 5.0 
with chapter 5.1 describing the results of the PCSS itself. A discussion o f the methodology o f  
conducting studies o f ablative treatment in EPC forms chapter 6.0 with the outcomes o f the PCSS 
discussed in chapter 6.1.
The following hypotheses relating to HRQOL were addressed in the PCSS:
i. HRQOL following prostate brachytherapy will be reduced by clinically significant levels 
in the first year after brachytherapy but not afterwards.
ii. The duration o f changes in general HRQOL will be similar in patients treated with BXT, 
HBXT and BXTC.
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iii. The magnitude o f deterioration in sexual function and urinary function will be smaller in 
the BXT group than the HBXT and BXTC groups.
iv. The distress o f men treated for early prostate cancer will decrease with time after 
treatment as will the distress o f their partners
The second objective regarding the pre-implant identification o f patients at high risk o f toxicity was 
addressed by performing pre-implant urodynamic assessment, prostate volume studies, 
questionnaire assessment o f urinary symptoms and post-implant dosimetry to determine which was 
most predictive of acute urinary retention, which is a common problem after brachytherapy. The 
methods and results and discussion are described in chapters 4.2, 5.2 and 6.2 respectively. In the 
urodynamic study the hypothesis tested was that urodynamic assessment would identify patients 
with evidence of bladder outlet obstruction, which would predict urinary retention following 
prostate brachytherapy both in univariate analysis and when combined with known risk factors in 
multivariate analyses.
The third objective was addressed by investigating prostate volume reduction in a group o f patients 
who received androgen deprivation as part of their treatment. The hypothesis tested was that 
bicalutamide would have equivalent cytoreductive efficacy to goserelin when given as neoadjuvant 
treatment to patients prior to brachytherapy. In order to test this hypothesis prostate volume was 
measured in patients exposed to these drugs before brachytherapy and in patients who did not 
receive any androgen deprivation. Volume measurements were repeated at the time of 
brachytherapy implant to determine prostate volume reduction. This work is described in the 
methods chapter 4.3, results chapter 5.3 and discussion chapter 6.3. Finally, conclusions are drawn 
and recommendations made regarding HRQOL research (chapters 7.0 and 7.2) and brachytherapy 
treatment (chapter 7.1) in the future.
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Chapter 4 
Patients and methods
Chapter 4.0 - Brachytherapy protocols and patient selection
Many variations o f prostate brachytherapy using 125Iodine sources have been reported. Our 
treatment protocols are as follows and are summarised in figure 14 (p 121). These protocols were 
applied throughout the 3 research projects described in this thesis.
All patients were assessed using history, physical examination, transrectal ultrasound, International 
Prostate Symptom Score (IPSS), uroflowometry and post-void residual urine volume 
determination. Patients with post-void residual urine volumes above 200ml were offered 
alternative treatment. Previous TURP was considered a contraindication to brachytherapy if  there 
was a residual TURP defect on transrectal ultrasound scanning which would prevent source 
placement (see figure 13 a and b).
St Luke s  Cancer C e n tre .  G u ild fo rd  2003-08-20 88S8/T.
10-32 23 S .Orete 
FR = 3a5 6 ............................BRACHY............................... 6.4.
Figure 13a Transrectal ultrasound Figure 13 b Transrectal ultrasound
(Non-resected prostate) (Post TURP prostate with urethral defect)
Patients who had prostate volumes in excess o f 50cc received cytoreductive androgen deprivation. 
Significant pubic arch interference preventing anterior needle placement on the planning ultrasound 
(following cytoreduction if  necessary) was considered a contraindication to brachytherapy. The 
author has published a validation study o f this method o f checking for pubic arch interference 
(119).
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All patients were treated with 125Iodine sources. The prostate was contoured on a step-section 
transrectal ultrasound image and the clinical target volume (CTV) was defined as the capsule o f the 
prostate plus a 3-5mm lateral margin and a 2-3mm anterior margin with no margin posteriorly to 
limit rectal toxicity according to recent ESTRO guidelines (229). The planning target volume 
(PTV) was the same as the CTV. A minimum prescription dose (MPD) of 145 Gy to the PTV was 
used for patients treated with brachytherapy as monotherapy according to American Brachytherapy 
Society and ESTRO guidelines (118, 229, 230). Dosimetry for the clinical target volume o f the 
prostate was calculated from dose volume histograms and expressed as the highest dose to 90% of 
the prostate (D90) and the percent o f the prostate volume receiving 100% and 150% of the 
prescription dose (V I00 and V I50). The target dosimety ranges obtained on the preimplant plan 
were D90> MPD, V150 30-60% of CTV and V100>90% of the CTV.
The MSKCC risk stratification was used to divide patients into those with high medium and low 
risk disease as described in table 4, p52 (Zelefsky et al (74)). Patients described in this thesis were 
treated with BXT monotherapy if  they were in the low risk group. BXT monotherapy plus AD 
(comprising bicalutamide 150mg or LHRH analogue for 3 months prior to implantation) was used 
in the intermediate risk group or in patients who required cytoreduction as described above. High 
risk patients or patients with T3a disease received whole pelvis external beam radiotherapy at a 
dose of 45Gy in 25 daily fractions followed by a 110 Gy brachytherapy boost to the prostate. All 
of these patients received neoadjuvant androgen deprivation.
Preoperative alpha-blockers (Alfuzosin lOmg OD or Tamsulosin 400mcg OD) were used in 
patients with IPSS >15. Following brachytherapy, alpha-blockers were prescribed to all patients 
for three months or until bothersome symptoms resolved. In the event of urinary retention, patients 
were taught clean intermittent self-catheterisation (CISC) in preference to using an indwelling 
catheter in order to avoid bacterial colonisation o f the bladder (231). CISC was also used to
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improve symptoms in patients who although able to void suffered troublesome LUTS due to mild 
chronic urinary retention. Analgesia and anticholinergics were prescribed as needed.
Postoperative computed tomography (CT) for dosimetric analysis was performed as recommended 
by recent guidelines(229). CT scanning was performed 4-6 weeks post-implant for all patients. 
Dosimetry data was calculated from CT scans taken at 0.5cm intervals using Variseed 6.7 software. 
The prostate and rectum were outlined by a single consultant oncologist (R.W. Laing). The 
prostate and rectal volumes and the position of the seeds were then manually digitised from CT 
hardcopies on a lightbox. Dosimetry for the clinical target volume o f the prostate was again 
calculated from dose volume histograms and expressed as D90, V I00 and V I50. Recent guidelines 
have been produced recommending further dosimetry be undertaken to determine the dose to the 
organs at risk of toxicity from high doses o f radiotherapy (229). These include more detailed 
dosimetry o f the rectum and urethra. Though urethral dosimetry was obtained as part o f the study 
(detailed in Chapter 4.2, page 141), it was only performed in an exploratory manner in a limited 
number o f patients due to time constraints and difficulties with obtaining imaging with a catheter or 
contrast gel in the urethra to determine its position.
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Figure 14. Summarised treatment protocol for brachytherapy
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Patient offered BXT, BXT+AD or BXTC
Diagnosis o f Prostate Adenocarcinoma 
Made on Needle Biopsy
Voiding Studies (Uroflow+PVR)
Transrectal U/S (Check Volume)
Pre-implant Assessment
Clinical Review + IPSS
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Chapter 4.1 - Quality of life among patients treated with low dose- 
rate brachytherapy in the Prostate Cancer Symptoms Study
Commonly used questionnaires in quality o f life research are summarised in table 10, 
(p96). The Prostate Cancer Symptoms Study (PCSS) was designed to capture 
prospective data in a longitudinal study design.
Study design
The study design was a prospective longitudinal descriptive study collecting data to 
represent a variety o f outcomes to reflect the impact of radical treatment on men with 
prostate cancer and their partners. Study design is summarised in Figure 15. Phase 1 
will be reported in this thesis whilst patients recruited in phase 2 (running 
concurrently) will be published elsewhere as their follow-up is incomplete.
Figure 15. Summary o f design o f Prostate Cancer Symptom Study
Initial follow-up terminated at 2 years
PSA progression and recurrence recorded prospectively
Consent and collection o f  staging information
Baseline Pretreatment Questionnaires
Follow-up Questionnaires at 6 wk 3,6,9,12,18 & 24 months
Phase 1 Recruitment: Brachytherapy (BXT/HBXT/BXTC) 
Phase 2 Recruitment: RRP/Laparoscopic RRP/EBRT
Prostate Cancer - Symptoms Study
Patients Chose Method o f  Curative Treatment:
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Study population
The study population comprised men who have chosen radical treatment for prostate 
cancer (T 1-3, PSA<30, Negative MRI/Bone scan if  clinically indicated), with 
curative intent in one o f the participating centres. The study recruited men with any 
health characteristics and men who were either single or married (or have a partner). 
As sexual toxicity will be an important endpoint the study was powered to detect 
changes in a population o f men who potent and sexually active pre-procedure 
although this will not be an inclusion criteria. The brachytherapy element o f the study 
is now closed with adequate accrual except in the BXTC group.
Although it was initially thought that phase 2 o f the study (including patients 
undergoing surgery and radiotherapy as their chosen treatment) might be possible in a 
single centre (St.Luke’s Cancer Centre) recruitment difficulties led us to open the 
study at other centres and during this process we acquired Multi-centre Research 
Ethics (MREC) and National Cancer Research Network (NCRN) approval.
Hospital City Patient Groups Start Date
Royal Surrey County Hospital/ 
St. Luke’s Cancer Centre 
(NHS & Private Patients)
Guildford, Surrey BXT Sept 2001
BXTC
cEBRT
RP
Frimley Park Hospital (NHS) Frimley, Surrey LRP Oct 2001
North Hampshire Hospital (NHS) Basingstoke, Hants LRP Jan 2002
Hampshire Clinic 
(Private Patients)
Basingstoke, Hants LRP May 2002
St. Georges Hospital (NHS) Wandsworth, London RP May 2002
The London Clinic 
(Private Patients)
London RP June 2003
Bristol Royal Infirmary 
(NHS & Private Patients)
Bristol, Avon RP Sept 2002
LRP
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Treatment Specification for Phase 2 -  Prostate Cancer Symptom Study 
cEBRT
Conformal external beam radiotherapy was delivered according to standard treatment 
protocols in use at St.Luke’s Cancer Centre. These were derived from those described 
in the MRC-RT01 trial o f radiotherapy dose escalation in early prostate cancer. 
Radiotherapy was preceded by 3 months o f neoadjuvant androgen deprivation 
comprising either Goserelin 3.6mg monthly or Goserelin 10.8mg three monthly. 14- 
20 days cover with an antiandrogen was used to prevent tumour flare. CT based 
conformal planning methods were used. 74Gy o f radiotherapy was delivered in 37 
fractions over 7.4 weeks o f treatment.
BXT/BXTC
Brachytherapy as monotherapy or in combination with AD or as CBXT was 
performed as described in Chapter 4.0, p i 18.
RP
Anatomical radical prostatectomy was performed according to the method described 
by Walsh et al (232). Nerve sparing and pelvic lymph node sampling was at the 
surgeon’s discretion. Neo-adjuvant androgen deprivation was prescribed to a subset 
of patients but these will be separated in future analyses. Nerve sparing outcome was 
recorded prospectively.
LRP
Laparoscopic radical prostatectomy was performed as described by Stolzenburg et al 
(233) with an extraperitoneal approach to the prostate. As for RP Nerve sparing and 
pelvic lymph node sampling was at the surgeon’s discretion, Neo-adjuvant androgen
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deprivation was prescribed to a very small subset o f patients but these will be 
separated in future analyses. Nerve sparing outcome was recorded prospectively. 
Questionnaires
A battery o f questionnaires was used to capture different aspects o f the impact of 
treatment on patient reported symptoms and HRQOL. And these are summarised in 
table 13. (below). These are combined with a further detailed questionnaire collecting 
data on concurrent treatment for ED or urinary retention and health services usage 
questionnaire. The questionnaire booklet used is reproduced in Appendix III (p295) 
for information. The questionnaires are discussed further in the following pages.
Table 13. Questionnaires used in the Prostate Cancer Symptom Study
Cancer-specific Quality o f Life (CSQOL), Prostate Cancer-specific Quality o f Life 
(PCSQOL), Symptom Index (SI), European Organisation for Research and Treatment 
of Cancer Quality o f life Questionnaire (EORTC QLQC30), EORTC Prostate-25 
(EORTC PR25), International Index of Erectile Function (IIEF), International Prostate 
Symptom Score (IPSS), Taunton Psychosocial Morbidity Questionnaire(TPSM), 
Items refers to number o f questions asked.
| Name Type Items Assesses Description
EORTC
QLQ
C30
(234)
CSQOL 30 CSQOL Well validated CSQOL questionnaire widely 
used in oncology trials. Validated in most 
European languages.
EORTC
PR25
(235)
PCSQOL 25 ED, Bowel, 
Urinary and 
toxicity from 
androgen 
deprivation
Comprehensive PCSQOL questionnaire, 
suitable for assessment of localised and 
metastatic disease.
Some further validation work required to 
establish value, scaling and clinical 
significance.
IIEF
(236)
SI 15 ED Well validated, familiar index of male sexual 
function, available in abbreviated forms 
(sexual health index for men, comprises five 
erectile subscales of IIEF and the EF domains 
comprise all 6 erection specific questions)
IPSS
(195)
SI 8 | LUTS Well validated index of LUTS, familiar to 
urologists
TPSM
(237)
Paired Pt 
and partner
10 Cancer Distress 
Social Impact
Validated instrument used in previous UK 
prostate cancer trials to describe 
anxiety/distress in patients and their partners
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Rationale for questionnaire choice
The aims o f our study required robust questionnaires for measuring general HRQOL 
and urinary and sexual toxicity as well as anxiety/distress. To this end I chose the 
EORTC QLQ-C30 as the questionnaire to describe general HRQOL and PR25 to 
measure urinary and sexual toxicity. As there was little published information on the 
significance of answers to the PR25 in 2001 when the study commenced the IIEF and 
IPSS were co administered such that if the PR25 was not shown to be a helpful 
method of assessing PCSQOL then the objectives of assessing sexual and urinary 
toxicity could still be achieved. General cancer distress was assessed using the 
Taunton Psychosocial Morbidity questionnaire. Further details o f scoring and clinical 
significance of these questionnaires is given later in this chapter.
Administration of questionnaires
Questionnaires were administered prior to treatment (baseline) and at 6 weeks, 3, 6, 9, 
12, 18 and 24 months post treatment. Patients received their first questionnaire after 
being consented for the study in an outpatient clinic. A reply paid envelope was 
enclosed and completed questionnaires were entered into an Excel (Microsoft 2000) 
database by the author or administrative staff. Further questionnaires were mailed out 
to patients at the above time points. Before data entry the date o f questionnaire return 
was checked and questionnaires with dates out by >10% of time elapsed since 
treatment were discarded. 6-week and 3-month questionnaires were collected in 
outpatients and subsequent questionnaires were returned by mail.
Other outcomes
Prostate cancer recurrence and death may occur within the study period. Prostate 
cancer recurrence was prospectively assessed and recorded.
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Scoring of EORTC questionnaires in the Prostate Cancer Symptoms Study
Version 3.0 o f the QLQ-C30 is reproduced in appendix III; it comprises both multi­
item scales and single item measures. Four-point ‘Likert’ scales for items 1 to 28, 
may be answered “Not at all”, “A little”, “Quite a bit” or “Very much. Questions 29 
and 30 ask patients to rate their health or quality o f life on a seven point scale from 
“very poor” to “excellent”. These may be used to generate summary scores as 
described below (summary from EORTC QLQc30 manual). Version 3.0 has been 
tested in EORTC field studies (238) and control data is available for men with early 
prostate cancer in the UK (239) and abroad (240).
Table 14. Scoring the QLQ-C30 version 3.0 (Reproduced from the QLQ C30 manual
produced by the EORTC)
Scale Number 
of items
Item
range*
Version 3.0
Item numbers
Function
scales
Global health status / QOL
Global health status/QOL (revised/ QL2 2 6 29, 30
Functional scales
Physical functioning (revised/ PF2 5 3 1 to 5 F
Role functioning (revised/ RF2 2 3 6 ,7 F
Emotional functioning EF 4 3 21 to 24 F
Cognitive functioning CF 2 3 20, 25 F
Social functioning SF 2 3 26, 27 F
Symptom scales / items
Fatigue FA 3 3 10, 12, 18
Nausea and vomiting NV 2 3 14, 15
Pain PA 2 3 9, 19
Dyspnoea DY 1 3 8
Insomnia SL 1 3 11
Appetite loss AP 1 3 13
Constipation CO 1 3 16
Diarrhoea DI 1 3 17
Financial difficulties FI 1 3 28
* Item range is the difference between the possible maximum and the minimum response to individual 
items;
most items take values from 1 to 4, giving range = 3.
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For all scales, the Raw Score, RS, is the mean o f the component items: 
Raw Score = RS = (I x + I2 +...+ I n)/n
Thus for Functional scales:
Score = jl -  f o " 1)}  x 100 
[ range J
and for Symptom scales / items and Global health status /  QOL:
Score = {(RS -  l)/range} x 100
Examples:
Emotional functioning Raw Score = (Q2l + Q22 + Q23 + Q24) /4
EF Score = {l -  (RawScore - 1)/3} x 100
Fatigue RawScore = (Ql0 + Qn + 0 lg)/3
FA Score = {(RawScore - 1)/3} x 100
Thus for functional and global health scales high scores represent better levels o f 
functioning/QOL and for symptom scales higher scores represent worse 
symptoms/more problems. This may seem counterintuitive as the algorithm used for 
processing symptom scales and global QOL is the same. However it is explained by 
analysis o f the questionnaires (reproduced in section 5.1 A, p i 65). Although the same 
algorithm is used for functional scales and global health scales the raw scores for 
functional questions e.g. ‘Have you been constipated?’ are scored from ‘not at a ll’= l 
to ‘very m uch’=4 in contrast to the global health question ‘how would you rate your 
overall health’, ‘very poor’= l to ‘Excellent’=7. Thus although the same algorithm is 
used the scaled data is scored in opposite ways as described above. A different 
algorithm is needed to generate data from functional scales with questions such as ‘Do 
you have any trouble doing strenuous activities like carrying a heavy shopping bag or 
suitcase?’ which are scored from ‘not at a ll’= l to ‘very m uch’=4 in order to generate
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a scale similar to that achieved for the general health questions where a high score 
represents good levels o f function.
These algorithms have been included in a program produced by Fayers et al (240) for 
the SPSS statistical package which may then be used to process the data from the 
QLQ-C30 into symptom scales. The Fayers code and instructions on how to process 
the raw data from our database are summarised in Appendix VI.
If patients missed out their whole baseline questionnaire and failed to reply to a 
reminder they were not sent subsequent questionnaires. Patients who failed to fill in 
at least one questionnaire post-implant were excluded from the analysis o f data. In 
the QLQ-C30 items are not weighted and therefore scores are presented in their 
subscales without a final summary score. Clinical significance o f changes in the 
QLQ-C30 raw scores were assessed by Osoba et al (241) (using the Subjective 
Significance Questionnaire (SSQ)). Patients rated ‘a little’ change as equating to 5- 
10%. Moderate changes were associated with score changes o f 10-20% and ‘very 
much’ changed patients changed scores by >20%.
EORTC PR25
We assessed the PR25 questionnaire using psychometric methods to confirm 
unpublished data from the EORTC and Bristol groups who suggested that it is a 
suitable tool for assessing patients with EPC (personal communication Professor 
N.Aaronson, EORTC chair o f QOL research and J.Rees, Bristol University Quality o f  
life group). Initial studies in a multinational study group using individual 
administration and critique o f the questionnaire and focus group critiquing of PR25
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have suggested that the questionnaire is suitable for assessing prostate cancer patients. 
Factor analysis, discriminant validity and test-retest reliability have all shown 
satisfactory results (235) and studies using the PR25 published in international 
journals (239, 242). Unlike the QLQ-C30, a formal scoring manual for the prostate 
cancer module has not yet been published. However, a tentative scoring system has 
been provided for this study by the EORTC (appendix V, p320). This divides the 
questionnaire into 5 separate multi-item scales.
Scale Number 
of items
Item
range
PR25 
Item numbers
Symptom scales /  items
Urinary Problems UR 8 3 1 to 7 and 9
Urinary Incontinence UI 1 3 8
Bowel Symptoms BS 4 3 10 to 13
Treatment Symptoms TS 6 3 14 to 19
Sexual Activity SA 2 3 20,21
Sexual Functioning SF 4 3 22 to 25
EORTC Guidance on analysing PR25
Guidance on scoring the PR25 produced by the EORTC is summarized in Appendix 
V. The individual tasks necessary to convert scores outlined on the questionnaire and 
original PCSS excel database are outlined in Appendix V.
Psychometrics of PR25 questionnaire
As published data on the test retest reliability o f the PR25 questionnaire are only 
available in summary form (235), test retest reliability was assessed using the Cohen’s 
Kappa statistic (243), to determine the degree o f agreement where the categories 
describe ordinal data. Internal Consistency o f the PR25 was also assessed using 
Cronbach’s alpha as recommended by the EORTC (Appendix V, p320, 
Recommendations from the EORTC on Processing PR25 Data).
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International Prostate Symptom Score
The IPSS has been validated as a self-administered questionnaire for LUTS in benign 
prostate disease and is widely used as a clinical tool to assess severity o f LUTS. It is 
recommended by the American Brachytherapy as a method of reporting LUTS after 
BXT(183) and is widely used in trials reporting toxicity after brachyterapy. IPSS 
scores will be expressed as a continuous variable and changes o f >3 points considered 
clinically significant as they increase bother as assessed by the global QOL score at 
the end of the IPSS (195). It is unsuitable for reporting toxicity where urinary leakage 
needs assessment and hence is co-administered alongside EORTC PR25.
International Index of Erectile function (IIEF)
This questionnaire was designed to help with the assessment of ED severity in clinical 
settings and research trials and has been extensively validated (244). The IIEF-5 
summary form of the questionnaire has also been well validated (245, 246) although 
both questionnaires have only been validated in patients who are currently in 
heterosexual relationships where sexual activity is attempted. In this patient group the 
IIEF scores given below describe the severity classes of ED and their associated 
scores. The ranges suggest that a change in score o f 4 points would be clinically 
significant (as it would change severity of ED by one class (246) however a change of 
as little as 2 points may be clinically significant (Personal Communication 
I.Eardley/R.Rosen). IIEF Scores will be expressed as mean scores and also % with 
each severity o f potency.
ED Severity IIEF-5 Score (Range 1-25)
Normal 25-22
Mild Dysfunction 21-17
Mild-Moderate Dysfunction 16-12
Moderate Dysfunction 11-8
Severe Dysfunction (</=7)
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Taunton Psychosocial Morbidity Questionnaire
This questionnaire has scaled outcomes in 7 domains (Worry from Treatment, Pain, 
Urinary Symptoms, Limitation, Sex, and General Cancer Distress), which are 
expressed separately according to an agreed scale (247) however the primary end 
point o f interest is the general cancer distress (GCD) subscale in both patients and 
partners and this will be analyzed as a continuous variable although it is also possible 
to classify people with scores o f >4 on the GCD subscale as morbid in terms of 
cancer distress (247).
Power calculations
One o f the difficulties of power calculations in quality of life research is that there are 
often a number of variables which are to form end points for the study including for 
example potency, general HRQOL and bowel dysfunction. The question then arises 
as to which item(s) should be used in determining the power calculations for a 
particular study. Clearly the most conservative power calculations based on the least 
sensitive items may significantly over-power the study with a substantial increase in 
the workload of data collection, input and hence cost.
During the design of the PCSS statistical advice was taken concerning power 
calculations. It was not felt appropriate to power the study to detect differences 
between different treatment groups as although these may be interesting they could 
not form a primary end-point as they would be subject to significant confounding due 
to non-random allocation o f patients to their treatment. We therefore decided that the 
most appropriate power calculations would be based on the ability to detect changes 
in symptoms and QOL from baseline in paired significance tests.
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The most important and well validated questionnaires where the minimum degree o f 
change that could be regarded as clinically significant is known are the EORTC-QLQ 
C30 questionnaire, the IPSS questionnaire and the IIEF-5 questionnaire which is a 
summary for o f the full IIEF assessing only erectile function and not other domains o f 
sexual function. Sample power calculations based on these outcome measures using a 
p-value o f <0.05 to determine significance and allowing an 80% power to detect a 
clinically significant change in outcome are reproduced in table 15 (below).
Table 15. Quality o f life measures, endpoints and power calculations for the PCSS. 
References which outline the minimally clinically significant changes for different 
outcome measures are included. Power calculations were initially based on data from 
our fist 10 brachytherapy patients and published data and revised as below using the 
corrected SD o f difference as presented
Name Key
Endpoint
M inimum Clinically 
Significant Change in 
score
Estim ated
Mean
Difference
Estimated  
SD o f  
difference
Num ber o f Patients 
Required to achieve 
specified power (n=)
90% 80%
E O R T C  
| Q LQ  C30
General
HRQOL
5-10 ‘A little’ (241) 5 15 97 73
10-20 ‘moderate’ (241) 10 15 26 20
>20 ‘very much’ (241) 20 15 9 7
E O R T C
PR25
Unknown 
but likely 
to be 
similar to 
QLQ-C30
As Above As Above As Above As Above As Above
IIEF Change in IIEF-5
2 points in 25 point scale 
(personal communication 
I.Eardley/R.Rosen)
2 8 171 128
4 points to change ED 
severity class(246) 4 8 44 34
IPSS
Change in 
7 item 
symptom 
subscale
3 points in 35 point scale 
(195) 3 8 77 58
T PSM
General
Cancer
Distress
Unknown. Mean 
difference between 
anxious and non anxious 
as diagnosed by HADS 
was 3.7 points (of 
12)(247)
1 1.8 37 28
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We therefore elected to attempt recruitment o f 80 patients per arm which would allow 
us to comment with 80% power on changes in EORTC QLQ-C30 score of ‘a little’ 
clinical significance or greater allowing for a 10% dropout rate. It would also 
(assuming that at least 50% of the sample were potent and sexually active) allow us to 
comment on clinically significant changes o f >4 points in the IIEF-5 score. 
Statistical tests can only strictly be applied to the paired data available from 
longitudinal follow-up.
Comparing the data from the PCSS groups i.e. RP vs. BXT or subgroups i.e. BXT vs. 
HBXT is not strictly possible as significant confounding during treatment allocation is 
likely (in most American studies the youngest fittest men got RP and older less fit 
men received EBRT). It will however be possible to use the data generated from this 
study to power future randomised studies o f HRQOL outcome after radical treatment 
for prostate cancer.
Statistical handling
This was performed using the SPSS package (SPSS inc. Chicago Illinois, USA  
Version 11.5.0 released 6/9/2002) and some graphics produced using SYSTAT 
(SPSS inc. Chicago Illinois, USA Version 10, released 2000).
Kappa and gamma statistics were used to check for test-retest reliability in the PR25 
questionnaire and Cronbach’s alpha scores used to test the reliability o f scale 
formation. Values above 0.7 accepted for scale formation.
Demographic data was collected for patients who underwent brachytherapy, who 
expressed willingness to complete the Prostate Cancer Symptom Study
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Questionnaires and who actually completed analysable questionnaires (pre and at least 
1 questionnaire post-treatment).
Exploratory analysis (results chapter 5.1 pages 157-163) was performed on various 
strategies for dealing with missing data (forms) and it was decided not to proceed with 
a last value carried forward analysis or imputation methods but simply to display the 
data point which exist with an explanation o f the completeness of the dataset at each 
point. Non-parametric methods (Wilcoxon Signed-Rank test) were used to describe 
changes from baseline in the study.
Handling of scaled data
Scaled data refers to the data generated by the EORTC questionnaires where Likert 
questions are transformed into a 100 point scale for analysis. Transformation (of the 
data which is not normally distributed) and the use o f parametric methods for data 
analysis are not appropriate due to the data distribution.
The data is essentially comprised of ordinal data points transformed into a 100 point 
scale and hence should not be manipulated into a normal distribution. This is because 
the number of possible values o f each domain is limited (for a single 4 item question 
the possible transformed values would be 0, 33, 66 and 100 points whereas for the 
general HRQOL question the transformed values increase in smaller units of 8.3 
points from 0 to 100 reflecting the possible outcomes o f two question each with 7 
possible answers).
Thus for even the most complex of the scaled outcomes there are a limited number o f  
frequency bins on a histogram and the data is not really continuous (although other
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organisations including the EORTC have treated it as such (248, 249)) and published 
studies using parametric methods (249). Because o f the limited number o f bins the 
distribution was not described by any of the recognised distributions which would be 
amenable to transformation. Therefore transformation was not attempted.
Chapter 4.2 - Predicting urinary symptoms after brachytherapy - 
role of preoperative investigations
A prospective analysis of urinary toxicity and complications was performed for the 
first 216 consecutively treated patients who had >3 months follow-up available post 
brachytherapy. All patients were assessed using history, physical examination, 
transrectal ultrasound (see chapter 4.0 pl21), International Prostate Symptom Score 
(IPSS), uroflowometry and post-void residual urine volume determination. In the 
series described one patient had undergone bladder neck incision, one patient had a 
previous TURP and one patient with a prominent middle lobe had this resected prior 
to treatment. Formal urodynamic studies were performed in an unselected group of 
136 patients, comprising filling cystometry and a pressure/flow study.
Clinical data collection
Clinical data was collected using an Excel database and stored securely. The database 
was registered under the data protection act and with the trust’s Caldicott guardian.
Data was coded to allow easy access for searching. As part o f the project a 
networked database was developed to allow easier access to the database and multi­
user input.
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Urodynamic assessment
Urodynamic studies (UDS) were performed as described by Abrams et al (154). With 
the patient supine a fine epidural catheter was introduced urethrally using the 8 f filling 
catheter and the ‘piggy back technique’. Any residual urine was drained and the 
volume recorded. A second pressure catheter was inserted into the rectum to record 
the intra-abdominal pressure. Fluid filled pressure transducers were then connected 
and the transducers zeroed. The bladder was filled at a flow rate o f 50 mis per minute 
with warmed normal saline. A schematic o f the urodynamic assessment set-up is 
outlined in figure 16. Initially the patients were also screened with video-fluoroscopy 
but due to difficulties with classification o f abnormalities and lack o f availability o f 
fluoroscopy for screening sessions this fluoroscopy was not included in the 
assessment o f the majority o f patients undergoing urodynamic investigation.
x-ray
screening
unit
TBP {
DP _ __ _ C\\A AlFR
AP X u
peristaltic
pump
pressure
transducer
pressure
transducer
flow control
meter computer
Figure 16. Schematic o f video-urodynamic assessment
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UDS allowed us to record information during both the filling and voiding phases. 
Criteria for defining the outcome o f male UDS were defined by Abrams et al (250).
During the filling phase traces were assessed for detrusor instability. Detrusor 
instability was defined as an unprovoked rise o f greater than 15cm o f water in 
detrusor pressure (detrusor pressure = intravesical pressure-intraabdominal pressure).
During the voiding phase patients were classified as obstructed, equivocal or 
unobstructed based on their maximal urinary flow rate (Qmax) and the detrusor 
pressure needed to generate the maximal flow rate (P.det.Qmax) as detailed in figure 
17. The bladder outflow obstruction index (BOOI=P.det.Qmax-2[Qmax]) was then 
calculated.
Figure 17. Urodynamic traces showing results from obstructed and unobstructed 
patients
Patients who had a low flow rate (Qmax) 
and a high P.Det.Qmax were classified 
as obstructed if  their BOOI was >40.
Patients with a high Qmax and low 
P.Det.Qmax were classified as 
unobstructed if  their BOOI was <20.
Patients with a BOOI of 20-40 were 
classified as having equivocal evidence 
o f obstruction.
Obstructed UDS
Detrusor
ex
P m s i i r p
P.Det.Qmax
Qmax
Flow rate
/-— r
Unobstructed
Detrusor
j P ro s s iirp
F.Det.Qmax
Qmax
Flow rate
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Patient selection was as described in section 4.0 (Treatment protocols and patient 
selection, p i 18). Outcomes o f interest were acute urinary retention (pain with 
inability to void urine requiring catheterisation) or the need to use intermittent self 
catheterisation for any reason (including patients with LUTS and a detectable residual 
urine volume after voiding). Total IPSS score was also measured pre-treatment and at 
6 weeks and 3, 6, 9, 12, 18 and 24 months post treatment and at 6 monthly intervals 
thereafter.
Prognostic factors for urinary retention were identified from literature review as 
outlined in table 8, (p81). Univariate analyses o f data was performed to assess 
potentially prognostic factors for urinary retention using non-parametric (Mann- 
Whitney U/Kruskall-Wallis) or parametric (t-test/Analysis o f Variance) methods as 
appropriate. As all catheterisation events had occurred during the first 3 months of 
follow-up unconditional logistic regression analysis (Stata 7.0 Stata Corp. Texas) was 
performed as described by Altman (251). All factors associated with catheter use at a 
significance level o f <0.10 in the univariate analysis were considered for inclusion in 
the model. Factors associated with catheter use at a significance level of <0.05 in the 
multivariate analysis were included in the final model. Changes in IPSS score post­
implant were compared with paired baseline IPSS score using the Wilcoxon Signed 
Rank Sum test.
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Radiotherapy - Dosimetry calculations
Post-implant dosimetry was considered necessary as part o f the study both for 
standard quality assurance of the brachytherapy implants and for assessment o f the 
effects o f dose on symptomatic outcome. Standard dosimetry data (V I00, V I50 and 
D90 o f CTV) was calculated according to the details given in chapter 4.0, p l20. As 
urethral catheters were not in situ during CT scanning a surrogate urethra was used 
according to the ‘mid gland’ method described and validated by Bucci et al (252).
Dosimetry was calculated from dose volume histograms and expressed as the highest 
dose to 90% of the prostate (D90) and the percent of the prostate volume receiving 
100% and 150% of the prescription dose (VI00 and V I50). Urethral dose was 
expressed as the highest dose to 50, 25 and 10% of the urethra (D50, D25, and D10).
Chapter 4.3 - The effects of bicalutamide and goserelin on prostate 
volume
In this non randomised, prospective, observational study 131 patients with biopsy 
proven carcinoma of the prostate were assessed prior to BXT. All patients were 
candidates for prostate brachytherapy treated between January 2000 and June 2002, 
fifty patients from this cohort who had not had their initial prostate volume measured 
by one of the operators were excluded from the study group. Prostate volume was 
measured in the outpatient clinic using a B&K 7.5MHz transrectal ultrasound probe. 
The height and width were measured in the transverse plane and length in the sagittal 
plane and the volume calculated using the prolate ellipsoid formula (HxWxLx7c/6). 
The study was repeated prior to the brachytherapy planning scan and identical 
methods used to calculate the prostate volume. The same 2 physicians performed all 
ultrasound scans.
Between ultrasound scans patients received either no hormonal treatment, daily 
bicalutamide 150mg as monotherapy or goserelin 3.6mg every 28 days with an initial 
course of 2-weeks o f antiandrogen (bicalutamide 50mg OD or cyproterone acetate 
lOOmg TDS). Patients received treatment with bicalutamide or goserelin according to 
physician preference with cytoreductive intent if  prostate volume was above 55cc or 
neoadjuvant intent for high risk disease (Gleason sum>6, stage>T2a, PSA>10ng/ml).
Statistical analysis o f reduction in prostate volume was performed using paired t-tests 
to compare change in volume within a treatment group. Unpaired t-tests were used to 
compare percentage reduction in prostate volume between groups.
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Results
Chapter 5.0 - Validation of the PR25 Module in prostate cancer
patients
Basic psychometric properties o f the PR25 questionnaire are presented below. 
Test-retest agreement
The Kappa statistic was used to analyze test-retest agreement for the PR25 and the 
results of this analysis are presented in Table 16.
Table 16. Test-retest agreement for EORTC-PR25
n=17 patients returned both questionnaires out of a sample size o f 25 patients. 
(Gamma Statistic Outcome >0.75= Excellent Agreement, 0.4-0.74 Good, 0.27-0.4 
Fair, <0.27 Poor) . A Gamma statistic is not shown where agreement was perfect 
[NC=Not Completed]
PR25Q Assesses Gamma Kappa Test-Retest Agreement 
Based on Gamma 
Statistic result
1 Urine Frequency Day 0.879 - Excellent
2 Urine Frequency Night 0.75 0.375 Excellent
3 Urine Hurry 1 1 Excellent
4 Urine Sleep Problem 1 0.448 Excellent
5 Urine Prob. Going Out - - Perfect
6 Urine Leakage 1 1 Excellent
7 Urine Pain - - Perfect
8 Incontinence Aid Problem NC NC Perfect
9 Limited Activity (Urine) - - Perfect
10 Limited Activity (Bowel) - - Perfect
11 Stool Leakage - - Perfect
12 Blood in Stool - Perfect
13 Abdominal Bloating 1 0.71 Excellent
14 Hot Flushes 0.886 0.691 Excellent
15 Enlarged Nipples 1 0.634 Excellent
16 Swollen Ankles 1 0.634 Perfect
17 Weight Loss - - Perfect
18 Weight Gain 1 0.231 Excellent
19 Less Masculine 0.28 0.127 Poor
20 Sex Interest 0.774 - Excellent
21 Sex Active 0.906 - Excellent
22 Sex Enjoyable 1 0.576 Excellent
23 Difficulty with Erections 0.882 0.609 Excellent
24 Ejaculation Problems 0.7 0.455 Good
25 Sexual Intimacy Problem 1 - Excellent
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There are however technical limitations to the kappa statistic when used on this type 
of dataset. The kappa statistic measures the expected agreement predicted from any 
dataset presented in 2x2 table format compared with the actual agreement and is a 
measure o f the improvement in agreement above that expected by chance (i.e. the 
value of Kappa is changed both by the agreement o f the groups and the proportion of 
subjects in each category) (253). Unfortunately in Likert scale questionnaires where 
responses at baseline may have little variability i.e. all or almost all patients answered 
that they were ‘not at all’ troubled by a symptom then the expected agreement would 
be very high as the 2x2 table would have only 1-2 rows/columns. Thus although the 
correlation as assessed by the Gamma statistic (an improved correlation coefficient 
similar to Spearman R or Kendall Tau for tiered observations) is high-perfect in most 
of the scales the agreement is little higher than that achieved at random and hence the 
kappa statistic is often below 0.5 in our small sample. This effect is illustrated using 
the data with the least agreement (Q2 o f PR25) in table 17.
Table 17. Tabulated 2x2 table for test retest variability in question 2 o f EORTC 
PR25 - “HAVE YOU HAD TO URINATE FREQUENTLY AT NIGHT?”. Kappa Statistic 
= 0.375 (Poor), Gamma statistic = 0.75 (Excellent). Perfect agreement achieved in 11/16 
(69%) with a difference of 1 category (from not at all to a little) present in the remaining 5/16
(31%)
Likert Score =1 
in 2nd test (n=)
Likert Score =2 
in 1st test
Total
Likert Score = 1 
in 1st test
7 (64%) 4(36%) 11
Likert Score = 2 
in 1st test
1(20%) 4(80%) 5
Total 8 8
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This effect is therefore a reflection o f low power to determine agreement and not low 
agreement. This problem would not be addressed by greater power as to assess this 
more fully subjects with greater variability in the symptoms at baseline would be 
required (and the population selected for brachytherapy treatment is relatively 
homogenous due to exclusion of patients with severe urinary symptoms at baseline). 
A more complete assessment o f the Kappa values may be possible by assessing 
patients when they have reached more stable symptoms later in the study and further 
work is planned on a variety of patients by the EORTC.
Test-retest analysis (Table 16, pl44) suggests that all questions other than Q19 ‘Have 
you felt less masculine as a result o f your illness or treatment?’ had good-excellent 
test-retest correlation using the Gamma Statistic and it is possible that the poor results 
from Q19 were due to random effects in the small sample size however the results 
from Q19 must be interpreted with some caution until further field testing data are 
available from the EORTC.
Further work on test-retest reliability could assess cohorts o f men who were more 
symptomatic (and hence more likely to have a greater spread o f answers on the Likert 
scales) however this was not feasible in our study as the symptomatic patients (further 
on in their treatment) were likely to display real changes in their symptoms over a 2 
week test-retest period. In addition to this test-retest analysis has been reported as 
favourable in initial studies by the EORTC(235) and large field studies of PR25 are 
expected to report shortly.
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Scaling the domains of PR25
Although the development process (235) suggests that the questions are important 
and describe significant domains o f quality o f life without excess duplication o f  
fields, further work is necessary to confirm that the initial grouping of questions into 
scales on urinary problems, urinary incontinence, bowel symptoms, treatment 
symptoms, sexual activity and sexual functioning is supported by robust psychometric 
data. If this psychometric data is lacking from the EORTC field studies (as yet 
unpublished) and studies o f particular subgroups by researchers such as ourselves do 
not support scale formation then guidance from the EORTC (Personal 
Communication Prof. Aaronson, Reproduced in Appendix V, p319) suggests that 
forming scales such as ‘sexual function’ where a number o f questions are grouped and 
a total scale value o f 0-100 produced is not supported. Given that the PR25 is still 
undergoing field-testing, it is recommended by the EORTC that basic psychometrics 
are carried out, in order to assess the internal consistency of the proposed multi-item 
scales. This can be calculated using the Cronbach’s alpha coefficient. For the 
purposes o f group comparison values above 0.8 for Cronbach’s alpha would be 
considered excellent and above 0.7 are considered acceptable by the EORTC for scale 
formation. Table 18 (p i48), shows the scores obtained at each visit for each o f the 
proposed multi-item scales.
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Table 18. Baseline and 6 week (maximum symptoms) internal consistency data 
[CA=Cronbach’s Alpha Statistic] for PR25. Scaling tests are applicable or required 
for single question scales
Scale Name PR25
Questions
CA (Pre) 
n=231
CA (6Wks) 
n=145
CA (3m) 
n=123
Reliability 
of Scale 
Data
Urinary
Problems
1-7 & 9 0.74 0.87 0.86 Good-
Excellent
Urinary 
Incontinence 
Aid Bother
8 Single
question
Bowel
Symptoms
10-13 0.51 0.51 0.41 Poor
Treatment
Symptoms
14-19 0.49 0.41 0.48 Poor
Sexual
Activity
20-21 0.84 0.82 0.83 Excellent
Sexual
Functioning
22-25 0.93 0.70 0.71 Good-
Excellent
This information suggests that scale formation is supported for urinary problems, 
urinary incontinence aid bother, sexual activity and sexual functioning. However that 
scales comprising treatment symptoms and bowel symptoms need to be interpreted 
with caution as there may be little evidence that they measure a single underlying 
construct. When the heterogenicity o f the questions (Appendix III, PR25 
questionnaire, p299) in these scales is considered this is perhaps unsurprising given 
that ‘treatment symptoms’ measures mostly but not exclusively symptoms reported by 
men experiencing toxicity from hormonal treatments rather than measuring problems 
in a single body system such as urinary problems and that the bowel symptoms 
construct measures symptoms in men who experience bleeding, constipation and 
diarrhoea. Although from a purely psychometric perspective, it makes little sense to 
form a multi-item scale o f items that do not correlate with one another (and thus yield 
a low Cronbach’s alpha); it is not uncommon that symptom checklists are scored
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additively, yielding a total score representing the total number (x intensity) of 
symptoms reported by the patients. For instance in development of the EORTC Head 
and Neck cancer module it was found that there was poor agreement between the two 
pain scales (assessing pain in mouth and pain in throat) and good correlations between 
throat pain and swallowing difficulties. However clinical sensibility indicated that 
these scaling errors could be ignored as it would be more sensible to describe pain and 
swallowing difficulties separately (171).
Thus urinary problems, urinary incontinence and sexual activity and function will be 
reported as scales. Bowel symptoms are in any case duplicated in the constipation 
and diarrhoea questions o f the EORTC-QLQC30 and treatment (hormonal) symptoms 
may be reported separately as a % of patients experiencing moderate-severe toxicity 
per question if  greater detail is deemed necessary to assess which part o f the scale has 
been affected.
Code for reproducing the EORTC recommendations and converting the data into 
scales is presented in Appendix VI, (p323). Processing code (for SPSS statistics 
package v ll .5 )  written by the author to allow automatic production o f PR25 scales 
from the raw data is highlighted in blue with original code by Fayers et al (248) in 
black.
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Chapter 5.1 - Quality of life among patients treated with low dose- 
rate brachytherapy in the Prostate Cancer Symptoms Study 
Demographics and missing data
The outcome o f patients approached to enter the brachytherapy arm of the prostate 
cancer symptoms study is outlined in figure 18. The outcome o f all 346 patients 
approached is known with no loss o f follow-up. 218 patients who are described in the 
bottom row of figure 18 are termed the primary dataset and analysed further.
Figure 18. Completeness o f questionnaire pack returns for patients recruited to 
brachytherapy arm of prostate cancer symptom study. No patients were unaccounted 
for at the end o f 2 year follow-up.
15.1 % of 
primary 
dataset have 
complete data 
(8 Completed 
Questionnaires) 
N=33
50.0 % have 1-2 
missing 
questionnaires
28.0%  have 3-4 
missing 
questionnaires
6.9 %  have 5-6 
missing 
questionnaires
N=T5
31.3 % of patients do 
not ‘opt in’ as required 
by ethics committee
N=105
9.5 % fail to return subsequent 
questionnaires despite 
reminders
N= 23
90.5% also return at least 1 
subsequent questionnaire 
These patients are eligible for primary 
dataset for analysis
N=218
69.7 % of patients return consent form 
and first questionnaire
N=241
All patients undergoing brachytherapy August 2001 - July 2004
Given information pack and initial discussion 
regarding recruitment to Prostate Cancer Symptoms Study.
N=346
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The demographics o f the patients in each o f the groups identified in figure 18 (page 
150), are described in table 19 (page 152). Significance tests were performed to 
compare the patients who were eligible for the study but who failed to consent or 
complete adequate questionnaires to be included in the primary dataset for analysis 
(Group 1) vs. those included in the primary dataset o f 218 patients. Parametric 
methods were used when the variable was normally distributed (age -  unpaired t-test), 
non-parametric methods when they were non-normally distributed (Mann-W hitney 
test) and Chi-Squared for categorical data. Patients eligible for the study but who 
were not recruited were younger than those in the primary dataset o f patients analysed 
(p=0.01 unpaired t-test). Analysed primary dataset patients were more likely to have 
been recruited from those patients approached in the 2nd and 4th hundred patients to 
receive brachytherapy at the study centre (See Figure 19. below, X2 p<0.0001). All 
other demographics were not significantly different between groups.
Figure 19. G raph  show ing  num ber o f  patien ts approached  to jo in  the b rachy therapy  arm  o f  
the prostate  cancer sym ptom  study included  vs. exc luded  from  the p rim ary  dataset by  
treatm ent cohort (2nd vs. 3rd vs. 4 th vs. 5th 100 patien ts treated).
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Table 19. Demographics of brachytherapy patients in three groups; those eligible for 
the prostate cancer symptom study, those who agreed to the study and signed the 
consent form, and those who returned at least 2 completed questionnaires and entered 
the primary dataset
All Eligible 
Patients
Consented
Patients
1 All Primary 
Dataset 
| Patients
N= | 346 241 | 218
Age in Years, Mean (SD) I 62.7 (6.1) 63.1 (5.9) | 63.4 (6.0)
Presenting PSA in ng/ml 
Median (Range) 1 8.2(0.7-23.6) 7.4(0.7-19.8) 7.4(0.7-19.8)
Biopsy Gleason Sum 
Median (Range) 6 (2-9) 6 (2-8) 6 (2-8)
TNM Stage T1 49.4 (171) 48.5 (117) 49.1 (107)
On DRE T2 48.8 (169) 49.8 (120) 49.1 (107)
% (N=) T3 1.7(6) 1.7(4) 1.8(4)
MSKCC Risk Low Risk 53.4 (185) 51.5 (124) 51.4(112)
Group Intermediate 35.2 (122) 38.2 (92) 38.5 (84)
% (N=) High Risk 11.3 (39) 10.4 (25) 10.9(22)
Private vs. PP % (N=) 48.3 (167) 48.5 (117) 50.5(110)
NHS NHS % (N=) 51.7(179) 51.5(124) 49.5 (108)
Presenting
Complaint
Screen %  (N=) 61.3(212) 61.8 (149) 61.9 (135)
LUTS % (N=) 26.3 (91) 27.8 (67) 28.0 (61)
Other % (N=) 12.4 (43) 10.4 (25) 10.1 (22)
2nd 100 Patients, % (N=) 27.5 (95) 29 (70) 31.2 (68)
Treatment 3rd 100 Patients, % (N=) 28.9 (100) 29.5 (71) 27.1 (59)
Cohort 4th 100 Patients, % (N=) 28.9 (100) 32.4 (78) 32.1 (70)
5th 100 Patients, % (N=) 14.7(51) 9.1 (22) 9.6 (21)
Baseline IPSS Score 
Median (Range) 5 (0-17) 5 (0-15) 5 (0-15)
Baseline IIEF-5 Score 
Median (Range) 13 (1-25) 11.5 (1-25) 10 (1-25)
Treatment
Delivered
BXT (N=) 40.8 (141) 42.3 (102) 43.1 (94)
HBXT (N=) 41.6 (144) 41.5 (100) 39.9 (87)
BXTC(N=) 17.6 (61) 16.2 (39) 16.9 (37)
Biochemical Recurrence 
% (n=) 2.6(9) 2.5 (6) 2.8 (6)
Partner Completed Questionnaire 
% (n=)
- 80.1 (193) 79.8 (174)
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Missing data
Figure 18 (pl50) identifies the percentages o f patients with missing questionnaires 
(None missing-15.1%, 1-2 missing-50.0%, 3-4 missing-28.0%, 5 missing-6.9%). 
Table 20 below shows that the most commonly omitted questionnaires were at 9 and 
12 months when up to 54% of the dataset was missing.
Table 20: Missing questionnaires for each questionnaire time-point after BXT 
inPCSS
Questionnaire Point Number of 218 Missing %  of Dataset Missing
6 Week 60 27.5
3 Month 43 19.7
6 Month 46 21.1
9 Month 118 54.1
12 Month 79 36.2
18 Month 53 24.3
24 Month 50 22.9
The demographics o f patients with various levels o f missing questionnaires are 
presented in table 21, page [+3 from this]. Appropriate statistical methods were used 
to test whether the demographics o f patients were significantly different depending on 
their level o f questionnaire return, (Analysis o f Variance for Normal Data (Age), 
Kruskall Wallis for Non-Normal Data (e.g. PSA) or Chi -  Squared test for 
Categorical Data (e.g. MSKCC Risk- Group Stratification) as appropriate.
Patients with different levels o f questionnaire response did have significantly different 
levels o f baseline IIEF-5 score (a measure o f potency, Kruskall-Wallis test p=0.04) 
but there was no relationship between IIEF and number o f missed questionnaire 
booklets. Patients missing 1-2 questionnaires had the highest mean scores with those 
missing 3-4 questionnaires or with complete data having equally the lowest mean 
scores at baseline.
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Figure 20 illustrates the observation that patients who completed all questionnaires 
were more likely to have been recruited from the 2nd or 3rd hundred patients treated in 
this series (X -test < 0.0001, first cohort o f 100 patients treated in this series before 
PCSS recruitment began). This mirrors the fact that early patients approached for the 
study were more likely to consent to entry and return their first questionnaire than 
those recruited from the 5th 100 patients in the series (table 19).
Figure 20. Graph o f number o f patients in the primary data analysis o f BXT arm o f 
the prostate cancer symptom study with varying levels o f missing data grouped by 
treatment cohort (2nd vs. 3rd vs. 4th vs. 5th 100 patients treated).
80
Missing Q's N
5 Missing Q's
3-4 Missing Q's
1-2 Missing Q's
2nd Hundred Pts 4th Hundred Pts
3rd Hundred Pts 5th Hundred Pts
Treatment Cohort
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The data was analysed to see if  the number o f missing data points was any different 
between the three types o f treatment delivered.
The likelihood o f patients completing all questionnaires was greater within the 
hormonally treated brachytherapy patients than amongst those who received 
brachytherapy alone (HBXT 20.7% vs. BXTC 16.2% vs. BXT 9.6%, see Figure 21, 
below and Table 21 p+1) however this did not reach statistical significance.
Figure 21. Graph o f number o f patients in the primary data analysis o f the prostate 
cancer symptom study with varying levels o f missing data grouped by treatment 
delivered
Missing Q s n=
5 M issing Q s
3-4 M issing Q's
1 -2 M issing Q s
Treatment Group
An ordinal regression analysis comparing the effects o f treatment cohort and type o f 
treatment delivered on number o f missing questionnaires reveals that there is a 
significant relationship between treatment cohort and number o f missing 
questionnaires (p<0.0001 with treatment cohorts 1 and 2 having significantly less 
missing questionnaires). Treatment delivered was not a significant predictor o f 
number o f missing questionnaires in this model.
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Table 21. Demographics of 218 analysed brachytherapy patients from the PCSS in 
four groups; those who completed all 8 questionnaires and those who missed 
respectively 1-2, 3-4 or 5-6 questionnaires. PSA = Prostate Specific Antigen, DRE is Digital 
Rectal Examination Staging According to the TNM 2002/Version 6) staging system(60). MSKCC is the 
risk grading system described in table 4. Private Patients funded their own treatment with insurance or 
self payment whilst NHS patients had treatment paid for by the National Health Service. Treatment 
Cohort describes where in the series of patients treated to date the patients were recruited from. IPSS is 
International Prostate Symptom Score (severity o f LUTS), IIEF-5 is the 5 item abridged version of the 
International Index o f Erectile Function
Primary 
Dataset 
Complete 
| Follow-up
I Primary Dataset with Missing 
Questionnaires
1 to 2 3 to 4 | 5 to 6
IN= 33 109 61 1 15
| Age in Years, Mean (SD) | 61.9(5.4) | 64.0(6.3) 63.3 (6.1) | 62.1 (5.3)
Presenting PSA in ng/ml 
Median (Range)
7.0
(2.0-19.8) l ?A(0.7-18)
6.8
(0.7-19.3)
I 8.5 
(5.1-11)
Biopsy Gleason Sum 
Median (Range) 6(2-7) 6 (4-8) 6 (3-8) I 6(4-7)
TNM T1 % (N=) 48.5 (16) 49.1 (53) 47.5 (29) 60 (9)
Stage On T2 % (N=) 51.5 (17) 49.1 (53) 50.8 (31) 40 (6)
DRE T3 % (N=) - 2.8 (3) 1.6(1) -
MSKCC
Risk
Group
Low Risk % (N=) 45.5 (15) 52.3 (57) 57.4(35) 33.3(5)
Intermediate % (N=) 45.5 (15) 38.5 (42) 29.5(18) 60.0(9)
High Risk % (N=) 9.1 (3) 9.2 (10) 13.1 (8) 1 6.7(1)
Private vs. PP % (N=) 57:6 (19) 47.7 (52) 50.8(31) | 53.3(8)
NHS NHS % (N=) 42.4 (14) 52.3 (57) 49.2 (30) I  46.7(7)
| Presenting 
Complaint
Screen % (N=) 60.6 (20) 64.2 (70) 59 (36) 60 (9)
LUTS % (N=) 39.4 (13) 27.5 (30) 26.2 (16) 13.3 (2)
Other % (N=) - 8.3 (9) 14.8 (9) 1 26.7(4)
2nd 100 Patients, % (N=) 75.8(25) 29.4(32) 13.1 (8) 20.0(3)
I Treatment 
Cohort
3rd 100 Patients, % (N=) 24.2 (8) 34.9(38) 14.8 (9) 26.7 (4)
4th 100 Patients, % (N=) - 32.1 (35) 44.3 (27) 53.3 (8)
5th 100 Patients, % (N=) 3.7(4) | 27.9 (17) 1
Baseline IPSS Score 
Median (Range) 5(0-13) | 5.5 (0-15) 5 (0-13) 4(0-11)
Baseline IIEF-5 Score 
Median (Range) 1 (1-2) 10(1-25) 1 (1-2) 3(1-25)
Treatment BXT N=94 9.6 (9) 52.1 (49) 30.9 (29) 7.4 (7)
Delivered
Ac n f  T ra a fm o iif HBXT N=87 20.7 (18) 47.1 (41) 25.3 (22) 6.9 (6)
(N=) BXTC N=37 16.2 (6) 51.4(19) 27.0 (10) 5.4(2)
Biochemical Recurrence j
% (n=) I 9.1 (3) 1.8(2) 0 6.7(1)
Partner Completed Questionnaire 1
1 %  ( N = )  I 75.8 (25) 83.5 (91) 77(47) 73.3(11)
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Exploration of types of data analysis and general HRQOL in EORTC QLQ-C30 
(General Health Related Quality of Life after brachytherapy)
The data from the EORTC QLQ-C30 describing General HRQOL post brachytherapy is 
presented in 4 different analyses to examine the possible confounding effects o f patients who did 
not return one or more questionnaires. These methods included analysing the data points as they 
exist without any further processing, performing a last value carried forward analysis, showing 
only the change in data from the baseline value and performing a subgroup analysis where only 
patients with complete data were analysed. The outcomes o f the different analyses are 
summarised in table 22 (p i59).
The data spread for HRQOL outcomes was not normally distributed and hence box and whisker 
plots are used to describe the data. When reading these, the box represents inter-quartile range 
(IQR) with the bar showing median value. Whiskers extend to the most outlying existing data 
point within 1.5x IQR. Where the median bar lies at the upper or lower IQR (if at least 25% of  
the data above the median is at the median value) no box is seen above the bar which may be less 
clearly visible; therefore median values are also given separately in an accompanying table. 
Circles represent values >1.5x but <3x IQR (near outliers) and asterisks values >3x IQR (far 
outliers). Interpretation guidelines are summarised in fold-out appendix IX in the back sleeve. 
Transformation (of the data which is not normally distributed) and the use o f parametric methods 
for data analysis are not appropriate due to the data distribution (see chapter 4.1, p i35).
Figure 22 (p i58) is a box and whisker plot which demonstrates the changes seen when the raw 
data is plotted without manipulation; median and median change are shown in the first rows o f 
table 22, pl59. Figure 23 (pl61) shows that the median for general HRQOL is the same after 6 
months o f follow-up as at baseline. However the 6-month dataset is missing replies from 21.2% 
of patients. The median change for those patients with data at both baseline and 6m follow-up is 
8.3 points (Table 22, p i59).
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We have therefore decided to use median-change (or median A) to describe whether the 
magnitude o f change in quality o f life after follow-up is clinically significant according to the 
criteria o f Osoba(241) (‘a little’ change - 5-10points, moderate changes - >10-20points and ‘very 
much’ change >20points).
This methodology implies that we accept that were the dataset at 6 months complete that the 
missing data would have the same magnitude o f change from baseline as that o f patients who 
returned their questionnaires. We have also conducted a last value carried forward (LVCF) 
analysis to see whether this method gives significantly different results.
Figure 22. Box and whisker plot of all available data on General Health Related Quality o f Life 
vs. time post brachytherapy implant for all 218 patients.
p-value relates to Wilcoxon Signed Rank Test comparing baseline HRQOL with paired values at 
follow-up. Guidance on interpreting box and whisker plots - see fold out appendix IX p333.
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Chapter 5.1
Last value carried forward analysis
Last value carried forward (LVCF) analysis can help to deal with missing data. When data 
points are missing the last existing data point is carried forward into the next cell. This technique 
can be used to minimise the effect o f patients with bad toxicity dropping out o f follow-up and 
therefore affecting the results.
Figure 23. and table 23 (page 161) show the LVCF data compared with the existing original data 
points. Much o f the missing data (27%) was missing at the 6 week point. It would clearly be 
inadvisable to insert pre-treatment values into the 6-week dataset or subsequent data points where 
there was not an immediate post treatment nadir value as this would inappropriately minimise the 
true toxicity o f the treatment.
This means that the early follow-up dataset is still incomplete despite using LVCF, although the 
completeness of data (compared with the original dataset) improves over time. Populating the 
cells with additional imputed data did not make the General HRQOL of patients significantly 
different at any time point. Statistical analysis o f the difference between LVCF and the original 
dataset (Mann-Whitney U test) did not show significant differences at any point in follow-up.
The last value carried forward methodology was rejected for this study as we felt it more 
representative to report the true data points at each follow-up.
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Chapter 5.1
Subgroup analysis of patients without missing data
Figure 24, below shows the data for all 33 patients (15.1%) who returned their 
complete questionnaire set. The data is also presented in table 22 (page 159) which 
allows comparison with the other methods o f exploratory analysis. All o f the analyses 
reveal a statistically significant reduction in general HRQOL at 6 weeks and 3 months 
post-treatment. Unfortunately this analysis cannot be regarded as representative of  
the study results as it excludes approximately 85% of the patients from analysis. We 
have therefore not used this type o f analysis further in the presented work.
Figure 24. Box and whisker plot of all available data on General Health Related 
Quality o f Life vs. time post brachytherapy implant for 33 patients with no missing 
data, p-value relates to Wilcoxon Signed Rank Test comparing baseline HRQOL 
with paired vales at each follow-up. Further guidance on interpreting box and whisker 
plots - see appendix IX, p333.
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Chapter 5.1
Figure 25. Box and whisker plot o f change in General Health Related Quality o f Life 
compared with baseline vs. time post brachytherapy implant (218 patients had 
baseline plus at least one other value at a later time point). Further guidance on 
interpreting box and whisker plots - see fold out appendix IX p333.
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Figure 25 shows changes in HRQOL compared with baseline. This is a graphical 
illustration of the spread o f data from which Median A is derived.
Table 22 (page 159), shows the data from the various methods o f presentation for 
comparison. The most striking feature o f the different manners o f presentation are 
that other than the lack o f statistical power in the group where only complete datasets 
were considered (n=33) that there was little difference in median or median change 
between the groups.
- 1 6 3 -
Chapter 5.1
Health related quality of life domain outcomes from EORTC QLQ-C30 after 
brachytherapy
The specific domains of the QLQ-C30 are reported in the following chapter. Box and 
whisker plots are used to present all available data points without exclusion o f  
patients with some missing questionnaire packets or imputation of missing data. The 
data for each treatment subtype (BXT, HBXT and BXTC) is presented separately in 
tables below the box and whisker plots which allow a more complete description o f  
the data including paired significance testing comparing baseline function with 
function at further follow-up. Median-A is reported as explained on p i59. Appendix 
IX (fold out from back cover, p333) has further guidance on interpreting figures.
Clinically significant change is defined as statistically significant change (p<0.05) 
from baseline with a median-A of > 5 points. Clinically significant change is 
highlighted in tables: red for ‘very much’ changed data (>20 point change), amber for 
‘moderate’ change (>10 but <20 point change) or green for ‘a little’ change (of 5-10 
points) in HRQOL according to the criteria o f Osoba(241) . Tables showing the 
percentage o f patients affected by moderate or worse deterioration or improvement 
are reported separately where statistically significant change persists at 2 years as this 
may be a figure which is important to discuss with patients.
The demographics o f the three treatment groups are reported in table 24, (p i67). 
Significance tests were performed to compare the patients who received each o f the 
three treatment subtypes. Parametric methods were used when the variable was 
normally distributed (age, dosimetry -  analysis o f variance), non-parametric methods 
when they were non-normally distributed (Kruskall-Wallis). Unsurprisingly given 
that they were part of the criteria for accepting patients into different treatment plans;
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PSA, Gleason score on prostate biopsy, TNM clinical stage and the MSKCC risk 
grouping which is derived from these items of data were all significantly (p<0.001) 
different in the three groups with increasingly high risk patients allocated to more 
aggressive treatment options, of HBXT and BXTC.
IIEF-5 score at baseline was significantly different (p<0.001) by treatment received 
with lower baseline scores in the groups who received hormonal therapy than in those 
who received monotherapy and this may reflect patients who had received AD prior 
to their first clinic assessment or possibly that men who were impotent were more 
likely to be prescribed AD. Significantly (p=0.04) more men who underwent HBXT 
than the other treatments initially presented to the urology team with lower urinary 
tract symptoms (vs. those diagnosed as a result of PSA screening). Although this may 
be related to the fact that some of the HBXT patient received their AD to reduce the 
volume o f enlarged prostates, IPSS urinary symptom score was not related to 
treatment allocation. Interestingly age is related to treatment group allocation with 
older men more likely to receive HBXT. This is may be due to the fact that prostate 
volume is related to age and men who received HBXT were often allocated this 
treatment due to prostate enlargement.
More patients who had insurance or self-paid for brachytherapy vs. NHS provided 
treatment had BXTC whereas the converse is true for BXT and HBXT (p=0.04). 
Treatment cohort was related to HBXT use with earlier patients more likely to receive 
AD (p=0.03), this was when HBXT was used as a ‘holding measure’ to prevent 
disease progression whilst patients were on the waiting list for treatment.
Chapter 5.1
Analysis o f the dosimetry (V I00, V I50 and D90) o f implants showed that patients 
who underwent HBXT had significantly lower dose implants than those who 
underwent BXT (p<0.001 for all 3 dosimetric measurements). This was surprising as 
the planning process and dose prescription described in chapter 4.0 (pi 19) was 
identical for the BXT and HBXT patients. Volume change between pre-implant dose 
plan and the post implant CT scan o f the prostate may affect dosimetry. This was 
analysed to see if  the HBXT patients were found to have a greater volume increase 
which could result from cessation o f the hormonal therapy at implant, with a rebound 
increase in prostate volume.
Change in volume between dose planning and post-implant CT was not significantly 
associated with treatment using BXT compared to HBXT (ANOVA, p=0.55). During 
the PCSS recruitment an increasing number of men received BXT monotherapy 
whilst the number o f men receiving HBXT declined (table 24, p i67). The higher 
values for dosimetric parameters might therefore be related to changes in the planning 
or delivery o f brachytherapy as experience with the technique developed. V I50, V I00 
and D90 were analysed with respect to treatment cohort. A statistically significant 
relationship exists between both pre-implant dosimetric parameters and treatment 
cohort with patients treated later receiving significantly higher activity implants 
(p<0.05 for D90, V I00, V I50). The same parameters as assessed by post-implant CT 
based dosimetry also increase in patients treated later in the series (P<0.05). 
Although the range o f target dosimety remained the same, patients treated later in the 
series received higher dose implants. The differences by treatment group are likely to 
reflect higher V I00 and D90 values in later patients and not a specific effect o f AD on 
dosimetric parameters.
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Table 24. Demographics o f all brachytherapy patients from the PCSS subdivided by 
treatment received. PSA = Prostate Specific Antigen, DRE is Digital Rectal 
Examination Staging According to the TNM 2002/Version 6) staging system (60). 
MSKCC is the risk grading system described in table 4 (p- was41). Private Patients 
funded their own treatment with insurance or self payment whilst NHS patients had 
treatment paid for by the National Health Service. Treatment Cohort describes where 
in the series o f patients treated to date the patients were recruited from. IPSS is 
International Prostate Symptom Score (severity of LUTS), IIEF-5 is the 5 item 
abridged version of the International Index o f Erectile Function
All Demographics By Treatment Group
Patients BXT HBXT BXTC
I N= (% of All 218 Patients) 218 94 (43.1) 87 (39.9) 37(16.9)
1 Age in Years, Mean (SD) 63.4 (6.0) 62.7 (6.1) 64.8 (5.7) 61.4 (6.1)
Presenting PSA in ng/ml 
Median (Range)
7.4
(0.7-19.8)
6.83
(0.7-16.6)
8.4
(1.8-19)
11.0
(3.8-19.8)
Biopsy Gleason Sum 
Median (Range) 6 (2-8) 6(2-7) 6 (3-8) 7 (4-8)
TNM T1 % (N=) 49.1 (107) 61.7 (58) 47.1 (41) 21.6 (8)
Stage On T2 % (N=) 49.1 (107) 38.3 (36) 51.7 (45) 70.3 (26)
DRE T3 % (N=) 1.8(4) - 1.1(1) 8.1 (3)
MSKCC Low Risk 51.4(112) 74.5 (70) 44.8 (39) 8.1 (3)
Risk Intermediate 38.5 (84) 25.5 (24) 50.6 (44) 43.2 (16)
Group
% (N=) High Risk 10.9 (22) - 4.6 (4) 48.6 (18)
Private vs. PP % (N=) 50.5(110) 45.7 (43) 47.1 (41) 70.3 (26)
NHS NHS % (N=) 49.5 (108) 54.3 (51) 52.9 (46) 29.7 (11)
Presenting
Complaint
Screen % (N=) 61.9 (135) 68.1 (64) 52.9 (46) 67.6 (25)
LUTS % (N=) 28.0 (61) 23.4 (22) 33.3 (29) 27.0 (10)
Other % (N=) 10.1 (22) 8.5 (8) 13.8(12) 5.4 (2)
2nd 100 Patients, % (N=) 31.2 (68) 19.1 (18) 44.8 (39) 29.7(11)
Treatment 3rd 100 Patients, % (N=) 27.1 (59) 25.5 (24) 26.4 (23) 32.4 (12)
Cohort 4th 100 Patients, % (N=) 32.1 (70) 48.9 (46) 14.9 (13) 29.7 (11)
5,b 100 Patients, % (N=) 9.6 (21) 6.4 (6) 13.8 (12) 8.1 (3)
Baseline IPSS Score 
Median (Range) 5(0-15) 5 (0-15) 5(0-15) 6(0-15)
Baseline IIEF-5 Score 
Median (Range) 10(1-25)
20.5
(1-25) 3 (1-25) 8 (1-25)
Biochemical Recurrence 
%(n=) 2.8 (6) 1.1 (1) 3.4(3) 5.4(2)
Partner Completed Questionnaire 
% (N=) 79.8 (174) 80.9 (76) 78.2 (68) 81.1 (30)
Post-Implant CT- V150 - 56.3 (11.1) 49.5 (9.6) 54.3 (13.8)
Based Dosimetry in Gy V100 - 90.7 (5.8) 87.4(12.1) 90.0 (7.7)
Mean (SD) D90 - 149.6 (20.7) 140.3 (19.5) 115.2 (17.5)
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EORTC -  QLQ C30 General HRQOL
General HRQOL data is shown in Figure 26 and Table 25 (pl69). The general 
HRQOL derived from the EORTC QLQ-C30 shows statistically significant 
deterioration at all follow-up points to 2 years for BXT monotherapy (apart from 12m 
follow-up). The magnitude of change (median-A) was moderate at 6-weeks before 
reducing to ‘a little’ level o f change at 3-9 months post-implant. However at >12 
months of follow-up the median-A was clinically insignificant for BXT with a zero 
median change.
Within the group o f patients who received androgen deprivation in addition to 
brachytherapy (HBXT) both statistically and clinically significant changes in HRQOL 
were absent at >6 months, and at <6m deterioration in HRQOL was o f ‘a little clinical 
significance.
For the BXTC group who received external beam radiotherapy in addition to 
androgen deprivation and brachytherapy the changes were similar to those observed 
in the BXT group with ‘moderate’ deterioration in HRQOL at 6 weeks which were 
absent at 3m before recurring at ‘a little’ clinical significance at 6m and then returning 
to levels not significantly different from baseline at >9m.
Although the descriptive information derived from box and whisker plots gives an 
understanding o f the distribution and statistical significance o f the described changes, 
it is not possible to derive a % affected by severe toxicity. The % of patients who 
experienced moderate or greater deterioration in HRQOL vs. unchanged or affected 
by changes o f only ‘a little’ significance vs. those experiencing moderate or greater 
improvement by treatment is given in table 26 (p i70).
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Chapter 5.1
Whilst a median change of zero is described in all groups at 2 years; 27.5% of men 
returning questionnaires at 2 years had at least a moderate worsening in HRQOL which 
was somewhat offset by the 15% who reported at least a moderately improved 
HRQOL.
Table 26. Number o f patients affected by changes o f ‘moderate’ or greater intensity 
change in HRQOL at 2 years follow-up after BXT, HBXT and BXTC.
> ‘Moderate’ 
Improvement in 
HRQOL n=
(% of recorded data)
Change of <
‘a little’ Clinical 
Significance n=
(% of recorded data)
> ‘Moderate’ 
Worsening in 
HRQOL n=
(% of recorded data)
Missing
Data
n=
BXT 8 (10.1) 46 (58.2) 25 (31.6) 15
HBXT 12 (20 .0) 36 (60.0) 12 (20 .0) 27
BXTC 5 (17.5) 14 (50.0) 9(32) 9
All BXT 25 (15.0) 96 (57.5) 46 (27.5) 50
Physical function after brachytherapy
Physical function (Figure 27 & Table 28, pl71) was less affected by treatment. 
Although BXT patients had a statistically significant deterioration in physical function 
at 6wk-3m this was deemed clinically insignificant with a median change of zero. 
Changes within the HBXT group were similar (statistically significant but clinically 
insignificant change at 6wk only). BXTC patients described a statistically significant 
change of ‘moderate’ intensity deterioration in physical function at 6-weeks which 
resolved at further follow-up. Few ‘moderate’ or greater intensity changes at 2-years 
(Table 27, below) reflect the lack of significant change detected in Figure 27 & Table 
28 (pl71).
Table 27. Number o f patients affected by changes > ‘moderate’ intensity change in 
physical function at 2 years follow-up after BXT, HBXT and BXTC.
> ‘Moderate’ 
Improvement in 
Physical Function n= 
(% of recorded data)
Change of <
‘a little’ Clinical 
Significance n=
(% of recorded data)
> ‘Moderate’ 
Worsening in 
Physical Function n= 
(% of recorded data)
Missing
Data
n=
BXT 1 (1.3) 72 (91.1) 6(7.6) 15
HBXT 7(11.3) 53 (85.4) 2 (3.2) 25
BXTC 3 (10.7) 23 (82.1) 2(7.1) 8
All BXT 11 (6.5) 148 (87.6) 10 (5.9) 48
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Chapter 5.1
Social function after brachytherapy
Social function (Figure 28 & Table 31, p i74) was affected only in the immediate post­
treatment phase with moderate deterioration for patients treated with BXT and BXTC at 6 
weeks and no clinically significant change thereafter. HBXT was not significantly affected at 
any time point.
Role function after brachytherapy
Role function (Figure 29 & Table 32, p i75) was unaffected by clinically significant change 
except at the 6 week assessment in the BXTC group where a significant deterioration of 
moderate intensity was detected.
Emotional function after brachytherapy
Emotional function (Figure 30 & Table 33, p i76) was interesting as levels of function 
improved after treatment. This effect only reached statistical significance in the BXT 
group at 2 years and the results were not clinically significant in any group. Table 29. 
below, details the % of men describing moderate or greater change which supports the 
findings of the group as a whole.
Table 29. Number of patients affected by changes > ‘moderate’ intensity change in 
emotional function at 2 years follow-up after BXT, HBXT and BXTC._______________
> ‘Moderate’ 
Improvement in 
Emotional Function 
n= (%  of recorded data)
Change of
< ‘a little’ Clinical
Significance
n= (% of recorded data)
> ‘Moderate’
Worsening in 
Emotional Function 
n= (% of recorded data)
Missing
Data
n=
BXT 22 (27.8) 49 (62.0) 8 (10.1) 15
HBXT 15 (25.0) 39 (65.0) 6 (10.0) 27
BXTC 6 (20.7) 20 (69.0) 3 (3.4) 8
All BXT 43 (25.6) 108 (64.3) 17(10.1) 50
Cognitive function after brachytherapy
Cognitive function (figure 31 & Table 34, p i77) did not show clinically relevant changes 
after treatment.
- 172-
Chapter 5.1
Fatigue after brachytherapy
Fatigue (Figure 32 & Table 35, pl78) was transiently affected by treatment. All patients had 
a statistically significant increased level o f fatigue (i.e. worse) at 6wk (‘moderate’ intensity 
for BXT and BXTC and ‘a little’ intensity for HBXT).
Pain
Pain (Figure 33 & Table 36, p i79) was transiently affected by treatment with the BXTC 
group reporting moderate pain at 6 weeks. Thereafter pain was not reported at clinically 
significant levels.
Other symptom domains of the EORTC-QLQ C30
Nausea and Vomiting, Dyspnoea, Insomnia, Appetite Loss, Constipation and Financial 
changes were not found at clinically significant levels after brachytherapy (Figure 34-40 and 
tables 37-43, p+180-186).
Diarrhoea (Figure 39 and table 42, p i85), has been reported in other studies as a result o f  
brachytherapy treatment. Although statistically significant increase in symptoms occurred in 
all three groups 6 weeks post treatment this was never deemed clinically significant and 
statistical significance disappeared 12 months after BXT , 6m after HBXT and at 3 months 
after BXTC. Moderate change in diarrhoea at 2 years is detailed in table 30.
Table 30. Number of patients affected by changes > ‘moderate’ intensity change in 
diarrhoea at 2 years follow-up after BXT, HBXT and BXTC.
> ‘Moderate’ 
Improvement in 
Diarrhoea
n= (% of recorded data)
Change of
< ‘a little’ Clinical
Significance
n= (% of recorded data)
> ‘Moderate’
Worsening in 
Diarrhoea
n= (% of recorded data)
Missing
Data
n=
BXT 6(7.7) 68 (87.2) 4(5.1) 16
HBXT 10(16.7) 38 (63.3) 12 (20 .0) 27
BXTC 5 (17.9) 12 (42.9) 11 (39.3) 9
All BXT 21 (12.7) 118(71.1) 27 (16.3) 52
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Chapter 5.1
HRQOL domain outcomes from EORTC PR25 in brachytherapy patients from 
the prostate cancer symptom study
EORTC PR25 Urinary problems domain
The urinary problems domain (shown in Figure 41 and table 45, p i90) shows 
statistically significant change at all points o f follow-up for patients treated with BXT. 
The changes are consistent with ‘very much’ worse urinary problems at 6 weeks 
assuming that the Osoba (241) criteria are true for PR25 domains. At further follow- 
up the level o f symptoms reduce with ‘moderate’ levels of symptoms at 3-6m, and by 
>9m symptoms consistent with ‘a little’ worse urinary problems occur.
By 24 months the breakdown of men with > moderate deterioration in symptoms (>10 
point on a 100 point scale) is shown in table 44 (below). Clearly urinary symptoms 
may remain a significant problem after all three subtypes o f brachytherapy with 31- 
46% of men reporting moderate or worse new urinary symptoms at 2 years.
Table 44. Number o f patients affected by changes > ‘moderate’ intensity
change in urinary problems at 2 years follow-up after BXT, HBXT and BXTC.
> ‘Moderate’ 
Improvement in 
Urinary Problems 
n= (% of recorded data)
Change of <
‘a little’ Clinical 
Significance
n= (% of recorded data)
> ‘Moderate’
Worsening in 
Urinary Problems 
n= (% of recorded data)
Missing
Data
n=
BXT 3 (8.8%) 40 (50.6%) 36 (45.6%) 15
HBXT 4 (6 .6%) 35 (57.4%) 22 (36.1%) 26
BXTC 3 (10.3%) 17 (58.6%) 9(31.0%) 8
All BXT 10 (5.9%) 92 (54.4%) 67 (39.6%) 49
We have therefore explored the changes in question responses at 6 wk and 2 years to 
see if changing symptoms or persistence o f similar problems is apparent and to 
describe which domains are persistently altered after brachytherapy. The 8 questions 
making up the urinary problems scale are reported in Table 46(pl91), at 6 weeks and 
24m. Median change in Likert scale score per question and % of men changing score 
by >2 point deterioration on the Likert scale (e.g. Q1 on urinary frequency below, 2
- 1 8 7 -
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points represents change from ‘not at all’ to ‘quite a bit’ or ‘very much’, PR25 
questionnaire reproduced in appendix III, p299).
D u r i n g  t h e  p a s t  w e e k
Not 
at all
A little Quite a 
bit
Very
much
31. Have vou had to urinate freauentlv during the dav? 1 2 3 4
Affected urinary questions
For BXT the most prevalent (% of men affected) severe toxicity reported at 6 weeks 
was: daytime frequency 34%, urgency 33% and nocturnal frequency 27%, with 24% 
sleep disturbance secondary to nocturia. By 2 years the number o f men reporting 
severe symptoms was markedly reduced and the most prevalent symptom was urinary 
urgency (16.5%) followed by problems with going out o f the home due to need to be 
close to a toilet (12.7%) and daytime frequency (10.4%).
A similar pattern occurred after HBXT with daytime frequency and urgency both 
occurring in 31% of the sample at 6 weeks and the most common problem at 2 year 
follow-up being urinary urgency affecting 10% of men.
BXTC produced a different symptom profile with pain from urination and problems 
with leaving the house (both 21%) affecting men at 6 weeks. Urinary frequency 
appeared less of a problem at 6 weeks (17% daytime frequency). At 2 years urinary 
urgency was the most prevalent severe symptom (17%).
EORTC PR25 Urinary incontinence and incontinence aid bother domains
Urinary incontinence is one o f the symptom scales that make up the urinary problems 
domain. A separate domain ‘urinary incontinence aid bother’ (UIAB) is completed 
only if men wear incontinence aid (usually some form of pad). The rate o f
- 188-
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completion o f UIAB rises over time post-implant within the first 2 years for all 
treatment groups (table 47 p i92). UIAB was rarely completed at baseline (1.4% 
completed the ‘not at all bothered’ stem at baseline) and none of the recruited patients 
reported urinary incontinence in their clinic interview.
Only one man completed the ‘quite a bit’ bothered by need to wear incontinence aid 
stem (3m after HBXT) and this resolved spontaneously. At 2-years post BXT the 
rates of completion for the UIAB stem were 15%: 13% ‘not at all’ bothered with 2% 
‘quite a bit’ or ‘very much’ bothered. For question 6 on the presence o f urinary 
leakage after BXT this was worst at 6 weeks and 24months. At 24m 39.2% of men 
reported ‘a little’ urinary incontinence compared with 9.6% at baseline although only 
an additional 2.6% reported more than ‘a little’ urinary incontinence.
2-years after HBXT rates o f completion o f the UIAB stem were 9% ‘Not at A ll’ 
bothered with no worse toxicity reported. 33% of men reported ‘a little’ urinary 
leakage which increased from 13% at baseline. <2% reported more than ‘a little’ 
urinary leakage. 2-years post BXTC rates o f completion o f the UIAB stem were 14% 
‘Not at All’ bothered with 3% ‘a little’ bothered. This correlated with an increase 
from 24% to 41% in ‘a little’ urinary incontinence and from 0% to 3% for more than 
‘a little’ incontinence.
Of the men with marked new incontinence (n=4) 2 had received BXT, 1 HBXT and 
one BXTC. None had had TURP before or after implantation. None were part o f the 
urodynamics study. Their IPSS scores were low (4-7) and dosimetry was not outside 
of limits acceptable in our practice VI 50 30-60%, V100>90%, D90>90% although 
more detailed dosimetric parameters were not available.
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Chapter 5.1
Table 46. Exploration of change from baseline in the stem questions o f the 
EORTC-PR25 urinary problem scale .
Median change reported where data present at baseline and follow-up. N and % reported for 
change in score >2 points (On 4 point Likert scale i.e. from ‘Not at all’ to Quite a bit’ or from ‘a 
little’ to very much’.
Median A 
Score 6Wk
N= (%) 
Reporting >2 
Point Change 
at 6wk
Change in score 
24m
N= (%) 
Reporting >2 
Point Change 
at 24m
BXT
N= 67 78
1. Day Frequency -1 23 (34.3) 0 8 (10.4)
2. Night Frequency -1 18 (26.9) 0 6 (7.7)
3. Urgency -1 22 (32.8) 0 13 (16.5)
4. 2ndry Sleep problem -1 16 (23.9) 0 6(7.6)
5. Problem Leaving House 0 4 (6.0) 0 10(12.7)
6. Urine Leakage 0 4 (6.0) 0 2 (2.5)
7. Pain from urination -1 8(11.9) 0 6(7.6)
9. Limited Daily Activity 0 3 (5.8) 0 2(2.5)
8. Urinary Inc. Aid Bother 0 0 0 0
Median A 
Score 6Wk
N= (%) 
Reporting >2 
Point Change 
at 6wk
Change in score 
24m
N= (%) 
Reporting >2 
Point Change 
at 24m
HBXT
N= 61 61
1. Day Frequency -1 19(31.1) 0 1 (1-6)
2. Night Frequency -1 17 (27.9) 0 3 (4.9)
3. Urgency -1 19(31.1) 0 6 (9.8)
4. 2ndry Sleep problem -1 17 (27.9) 0 1 (1.6)
5. Problem Leaving House 0 6 (9.8) 0 0
6. Urine Leakage 0 4 (6.6) 0 1 (1.6)
7. Pain from urination -1 10(16.4) 0 3 (4.9)
9. Limited Daily Activity -1 6 (9.8) 0 0
8. Urinary Inc. Aid Bother 0 0 0 0
Median A 
Score 6Wk
N= (%) 
Reporting >2 
Point Change 
at 6wk
Change in score 
24m
N= (%) 
Reporting >2 
Point Change 
at 24m
BXTC
N= 29 29
1. Day Frequency -1 5(17.2) 0 1 (3.4)
2. Night Frequency 0 4(13.8) 0 1 (3.4)
3. Urgency -1 5 (17.2) 0 5 (17.2)
4. 2ndry Sleep problem 0 3 (10.3) 0 2 (6.9)
5. Problem Leaving House -1 6 (20.7) 0 0
6. Urine Leakage 0 2 (6.9) 0 1 (3.4)
7. Pain from urination -1 6 (20.7) 0 2 (6.9)
9. Limited Daily Activity 0 4(13.8) 0 0
8. Urinary Inc. Aid Bother 0 0 0 0
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Table 47. EORTC PR25 questions 6-urinary incontinence and question 8-urinary 
incontinence aid bother; changes over time post treatment.
Urinary incontinence aid bother was scored a separately as an answer to the question ‘Has 
wearing an incontinence aid been a problem for you?’ which patients were expected to 
answer only if they wore an incontinence aid. For clarity the answers o f the urinary 
symptom subscale question relating to incontinence ‘Have you had any unintentional 
release (leakage) o f urine’ which all patients were asked to answer are presented 
alongside these data. UI=Urinary Incontinence (Q6), UIAB= Urinary Incontinence Aid 
Bother (Q8).
Whole Group n=218 Baseline 6 Wk 3 Months 6 Months 9 Months 12 Months 18 Months 24 Months
UI Completed
Completed Stem n = ( % ) 217(99.5) 157 (72.0) 174 (79.8) 172 (78.9) 100 (45.9) 139 (63.8) 166 (76.1) 169 (77.5)
‘Not at all’ n= (%) 188 (86.6) 81 (51.6) 112(64.4) 111 (64.5) 68 (68.0) 95 (68.3) 117(70.5) 102 (60.4)
‘A Little’ 29(13.4) 62 (39.5) 56 (32.2) 56 (32.6) 30 (30.0) 39 (28.1) 44 (26.5 ) 63 (37.3)
‘Quite a bit’ n =  ( % ) 0 11 (7.0) 5 (2.9) 3(1.7) 2 (2.0) 4 (2.9) 5 (3 ) 3 (1.8)
‘Very much’ 0= (% ) 0 3(1.9) 1 (0.6) 2(1.2) 0 1 (0.7) 0 1 (0.6)
UIAB Completed
Completed Stem n= 3 6 10 6 2 12 9 28
‘Not at all’ n = 3 3 7 5 2 11 9 25
‘A Little’ n= 0 3 2 1 0 1 0 3
‘Quite a bit’ n = 0 0 1 0 0 0 0 0
‘Very much’ n = 0 0 0 0 0 0 0 0
BXT Alone n=94 Baseline 6 Wk 3 Months 6 Months 9 Months 12 Months 18 Months 24 Months
UI Completed
Completed Stem n = ( % ) 94 (100) 67 (71.3) 74 (78.7) 70 (74.5) 28 (29.8) 57 (60.6) 69 (73.4) 79 (84.0)
‘Not at all’ n=(% ) 85 (90.4) 37 (55.2) 52 (70.3) 45 (64.3) 20(71.4) 39 (68.4) 51 (73.9) 46 (58.2)
‘A Little’ n=(% ) 9 (9.6) 23 (34.3) 18(24.3) 22 (31.4) 8 (28.6) 15(26.3) i 16(23.2) 31 (39.2)
‘Quite a bit’ n= (%) 0 6 (9.0) 3(4.1) 1 (1.4) 0 2 (3.5) 2 (2.9) 1 (1.3)
‘Very much’ n= 0 1 (1.5) 1 (1.4) 2 (2.9) 0 1 (1.8) 0 1(1.3)
UIAB Completed
Completed Stem n=(% ) 2 2 3 3 0 5 5 14
‘Not at all’ n  = ( % ) 2 1 2 2 0 5 5 12
‘A Little’ n =  ( % ) 0 1 0 1 0 0 0 2
‘Quite a bit’ n= (%) 0 0 1 0 0 0 0 0
‘Very much’ n =  ( % ) 0 0 0 0 0 0 0 0
HBXT 2 II OO ■-J Baseline 6 Wk 3 Months 6 Months 9 Months 12 Months 18 Months 24 Months
UI Completed
Completed Stem n= (%) 86 (98.9) 61 (70.1) 72 (82.8) 72 (82.8) 53 (60.9) 59 (67.8) 68 (78.2) 61 (70.1) I
‘Not at all’ n =  ( % ) 75 (87.2) 32 (52.5) 45 (62.5) 49 (68.1) 35 (66.0) 43 (72.9) 47 (69.1) 40 (65.6)
‘A Little’ n =  ( % ) 11 (12.8) 24 (39.5) 26 (36.1) 21 (29.2) 18(34.0) 16(27.1) 19(27.9) 20 (32.8)
‘Quite a bit’ n - r „ i 0 4 (6.6) 1 (1-4) 2 (2.8) 0 0 2 (2.9) 1 (1.6)
‘Very much’ n= 0 1 (1.6) 0 0 0 0 0 0
UIAB Completed
Completed Stem n= (%) 1 4 4 3 2 7 2 8
‘Not at all’ n= (%) 1 2 3 3 2 6 2 8
‘A Little’ n = ( % » 0 2 1 0 0 1 0 0
‘Quite a bit’ n =  ( % ) 0 0 0 0 0 0 0 0
‘Very much’ n = ( % ) 0 0 0 0 0 0 0 0
BXTC n=37 Baseline 6 Wk 3 Months 6 Months 9 Months 12 Months 18 Months 24 Months
UI Completed
Completed Stem n = < % ) 37(100) 29 (78.4) 29 (78.4) 30(81.1) 19(51.4) 23 (62.2) 29 (78.4) 29 (78.4)
‘Not at all’ n =  ( % ) 28 (75.7) 12(41.4) 16(55.2) 17(56.7) 13(68.4) 13 (56.5) 19(65.5) 16(55.2)
‘A Little’ n= (%) 9 (24.3) 15(51.7) 12 (41.4) 13(43.3) 4(21.1) 8 (34.8) 9(31.0) 12(41.4) j
‘Quite a bit’ n =  ( % ) 0 1 (3.5) 1 (3.5) 0 2(10.5) 2 (8.7) 1 (3.5) 1 (3.5)
‘Very much’ n= 0 1 (3.5) 0 0 0 0 0 0
Completed Stem n= (%) 0 0 3 0 0 0 2 6
‘Not at all’ 0 0 2 0 0 0 2 5
‘A Little’ n =  ( % ) 0 0 1 0 0 1 0 0 1
‘Quite a bit’ n = ( % ) 0 0 0 0 0 0 0 0
‘Very much’ n= (%) 0 0 0 0 0 0 0 0
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EORTC PR25 Bowel problems domain
The bowel problems domain (Figure 42 and table 48, p i94) shows statistically significant 
changes for all groups after treatment. For BXT and HBXT the Median-A was zero. The 
slightly larger changes in bowel symptoms in the BXTC were clinically significant (at 6 
weeks, 9m and 24m) and it is possible that had greater power been achieved in the BXTC 
group that clinically significant change would have occurred at each point in follow-up.
When the presence o f new symptoms o f moderate intensity at 2 years is assessed (table 
49, p i95) the higher incidence o f bowel symptoms at two years in the BXTC group is 
further reinforced with approximately double the incidence in the BXTC group compared 
with the BXT group. Although the incidence o f bowel problems was higher after BXTC 
the three patients who reported ‘very much’ toxicity (>20 point change) did not have 
EBRT as a part of their brachytherapy treatment (FEBXT n=3 and BXT n=2).
Because the analysis o f the internal consistency o f the bowel problems scale showed 
heterogeneity for the scaling o f bowel problems the results for individual stems are 
reproduced on a per question basis in table 50 (p i95). Median changes o f more than 1 
Likert point in any question did not occur for any question, in any treatment group at any 
time point. Although BXTC showed fewer questions changed by >2 points at 2 years the 
results o f table 49 reflect the higher chance o f more than 2 questions worsening after 
BXTC (1 point change in each question changes the scaled domain score by 8.3 points 
therefore any change by 2 points or more than one stem changed by 1 point reflects 
‘moderate’ significance according to the Osaba criteria).
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Chapter 5.1
Table 49. Number o f patients affected by > ‘moderate’ intensity change in bowel problems 
at 2 years follow-up after BXT, HBXT and BXTC.
> ‘Moderate’ 
Improvement in 
Bowel Problems 
n= (% of recorded data)
1 Change of <
H ‘a little’ Clinical 
I Significance 
| n= (% of recorded data)
> ‘Moderate’
Worsening in
Bowel Problems
n= (% of recorded data)
Missing
Data
n=
BXT 0 62 (88 .6) 8(11.4) 24
HBXT 2 (3.9) 41 (80.4) 8 (15.7) 36
BXTC 1 (4.3) I 17(73.9) 5 (21.7) 14
All BXT 3 (2.1) I 120(83.3) 21 (14.6) 74
Table 50. Exploration o f  change from baseline in the stem questions o f  the EORTC-PR25 bowel 
problem scale.
Median change reported where data present at baseline and fu. N and % Reported for Change in score >2 
points (On 4 point Likert scale i.e. from ‘Not at all’ to Quite a bit’ or from ‘a little’ to very much’.
M edian A 
Score 6W k
N= (%) 
Reporting >2 
Point Change 
at 6wk
M edian A 
Score 24m
N= (%) 
Reporting >2 
Point Change 
at 24m
N = 1 52 70
10. Activity Limited 0 ' 1 (1.9) 0 0
BXT 11. Faecal Leakage 0 0 0 3 (4.3)
12. Blood in Stool 0 0 0 0
13. Abdominal Bloat 0 3 (5.8) 0 0
M edian A 
Score 6W k
N= (%) 
Reporting >2 
Point Change 
at 6wk
M edian A 
Score 24m
N= (%) 
Reporting >2 
Point Change 
at 24m
N= | 50 51
10. Activity Limited 0 1 (2.0) 0 0
HBXT 11. Faecal Leakage 0 0 0 0
12. Blood in Stool 0 2 (4.0) 0 2 (3.9)
13. Abdominal Bloat o 1 (2.0) 0 2 (3.9)
M edian A 
Score 6W k
N= (%) 
Reporting >2 
Point Change 
at 6wk
M edian A 
Score 24m
N = (%) 
Reporting >2 
Point Change 
at 24m
N= 20 23
10. Activity Limited 0 3 (15.0) 0 0
BXTC 11. Faecal Leakage 0 1 (5.0) 0 0
12. Blood in Stool 0 0 0 0
13. Abdominal Bloat 0 0 0 0
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EORTC PR25 Treatment symptoms following brachytherapy domain
The treatment symptoms domain (figure 43 and table 51, p i 97) is designed to show changes in 
symptoms associated with androgen deprivation treatment. It is made up o f  6 questions. These 
were on hot flushes, nipple tenderness, ankle swelling, weight loss or gain and feelings o f  
decreased masculinity as a result o f  treatment.
The three groups described in table 51 (p i97) were heterogeneous in their levels o f  treatment 
symptoms at baseline (Kruskall Wallis test p<0.001). The two hormonally treated groups had 
‘moderate’ reported symptoms at baseline (median 16.7 points on a 100 point scale) i.e. these 
patients were 3 Likert points worse than the BXT monotherapy group before brachytherapy 
treatment. The number o f  patients reporting > moderate treatment symptoms at baseline was: 
18/94 (19.1%) o f  BXT patients, 63/86 (73.3%) o f HBXT patients and 27/36 (75.0%) o f  BXTC 
patients.
Whilst the BXT patients developed a statistically significant increase in symptoms at all time 
points after treatment, the median-A never reached levels o f clinical significance. In contrast the 
groups who received neoadjuvant androgen deprivation reported a clinically and statistically 
significant improvement in treatment symptoms at all time points except 6 weeks and 9months post 
treatment for HBXT and all points other than 6 weeks, 6 and 9 months for BXTC.
These findings raise the possibility o f  confounding with patients filling in the questionnaires to 
describe their health as it was on the androgen deprivation that they had received prior to the 
brachytherapy implant instead o f  as it was in clinic prior to starting androgens. Some patients may 
also have received AD from their referring hospitals.
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Chapter 5.1
EORTC PR25 Sexual activity domain
The sexual activity domain comprises two questions on sexual interest and activity and results are 
shown in figure 44 and table 53 (p202). The baseline scores were much poorer in the two groups 
who were exposed to AD (Kruskall Wallis test pO.OOl).
After BXT, scores reduced significantly at 6wk and 3m time points and clinically significant 
change was present at 3m. With further follow-up statistically significant change disappeared. 
HBXT patients showed statistically significant deterioration at 6 weeks and 12-18 months post 
implant although the median-A was not clinically significant. After BXTC sexual activity 
deteriorated by statistically but not clinically significant amounts at 6 weeks and a single point 
(9m) showed statistically but not clinically significant improvement in sexual activity.
EORTC PR25 Sexual function domain
The sexual function domain (figure 45 and table 54, p203) is made up o f  4 domains, sexual 
enjoyment, erection difficulty, ejaculation problems and feelings o f  discomfort with sexual 
intimacy. Men are instructed only to complete the domain if  they are sexually active (although 
type o f  activity is unspecified).
Completion rates and median baseline scores were different by group at baseline: 65/94 (69.1%) 
BXT patients completed baseline assessment, 33/87 (37.9%) o f HBXT patients and 17/37 (45.9%) 
o f men undergoing BXTC. At the end o f 2-year follow-up this reduced to 46/94 (29 % reduction 
in completion rate) after BXT, 21/87 (36% reduction) after HBXT, and 12/37 (29% reduction) 
after BXTC. The scores o f those patients who felt that they should complete the stem also fell. 
BXT patients reported a statistically significant reduction in sexual function at all time points after 
brachytherapy o f at least moderate intensity. For the HBXT group statistical significance was not 
reached for those patients who still returned questionnaires. In the limited sample that completed
- 198-
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the questionnaire 6-weeks after BXTC there was a clinically significant change o f  severe intensity 
but not at further follow up.
Further exploration o f  the answers to the sexual activity and function stems are presented in table 
55, page 204. After BXT the questions associated with a change in median answer per scale at 6 
weeks were deterioration in sexual enjoyment and erectile difficulties. At 6 weeks these were also 
the scales o f  the PR25 most likely to be associated with a 2-point change in Likert scaled answer 
(23% for both). By two years post-BXT sexual enjoyment and erectile difficulties were still the 
questions likely to be associated with change to median score. Erectile function was associated 
with>2 point deterioration in 41% o f  the 46 men who still considered themselves sexually active, if  
this is considered alongside the 19 men who failed to return a questionnaire confirming sexual 
activity then as many as 58.5% o f  men may have developed important new erectile difficulties 2 
years after BXT. At 2 years post-implant, ejaculation problems which changed the Likert scaled 
response by >2 points occurred in 20% o f  men.
For men undergoing HBXT completion rates o f  the sexual function scales at baseline were poor; 
only 33/86 (38.4%) o f  the group completed a baseline questionnaire and only 10/86 (11.6%) 
completed a 6-week questionnaire. Low scores at baseline, possibly due to patients, who had 
completed the questionnaire as they were having been exposed to AD, may have resulted in some 
floor effects as patients reduced their sexual activity or lost function as a result o f  AD. Men who 
returned the 6-week questionnaire most frequently reported a >2 points Likert scale change in the 
same 2 questions as BXT patients (1/10 patients each). By 12 months >2 points Likert scale 
change in ejaculation problems and sexual intimacy issues were more prevalent than problems with 
sexual enjoyment and erectile difficulties.
For the BXTC group completion rates o f  the sexual function scales were better at baseline 17/37 
(46%) than in the other AD exposed group who had HBXT. 10 o f  these patients also replied at 6-
- 199-
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weeks (27%) and by 2 years 12 patients regarded themselves as sexually active enough to complete 
the questions on sexual function. As in the BXT group, the sexual enjoyment and sexual intimacy 
question replies were affected with median change o f  1 Likert point each. All scales reported a 
1/10 rate o f >2 points Likert scale change in sexual enjoyment, erectile difficulties, ejaculation 
problems with a 2/10 rate o f  sexual intimacy problems at 6 weeks. Similar rates o f  1/12 for sexual 
enjoyment, erectile difficulties, ejaculation problems and 2/12 for sexual intimacy problems at 2 
years were noted.
International Index of Erectile Function (IIEF) -  assessment of potency post brachytherapy
The international index o f  erectile function (IIEF) scale assessed post brachytherapy erectile 
function (figure 46. and table 56, p205). All groups showed statistically significant reductions in 
IIEF-5 item score at 6 weeks post implant. Thereafter a statistically significant change occurred 
only in the BXT group. Low IIEF-5 scores in the HBXT and BXTC groups at baseline may reflect 
similar problems to those affecting the PR25 scales where patients may be reporting their function 
on AD.
The IIEF-5 may be used to classify patients by ED severity category. This allows a % o f  men who 
are free o f  moderate-severe ED to be given (table 57, p206). As a significant amount o f  the data is 
missing these scores must be interpreted with caution as 22% o f  men who completed QLQ-C30 did 
not complete the IIEF at baseline and non-completion may not be a random event. The sexual 
function questionnaire o f  PR25 was completed by 115/218 men who regarded themselves as 
‘sexually active’. Higher completion rates were observed for the IIEF-5 with 209 men completing 
the questionnaire at baseline. O f these men 170 men (81%) had partners who replied to the 
Taunton questionnaire and IIEF-5 severity class for these men is described in figure 47 and table 
57 (page 206). O f the men who underwent all forms o f  brachytherapy and completed the IIEF-5 
half (91/170) would be regarded as free from moderate-severe erectile dysfunction at baseline 
based on their IIEF-5 score (figure 47 and table 57 p206).
- 2 0 0 -
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The outcome o f  treatment for these men is presented for all potent man (figure 48, p207) and 
divided by treatment group in figure 49-51 and table 59-61, (p209-211). Because o f  a significant 
amount o f  missing data the results must be interpreted with caution as there were limited numbers 
o f  potent patients in the HBXT and BXTC groups. The rate o f  use o f oral agents to treat erectile 
dysfunction and gain these results also increased during the study as outlined in table 52 below. 
These results apply to the outcome groups described in fig 49-51 (p208-210).
Table 52. Rate o f  use o f treatments for erectile dysfunction in men potent prior to brachytherapy 
who were in a sexual relationship with a partner._______________________________________________
Treatment Number o f Potent Men 
taking ED
Treatment Preimplant
Number o f Potent 
Men taking ED 
Treatment 6m
Number o f  Potent 
Men taking ED 
Treatment 12m
Number o f  Potent 
Men taking ED 
Treatment 24m
BXT 8/56 (14.3%) 24/42 (57.1%) 22/31 (66.7%) 28/45 (62.2%)
HBXT 2/22 (9.1%) 7/17 (5.9%) 8/16 (50.0%) 8/16 (50.0%)
BXTC 0/13 3/10 (30.0%) 5/8 (62.5%) 9/11 (81.8%)
All BXT 10/91 (11.0%) 34/69 (49.3) 35/55 (63.6%) 45/72 (62.5%)
Rates o f  potency preservation in the HBXT group were better than those in the BXT group (75 vs. 
51 % at 2 years). However the number o f  men who were potent at baseline in the HBXT group is 
small and comparative analysis lacks power. Several possible explanations for better potency 
preservation in the HBXT group exist. Firstly, men with artificially lowered IIEF-5 scores at 
baseline due to completing baseline questionnaires on androgen deprivation in the HBXT group 
might have better sexual function than the cohort o f  men undergoing BXT who had accurate 
baseline data. Secondly men in the HBXT group had lower values for CTV dosimetry as described 
in table 24 p i67). If lower CTV dosimetry is associated with lower dose to critical structures such 
as the penile bulb, then the lower rates o f  potency preservation after BXT might be a result o f  dose 
escalation. Unfortunately dosimetric data on the penile bulb was not available due to limited 
staffing. Logistic regression analysis o f  effect o f  general dosimetric parameters (D90, V I 50, and 
V I00) on potency preservation was attempted but a stable model could not be achieved. This 
aspect o f  the data was therefore not explored further. Other authors have not found that dosimetry 
o f the CTV is able to predict sexual dysfunction on univariate or multivariate models (210).
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Chapter 5.1
Table 55. Exploration o f change from baseline in the stem questions o f  the 
EORTC-PR25 sexual activity and function scales
Median change reported where data present at baseline and follow-up. N and % reported for 
change in score >2 points (On 4 point Likert scale i.e. from ‘Not at all’ to Quite a bit’ or from ‘a 
little’ to very much’. Scores have been recoded so that -ve median change = worse outcome.
Median A 
Score 6Wk
N= (%) 
Reporting >2 
Point Change 
at 6wk
Change in score 
24m
N= (%) 
Reporting >2 
Point Change 
at 24m
N = 93 at Baseline 65 78
20. Sexual interest 0 5 (7.7) 0 0
21. Sexual activity 0 7 (10.8) 0 6 (7 .7 )
N = 65 at Baseline 1 30 46
BXT 22. Sexual enjoyment 1 -0.5 7 (23.3) -1 1 (2.2)
23. Erectile difficulties -1 7 (23.3) -1 19(41.3)
24. Ejaculation problems 0 5 (16.7) 0 9 (19.6)
25. Sexual intimacy prob. o 4(13 .3 ) 0 5 (10.9)
1
Median A 
Score 6Wk
N= (%) 
Reporting >2 
Point Change 
at 6wk
Change in score 
24m
N= (%) 
Reporting >2 
Point Change 
at 24m00& 60 61
20. Sexual interest 0 1 (1.7) 0 1 (1.6)
21. Sexual activity 0 1 (1.7) 0 2 (3.3)
HBXT
N= 33 10 21
22. Sexual enjoyment 0 1 (10.0) 0 1 (4.8)
23. Erectile difficulties 0 1 (10.0) 0 1 (4.8)
24. Ejaculation problems 0 0 0 2 (9 .1 )
25. Sexual intimacy prob. 0 0 0 2 (9 .1 )
Median A 
Score 6Wk
N= (%) 
Reporting >2 
Point Change 
at 6wk
Change in score 
24m
N= (%) 
Reporting >2 
Point Change 
at 24m
1 N = 36 25 26
20. Sexual interest 0 1 (4.0) 1 (3.8)
21. Sexual activity 0 0 0
BXTC N= 17 10 12
22. Sexual enjoyment -1 1 (10.0) 0 1(8.3)
23. Erectile difficulties 0 1 (10.0) -1 1 (8.3)
24. Ejaculation problems 0 1 (10.0) 0 1 (8.3)
25. Sexual intimacy prob. -1 2 (20.0) 0 2 (16.7)
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Chapter 5.1
International Prostate Symptom Score
The results o f the IPSS score interpreted from studies on the recovery o f  urinary function after 
brachytherapy are presented in chapter 5.2. In this section the results o f the PCSS cohort o f  men 
are reviewed (summarised in figure 52 and table 62, p213). For all groups the starting IPSS 
before treatment was <8 which in populations o f  men with benign prostatic disease is regarded as 
consistent with mild symptoms. The IPSS within men undergoing BXT showed statistically 
significant change from baseline at all points o f  follow up in the analysis o f  patients from the 
PCSS. The clinical significance o f  the change was only just clinically significant at time points 
o f >6 months post-implant (median change 3 points, with median scores only just reaching the 
borderline between men describing mild and moderate BPH symptoms). The changes were 
similar in men who received HBXT although the magnitude o f  the worsening dropped below  
levels regarded as clinically significant at >12 months.
A similar pattern emerged after BXTC although the smaller group size compromised the ability 
o f the study to show statistically significant change at >9m when the urinary toxicity was 
resolving. The magnitude o f  change is similar to the HBXT group.
Taunton Psychosocial Morbidity Score in patients and their partners after brachytherapy
Taunton psychosocial morbidity (TPSM) scores for General Cancer Distress (GCD) are not 
shown graphically for men without a partner although significance testing shows no statistically 
significant difference between men with and without a partner in terms o f  general cancer distress 
at baseline or further follow up. The scores for men with a partner are shown in figure 53 and 
table 63 (p214). Levels o f  general cancer distress improved steadily at all time points for men 
who continued to return questionnaires. This improvement was statistically significant for each 
o f the treatment subtypes (BXT/HBXT/BXTC) although they took longer after treatment to
-211 -
Chapter 5.1
attain statistical significance in the smaller BXTC group. Kruskall-Wallis significance testing to 
compare levels o f GCD showed that men receiving BXTC had significantly (p<0.05) higher 
levels o f GCD at baseline than the other 2 groups, this continued at all time points other than 3- 
6months and 24months. This may relate to their appreciation o f  the significance o f  their higher 
risk disease or to other aspects o f  their treatment.
The GCD o f partners (figure 54 and table 64, p215) improved after treatment. Statistically 
significant improvement occurred at all post-treatment time points after BXT, at >6wks for 
HBXT and at all follow-up >6wks apart from 9m in the CBXT group. The levels o f  GCD in 
partners were not related to type o f  treatment received (p>0.05 at all time points). Paired 
analysis for the whole dataset showed that the partners o f  men treated with brachytherapy had 
significantly higher (pO.OOl) levels o f  GCD than the patients themselves. This was true at all 
points o f  follow up and for all treatment types.
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Chapter 5.2 - Predicting urinary symptoms after brachytherapy - 
role of preoperative investigations
Patient demographics from this series are presented in table 65 (below).
Table 65. Patient demographics at presentation
Number of Patients Analysed N=216
Mean Age (SD) 64 (6.0) years
Median Presenting PSA (Range) 7.9 ng/ml (1.2-26 ng/ml)
Gleason Sum
2-4 45 (21%)
5-6 130 (60%)
7-10 41 (19%)
TNM Stage
T i No Mo 76 (35%)
T2 No Mo 133 (62%)
T3 No Mo 7 (3%)
Mean Initial Prostate Volume (Range) 38cm3 (16-91)
Mean Presenting IPSS (Range) 6.7 (0-26)
Presenting Complaint
Screen-Detected 90 (42%)
LUTS 107 (49%)
Other (e.g. haematuria, 
UTI) 19 (9%)
Brachytherapy Boost following EBRT 49 (23%)
Neoadjuvant Androgen Deprivation 154 (72%)
Urodynamic Evidence of Obstruction on ICS 
Nomogram (n=l36 had UDS analysed)
Obstructed 60
Equivocal 33
Unobstructed 43
Urodynamic Assessment of Bladder Stability
Stable Bladder 110
Unstable Bladder 26
Four patients (1.9%) have needed trans-urethral resection o f  prostate or bladder neck 
incision for bladder outflow obstruction and one o f  these patients had transient stress 
incontinence following TURP; however continence returned following pelvic floor 
exercises. This patient was the fifth treated in the series and would have been 
excluded by current guidelines(152) (Pt 4 - Presenting IPSS=21, Qmax=9ml/s, Initial
- 2 1 6 -
Chapter 5.2
Prostate Volume 68cc). The patient treated by salvage radical prostatectomy 
experienced bothersome postoperative incontinence and was treated by implantation 
o f  an artificial urinary sphincter. 95% o f  patients experienced deterioration in their 
urinary symptoms as shown in fig 55 (p219) with the worst symptoms at 6 weeks post 
implant. The deterioration in IPSS persisted at clinically significant levels (mean 
IPSS increase >3 points is clinically significant (195) ) for 9 months post-implant and 
continued to improve throughout the follow-up period (Figure 55, p219) although the 
amounts o f  data missing at longer follow-up was significant.
The severity o f  urinary symptoms (IPSS) post-implant was most closely related to 
IPSS at presentation (Fig 56, p220). Patients presenting with mild urinary symptoms 
(IPSS score 0-7) had significantly lower IPSS at all points o f follow-up (Mann- 
Whitney p<0.05) No statistically significant differences in IPSS score or IPSS score 
change were observed in patients who were treated with brachytherapy alone vs. 
EBRT plus brachytherapy boost (figure 57, p221). Dosimetry parameters were also 
related to acute postoperative urinary toxicity. As it is difficult to define 
radiobiologically equivalent doses between patients treated with seeds alone 
compared with combined EBRT and seeds, only patients receiving 125I monotherapy 
were assessed. Table 66 (p222) illustrates the dosimetry in the series to date: no 
significant differences in acute urinary toxicity as assessed by IPSS scores were found 
between patients with prostate D90 o f either greater or less than 90% o f  the prescribed 
dose (whole group) or in patients with urethral dosimetry (DIO, D25, D50) in the high 
medium and low dose tertiles.
- 2 1 7 -
Chapter 5.2
Acute urinary retention occurred in 20 (9.3%) patients with a further 26 (12.1%) 
patients using CISC to reduce voiding frequency associated with chronic retention. 
Median duration o f catheter use was 4 weeks although patients often elected to 
continue using CISC to reduce nocturnal frequency despite being able to void 
urethrally. The results o f  logistic regression analysis o f  factors associated with 
urinary retention are presented in table 67 (p222). No significant relationship between 
urethral DIO, D25 or D50 and catheter use post-implant was observed (Table 68, 
p222). Prostate D90, V I00 or V I 50 were not associated with increased risk o f  
catheter use post-implant (Table 68, p222). Dosimetry was therefore excluded from 
the logistic regression analysis.
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Chapter 5.2
Table 66. Dosimetric data in series to date
N= Mean SD
Dosimetric Data for I M onotherapy
D90 (Gy) 167 141 22
V I00 (%) 167 87 9
V I50 (%) 167 49 14
Urethral DIO (Gy) 60 232 54
Urethral D25 (Gy) 60 208 31
Urethral D50 (Gy) 60 182 23
Dosimetric Data based on activity o f  
implant only for EB R T +llO G y Boost
D90 (Gy) 49 105 16
V100(% ) 49 85 9
V I50 (%) 49 46 14
Table 67. Risk Factors for postoperative catheter use
Univariate
p-value
Multivariate Analysis
Odds Ratio 
(OR)
OR 95% Cl p-value
Patient Factors
Age 0.15 n.s.
Prostate Volume <35cc (vs. >35cc) 0.001 3.14 1.6-6.3 0.001
Baseline IPSS score >7 (vs. <7) 0.005 2.5 1.2-5.0 0.011
Uroflowometry 0.09 n.s.
Urodynamic Status (Unobstructed vs. Obstructed) 0.008 0.14 0.03-0.64 0.012Urodynamic Status (Equivocal vs. Obstructed) 0.80 0.27-2.34 0.684
Androgen Deprivation 0.51 n.s.
Preimplant Alpha Blocker 0.12 n.s.
EBRT Used (vs. monotherapy) 0.17 n.s.
Table 68. Dosimetric risk Factors for postoperative catheter use
Analysis o f dosimetry in I125 monotherapy n= Univariatep-value
Seed Strength 167 0.35
D90 167 0.33
V100 167 0.60
V150 167 0.46
Urethral D10 Continuous Variable 60 0.71
Urethral D10 analysed by Tertile 60 0.15
Urethral D25 Continuous Variable 60 0.43
Urethral D25 analysed by Tertile 60 0.15
Urethral D50 Continuous Variable 60 0.66
Urethral D50 analysed by Tertile 60 0.15
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Chapter 5.3 - The effects of bicalutamide and goserelin on prostate 
volume
Demographics are presented in table 69. Time between ultrasound scans was not 
equal and the LHRH treatment group contained patients with a larger mean initial 
gland volume. A subgroup analysis o f patients who had received active treatment for 
>3months with initial prostate volume below 55cc was therefore performed as it is 
clear that percentage reduction in prostate volume is greater in large volume prostates 
and is progressive with longer treatment periods (120). Significance levels o f 5% 
were used throughout the study.
Table 69. Demographics o f patients followed up in prostate volume study
No Rx Bicalutamide 
(all pts)
Goserelin 
(all pts)
Bicalutamide 
(<55cc prostate, 
>3m Rx)
Goserelin 
(<55cc prostate, 
>3m Rx)
N= 34 66 31 55 19
Mean Age [SD] 62 [6.5] 63 [6.6] 64 [4.4] 62 [6.7] 63 [4.5]
Mean PSA 7.3 8.6 10.3 8.2 10.5
Median 
Gleason Sum 6 6 6 6 6
Median TNM 
Stage TIC T2A T2A T2A T2A
Mean Initial 
Prostate 
Volume in cc 
TSD1
33.1[6.6] 34.7[11] 48.9[16] 33.7[10.7] 38[11.3]
Mean Time 
Between U/S in 
days [SD]
128 [78] 145 [64] 192 [83] 160 [54] 180 [60]
Results are summarised in table 70 (page 224). Patients receiving active treatment 
with bicalutamide or goserelin had significantly reduced prostate volume compared
Chapter 5.3
with baseline assessments (paired t-tests pO.OOOl) but untreated patients had a 
significant rise in prostate volume (paired t-test p=0.011).
Table 70. Effect o f hormonal therapy on prostate volume
No Rx Bicalutamide 
(all pts)
Goserelin 
(all pts)
Bicalutamide 
<55cc 
>3m Rx
Goserelin 
<55cc 
>3m Rx
N= 34 66 31 55 19
Mean Volume Change 
% [SD] +8 [16] -8 [15] -26 [14] -7 [15] -21 [11]
p-value for paired t- 
test comparing volume 
assessments [df]
0.011 [33] <0.0001 [65] <0.0001 [30] 0.001 [54] <0.0001[18]
The percentage reduction in volume was significantly greater in the goserelin group 
than in the bicalutamide group (Figure 58), [unpaired t-test pO.OOOl] and both forms 
of androgen deprivation resulted in a significant reduction in volume compared with 
the untreated group [unpaired t-test pO.OOOl].
Figure 58. Graph of change in prostate volume between ultrasound scans. 
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Significant reductions occurred after treatment with bicalutamide(unpaired t-test 
pO.OOOl, df=33) or goserelin compared with control (unpaired t-test pO.OOOl, 
df=30). Goserelin produced a significantly greater reduction in volume than 
bicalutamide (unpaired t-test pO.OOOl, df=30).
In a subgroup analysis o f patients with initial volume <55cc receiving treatment for 
>3months the percentage reduction in prostate volume (Figure 59) remained 
significantly greater in the goserelin than the bicalutamide group (unpaired t-test 
pO.OOOl).
Figure 59. Graph showing change in prostate volume between ultrasound scans. 
Subgroup Analysis (<55cm3, Treatment for >3m)
Androgen Manipulation 
M  No Treatment 
m Bicalutamide Monotherapy
m Goserelin
In order to try to assess whether the results reported above were due to greater time on 
treatment between scans and also to adjust for differences in initial prostate volume,
P-value<0.0001
- 2 25 -
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analysis o f covariance was performed (ANCOVA SPSS Sysat). The outcome 
analysed was percentage reduction in prostate volume during treatment and we 
analysed data on 97 patients receiving active treatment using agent prescribed 
(Bicalutamide vs. LHRH analogue) as the factor and initial prostate volume in clinic 
(continuous variable) and time between TRUS volume assessments (continuous 
variable) as covariates. As expected initial prostate volume was a significant 
covariate (pO.OOOl) but time between ultrasound scans was not a significant 
covariate (p=0.524). Agent prescribed was statistically significant (pO.OOOl), 
indicating that after adjustment for initial prostate volumes, goserelin remained 
superior in reducing prostate volume compared to bicalutamide.
Chapter 6
Discussion
Discussion
The findings of in this chapter relate to the findings o f the research in four areas:
I. The methodological issues of collection, interpretation and presentation of 
HRQOL data (chapter 6.0)
II. The findings o f the Prostate Cancer Symptoms Study (PCSS) in terms o f patient 
reported outcomes o f brachytherapy (chapter 6.1)
III. The utility o f urodynamic assessment in the prediction o f acute urinary 
retention after brachytherapy (chapter 6.2)
IV. The effectiveness o f different regimes o f androgen deprivation for cytoreduction 
of the prostate before brachytherapy (chapter 6.3)
The findings of each o f these areas will be presented in turn. Conclusions from 
the work comprising the PCSS will be addressed in chapter 7.0. The conclusions 
drawn from areas III-IV will be made in chapter 7.1. In addition suggestions for 
future research are made in chapter 7.2.
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Chapter 6.0 - Performance of the EORTC PR25 in the Prostate 
Cancer Symptom Study and design of future studies
Performance of the EORTC PR25 in the Prostate Cancer Symptom Study
The reliability o f PR25 on a limited test-retest analysis confirmed that all but one of 
the questions o f PR25 performed well (Q19 -  Tess masculine’ poor agreement). 
Scale formation (building multi-item scales to describe an underlying construct) was 
encouraging in three out of five multi-item scales which reported good to excellent 
agreement. These were urinary problems, sexual activity and sexual functioning. The 
grouping o f questions in the bowel symptoms and treatment symptoms domains were 
not supported by the psychometric testing. However they were grouped in a clinically 
sensible domain (in that they focused on a body system or related symptom group but 
the replies to each stem were not necessarily related in a way that would allow 
scaling). Quality of life authors from the EORTC quality o f life group have 
previously used the argument o f ‘clinical utility’ as a justification for the continued 
use o f scales with poor performance on internal consistency testing (171). Other 
authors publishing the results o f the PR25 have simply presented the scaled data 
despite their findings confirming low Cronbach’s alpha scores for the treatment 
symptoms and bowel symptoms domains, which indicate poor internal consistency 
(254). Unlike other studies these authors also reported Cronbach’s alpha scores 
below 0.75 for the sexual activity and function scales that have been previously 
reported to have adequate internal consistency (254). Formal guidance on scaling 
for the PR25 has yet to be produced by the EORTC despite planned completion o f  
field testing o f PR25 in 2005 (255). Delays in the planned production o f this ■ 
guidance may reflect difficulties with resolving the described problems with scaling.
- 2 2 9 -
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Presentation of data collected using the EORTC PR25
It can be challenging to present quality o f life data in a manner that is easy for 
clinicians and patients to interpret. Whilst presenting a percentage o f patients newly 
reporting change in a single question is easy to interpret it does not work well as a 
means of summarising changes that affect multiple related areas o f a patient’s life as 
there are more relevant questions than can be presented. This problem is magnified in 
studies that aim to administer the same questionnaires to patients undergoing different 
treatments. In these studies a number of different domains may need to be described 
(changes in urinary symptoms, bowel symptoms and potency), each o f which needs to 
be assessed with several questions.
For domains of the PR25 where scaling is supported it seems reasonable to present no 
further data analysis if  a statistically significant change from baseline values does not 
occur after treatment. Where statistically significant change does occur but median 
change is less than is thought clinically significant for the group, it may be helpful to 
present the percentage of men experiencing moderate change and to explore what 
items of the questionnaire are leading this change. Where scaling is not supported, it 
may be necessary to present the data on individual questions to allow further analysis 
of whether significant change is occurring. For questionnaires that have been 
developed where scaling has not been supported by robust psychometric data it may 
be necessary to change the questions included or redefine domains (perhaps by 
splitting up bowel function into 2 sub domains with better internal consistency) until 
adequate psychometrics for scaling are achieved. This may explain why the EORTC 
have chosen to separate the urinary incontinence aid bother question from the urinary 
function domain in the current version of PR25.
- 2 3 0 -
Chapter 6.0
Other authors have dealt with the problems o f scaling in PR25 simply by selecting a 
subset o f the administered questions and reporting these (194, 256). Interestingly, 
although these two papers both reported 9 questions of the 25 they administered, they 
only concurred on 6 questions. Both studies were published in the same international 
peer reviewed journal, and neither gave a justification for selecting this subset of 
questions. Although it is attractive to badge research as having used a validated 
HRQOL measure the selective publication o f questions is not appropriate.
Clinical significance of PR25 domains
In common with all of the other prostate cancer indices (UCLA-PCI, EPIC), the PR25 
has not been subject to published formal clinical significance studies in the same way 
as the EORTC QLQ-C30 to determine the magnitude o f change that represents 
clinically significant change. The Osoba criteria for the EORTC QLQ-C30 report 
point changes that correlate with ‘very much’ / ‘moderate’/ ‘a little’ or no change in 
health status after chemotherapy. Although these significance of change criteria are 
widely regarded as valid, they are derived from a single study of patients undergoing 
chemotherapy for lung cancer or breast cancer in Canada (241). The validity o f the 
Osoba criteria is supported by a reported general HRQOL decrease with increasing 
age in men over 50. Normative data from healthy populations has been used to 
confirm that for the EORTC QLQ-C30 the general HRQOL declines by about 4 
points per decade after 50. Therefore ‘a little’ change in score might reflect the 
general decrease in the health o f a population aging from 50 to 70. In general, the 
metrics of scoring Likert scaled questions would support a decision to use levels of 
change of 5-10% as the minimum clinically significant change across questionnaires 
with a similar design (257). However the application o f these general principles may
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not be robust and cannot be depended upon until validation studies have demonstrated 
that the clinical significance o f the PR25 is consistent with predictions.
Although other groups have utilised the Osoba levels o f change to interpret PR25 
findings (254) in the same manner as reported in this thesis, it is possible that 
‘clinically significant’ levels of change might vary between groups and be dependent 
on pre-existing pathology. For instance the impact of moderate erectile dysfunction 
becoming severe erectile dysfunction may not be the same as the impact of new 
erectile dysfunction on men without any pre-existing erectile problems.
Suitability of EORTC PR25 compared with alternative questionnaires in studies 
of treatment of early prostate cancer
Failing to identify toxicity in a particular area can be a result of excluding individual 
questionnaire stems (194, 256) or o f choosing a questionnaire that contains no 
assessment o f a relevant area o f toxicity. The FACT-P and UCLA-PCI questionnaires 
are o f limited value in studies of outcome comparing brachytherapy to other radical 
treatments, because they fail to collect data on incontinence, or urinary symptoms 
other than incontinence, respectively. Despite this they have both been used 
extensively in early prostate cancer studies. Justification for questionnaire selection is 
often not explicit in studies. It is likely that these questionnaires were selected for 
their reliability and acceptable internal consistency scores. However, despite 
widespread use, these questionnaires lack both face validity and content validity (see 
table 7, p-86) for studies o f the symptomatic outcome of men treated with 
brachytherapy.
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Questions remain about which instrument should be used to define disease-specific
QOL in larger studies o f treatment for early prostate cancer. Although checklists for
reporting QOL in prostate cancer research have been suggested, most recently by
Efficace et al (table 71) (258), they lave been largely ignored in the published
literature (especially in early prostate cancer where the majority of studies are limited
by non-randomised designs and a lack o f compliance with these guidelines).
Table 71. Checklist for reporting HRQOL issues in prostate cancer trials (not specific 
to EPC) and % o f RCTs (N=24 RCTs reviewed in 2003) including these items in 
published reports (from Efficace et al (258)). Table modified to show the 
performance o f reporting in the Prostate Cancer Symptom Study
Checklist Issue % of RCTs Include
Reported in 
PCSS
Location in 
thesis
Conceptual A priori hypothesis stated 13 Yes Chapter 3.0
Rationale for instrument(s) 29 Yes Chapter 4.1
Measurement Psychometric properties 
reported
87 Yes Chapters 4.1 
and 5.0
Cultural validity verified 81 Yes Chapter 4.1
Adequacy of domains 
covered
87 Yes Chapter 4.1
Methodology Instrument administration 
reported
25 Yes Chapter 4.1
Baseline compliance 
reported
46 Yes Chapter 5.1
Timing of assessments 
documented
96 Yes Chapter 4.1
Missing data reported 54 Yes Chapter 5.1
Interpretation Clinical significance 
addressed
12 Yes Chapter 6.0 
and 6.1
Presentation of results in 
general
67 Yes Chapter 5.1
To my knowledge, to date, only the American Brachytherapy Society has 
recommended patient reported outcome measures for brachytherapy (183) choosing 
the IPSS and EEIF-5 scores in 2002. Other groups have not defined recommended 
outcome measures and the ABS has not explored the reporting o f HRQOL.
Appendix VIII contains a reprinted article written by the author on behalf o f a group 
of researchers with an interest in trials of radiotherapy and quality o f life. This article
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addresses the problem of diverse and inappropriate questionnaire use by suggesting a 
portfolio o f questionnaires that may be suitable for studies o f HRQOL in patients with 
EPC.
Which o f these questionnaires is selected should depend on the stated aims o f a trial 
and the hypotheses it aims to test. It may also be influenced by practicalities such as 
translation issues and one of the strengths o f the work o f the EORTC quality o f life 
group is that it has made its questionnaires available in a number o f European 
languages. This makes them attractive when multi-centre international studies are 
considered in Europe. Certainly the PR25 is a reliable questionnaire that has 
questions addressing appropriate domains o f quality o f life. Scaling problems (in the 
bowel and treatment symptoms domains) mean that there are some difficulties with 
the interpretation and presentation o f results, however the questions, all o f which have 
good face and content validity, seem better than those used in the FACT-P and 
UCLA-PCI modules and the PR25 is shorter than the EPIC questionnaire.
Frequency of questionnaire assessment on studies of quality of life following 
ablative treatment
Bias may be introduced into studies of radical treatment for early prostate cancer by 
the time points of questionnaire assessment (217, 220). When brachytherapy was first 
introduced, a number of studies compared cross sections o f patients who had already 
been selected for brachytherapy or alternative radical treatment (table 12, p i07) and 
were being followed-up. Because at that time brachytherapy was a new treatment, 
the comparison with a cohort o f men much further on in their follow up, often after 
radical prostatectomy was invalid with results biased in favour o f radical 
prostatectomy (217, 220). They reached conclusions that may be inaccurate because
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symptoms continue to settle in the early years after both radical prostatectomy and 
brachytherapy (194, 201). As symptoms from both treatments improve in a non­
linear manner over time it is unlikely that trying to adjust statistically for time post­
procedure would be appropriate even if the patients had been comparable at baseline.
The timing o f questionnaire administration is crucial and longitudinal studies have 
suggested that to capture the worst toxicity after a radical prostatectomy an immediate 
questionnaire at discharge from hospital is important. For brachytherapy an 
assessment at 4-6 weeks after implant is important (194). A number o f studies 
including the PCSS suggest that maximum toxicity from brachytherapy occurs within 
4-6 weeks post-implant and that most toxicity resolves after the first 12 months (table 
12, p i07). Future studies should aim to address the relative lack o f long term quality 
of life data and to achieve better baseline data by recruiting patients as early as 
possible.
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Issues for consideration in future health related quality of life studies in early 
prostate cancer
Some issues may be identified relating to the conduct o f possible future studies of 
HRQOL in EPC:
• Clinically significant changes in general HRQOL have not been detected in any of 
the non-randomised studies o f outcome from ablative treatment in EPC.
• Although it may be important to consider assessing global HRQOL in future 
studies of radical ablative treatment for EPC, the burden o f questions in this area 
should be reduced by selecting short questionnaires, for instance the SF12, which 
is being used in the ProTeCT study (a large RCT providing a context for future 
work).
• Symptoms described by men who undergo current treatments for EPC include 
urinary incontinence, obstructive and irritative urinary symptoms and urinary 
pain, bowel symptoms and sexual toxicity. The PR25 is a good measure of urinary 
toxicity with results that are easy to present and understand. The scaled domains 
assessing bowel toxicity, treatment symptoms and sexual toxicity are less useful 
and less easily presented.
• Other questionnaires that aim to measure prostate cancer specific QOL have 
significant problems: the EPIC questionnaire is too long (50 items). The UCLA- 
PCI measures no urinary symptoms other than incontinence whilst the FACT-P is 
inappropriately brief with no measure o f urinary incontinence.
• The EPIC-26 short form (SF), is a 26-item questionnaire that may be a reasonable 
alternative to the EPIC. Limited psychometric data confirming reliability and 
internal consistency have been published electronically (259) although publication 
of a formal validation study o f the SF version is awaited.
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• Use o f a portfolio o f validated symptom specific questionnaires which may be 
added to or omitted from trials depending on their design may be the best option 
currently available (IIEF-5, ICSmaleSF, Vaizey bowel function questionnaire) 
(188) and is recommended in the review in appendix VII.
• The recommendation by the American Brachytherapy Society (ABS) morbidity 
reporting group that the IPSS is the best measure o f urinary function after 
brachytherapy is probably flawed (183). The IPSS is designed to assess 
symptoms common in benign prostatic hypertrophy, o f which obstructive urinary 
symptoms predominate. It fails to record dysuria and incontinence. Although the 
ABS have recommended recording o f additional data on dysuria, haematuria, 
urinary incontinence and medication use it is difficult to know how to interpret 
additional questions in combination with a summarised IPSS score and future 
studies might be better served using the questionnaires discussed above 
(PR25/EPIC-26 or ICS Male SF).
• In the studies reported in this thesis the 6, 9 and 18 month questionnaires added 
little information and the resolution o f symptoms within the first year has 
probably been adequately described by our study and existing published work, 
(table 11, p i07 and table 12 p i07). Future studies might be able to reduce the 
questionnaire burden by restricting questionnaires to a smaller number o f time 
points, perhaps including: 6wk to describe peak morbidity, 3m to report resolution 
rates of early symptoms and 1 and 2 year outcome to report medium term results.
• The focus on future studies of HRQOL/specific patient reported symptoms should 
move from concentrating on early to longer term results as there is very little data 
available in this area and most men who undergo brachytherapy have a life 
expectancy o f at least 10 years.
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Chapter 6.1 - Quality of life among patients treated with brachytherapy 
in the Prostate Cancer Symptoms Study
The aims and objectives in the first phase o f the Prostate Cancer Symptom Study (PCSS) 
were to investigate the following hypotheses relating to HRQOL:
i. HRQOL following prostate brachytherapy will be reduced by clinically 
significant levels in the first year after brachytherapy but not afterwards.
ii. The duration of changes in general HRQOL will be similar in patients treated 
with BXT, HBXT and BXTC.
iii. The magnitude o f deterioration in sexual function and urinary function will be 
smaller in the BXT group than the HBXT and BXTC groups.
iv. The distress o f men treated for early prostate cancer will decrease with time 
after treatment as will the distress o f their partners
i. Deterioration and recovery in general health related quality of life following 
prostate brachytherapy
Compared with baseline measurements HRQOL was permanently and adversely affected 
at all assessments (apart from 12 months p=0.08) up to 2 years after brachytherapy as 
monotherapy (BXT) by statistically significant amounts. The worst impact was at 6 
weeks post treatment when the median change in HRQOL was o f ‘moderate’ magnitude. 
After this gradual improvement occurred. Change from baseline HRQOL was clinically 
insignificant (median change = 0) at time points greater than 9 months. Despite this lack 
of clinically significant change for the group at 2 years post BXT, 32% of men reported > 
‘moderate’ deterioration in HRQOL compared to only 10.1% reporting a similar 
improvement in HRQOL.
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It is unclear whether this represents genuine improvement after an initial deterioration in 
quality o f life when the bowel, bladder and sexual side effects settle or merely a 
reflection o f patients accepting their symptoms. Regression to the mean is significant in 
the ‘subjective wellness’ scales of questionnaires typified by the general HRQOL 
summary question. In a classic study in 1978, Brickman et al reported on subjective 
wellness in populations who had positive change in their life (lottery winners), and a 
negative change (people who became paraplegic as a result of traumatic spinal cord 
injury) (260). Although the initial change was in predictably opposite directions for the 
two groups, by 1 year post event they were on average no different from each other in 
terms o f subjective wellness. The other possible effect other than a true improvement in 
QOL is cognitive dissonance (whereby subjects who have made an irrevocable decision 
seek to rationalise their choice by emphasizing the good features of their decision whilst 
minimising the bad features). Hence the more objectively measured problems such as 
urinary symptoms are likely to be reported accurately but the reports on more holistic 
descriptions o f ‘quality o f life’ may return to normal despite a higher level o f reported 
symptoms.
ii. Duration of changes following brachytherapy vs. hormonobrachytherapy and as 
a boost after external beam radiotherapy
Shorter durations o f clinically significant change in HRQOL following HBXT (3 months) 
and BXTC (6 months) may represent artificially low baseline HRQOL reported in the 
groups who received AD, perhaps because men delayed completion of their baseline 
questionnaire and reported the early effects o f AD. It seems unlikely that androgen 
deprivation which is known to produce adverse changes in quality o f life as monotherapy 
would as a combination treatment with brachytherapy result in a more rapid return to 
baseline QOL (261). General HRQOL was similar between all 3 groups at 2 years.
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iii. Sexual function and voiding bother following brachytherapy vs. 
hormonobrachytherapy and as a boost after external beam radiotherapy
Median change in urinary function was significant for BXT patients at all points of 
assessment up to the 2-year follow up. Urinary function improved from the ‘very much 
worse’ level at 6 weeks to levels which were of only a little clinical significance at 1 year. 
Levels o f missing data, although significant, particularly mid-study, were not worse at 2 
years than at 6 weeks. The changes in urinary function observed in the HBXT group were 
also significantly worse than baseline at all points o f follow up although changes dipped 
below levels regarded as clinically significant at 9-18 months before recurring at levels 
consistent with ‘a little’ change at 2 years. Urinary function after BXTC was worse at 
baseline than in the other 2 groups but returned to levels only ‘a little’ worse than 
baseline at 3 months and at time points >12 months they were no longer statistically 
different from baseline. The lack o f statistically significant change at >12 months post 
BXTC probably reflects lower statistical power to detect small changes in worsening of 
urinary function in a group with less than half the sample size.
The percentage o f the patients who returned questionnaires indicating moderate or greater 
worsening in urinary symptoms at 2 years was highest in the BXT group. This was 
unexpected as previous reports have suggested that urinary function might be worse after 
BXTC than BXT as monotherapy (197, 205). The events leading to these changes in all 
groups were predominantly urgency and frequency o f micturition, although the 
proportion o f men with moderate worsening in reported pain on micturition 2 years after 
brachytherapy was surprisingly high at 4.9-7.6%. This may have been missed by 
inappropriate questionnaire choice in previous studies. Urinary incontinence was equally 
uncommon in the three groups with <4% of men in any group reporting levels o f
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incontinence more than 4a little’ incontinence at 2 years. The levels of urinary 
incontinence aid bother correlated well with this level o f incontinence reporting with no 
men reporting bother after HBXT and <3% after BXT or BXTC.
Sexual function is perhaps the most challenging area to describe. Sexual dysfunction is 
highly prevalent in healthy men aged 60-70 (217, 262). Brachytherapy is typically 
delivered to men in this age range. Small differences in selection criteria for treatment 
might result in large differences in the baseline potency o f patients undergoing treatment. 
Thus the rates of sexual toxicity reported by cross sectional studies comparing patients 
who have already received radical treatment for prostate cancer are o f very limited value. 
The value of comparing the results o f published studies with similar outcome measures 
but different patient selection criteria are also limited. In addition investigators have used 
a wide range of definitions of potency and potency preservation; this makes it difficult to 
compare outcomes between studies. Reports in the literature suggest a wide range of 
possible outcomes in terms o f potency preservation depending on the definition of 
potency and the time point of assessment post treatment. Potency preservation three 
years post treatment ranges from 51% reported by Merrick et al (210) using the IIEF 
questionnaire to 80% reported by Mabjeesh et al using a global assessment questionnaire 
as well as a lower score on the IIEF to define potency (204). Whilst Merrick (210) 
showed that technical differences in the delivery of brachytherapy, including increased 
radiation dose to the bulb of the penis (D50) can predict new impotence, it is more likely 
that a 30% variability in potency preservation is explained by differing definitions of 
potency.
In the PCSS only 47% of men were free from moderate to severe erectile dysfunction 
(ED) based on their IIEF-5 score at baseline. A high rate o f baseline impotence (26%)
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was present even in the BXT group o f men who had partners where confounding due to 
possible reporting of AD was not an issue. By the completion of 2 year follow up after 
BXT, 53% of men potent at baseline remained potent. These figures are consistent with 
51% potency preservation using the IIEF-5 reported by Merrick in the USA (210).
The rates o f sexual activity assessed on the PR25 questionnaire remained reasonably 
stable in men returning questionnaires at >3months. Return rates were no worse than for 
domains not related to sexual function. In the PR25 sexual function is determined only in 
those men who are sexually active. In the PCSS, sexual function as measured via the 
PR25 worsened by clinically significant amounts at all time points after BXT. The 
number of men who completed the sexual function questionnaire after BXT dropped 
from 65 of the patients at baseline to 46 at 2 years (29% missing data). 16% of men 
completing the general HRQOL question at baseline did not complete the questionnaire 
at 2 years. The decision o f the questionnaire design team to ask men not to record 
answers if  they were sexually inactive means that non-completion is interpreted as sexual 
inactivity whereas it may represent unwillingness to complete this stem. A better design 
might be an active tick box to indicate that the patient was sexually inactive. If data 
present at baseline but not at further follow-up is interpreted as sexual inactivity, then at 
least 13% of men who were sexually active at baseline were sexually inactive 2 years 
after BXT. The PR25 questionnaire collects no further information on men who are 
sexually inactive and if  the questionnaire were modified than it might be valuable to add 
questions on reason for sexual inactivity. These might include impotence or lack of 
partner. Poor response rates to these types o f detailed questions may however have 
meant that they were removed from questionnaires at the design stage.
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Significant decreases in sexual function occurred in men who completed questionnaires. 
For the BXT patients this change was led by changes to the mean scores for both the 
sexual enjoyment and erectile difficulties questions. Ejaculation problems were also a 
common problem with 20% reporting a 2 point change in Likert scale answer. The 
median change to IIEF-5 score was 3.5 points at 2 years (almost the equivalent o f a 1 
category decrease in ED severity category i.e. from normal to mild dysfunction). This 
was despite 2/3 o f men who were potent before brachytherapy being treated with 
Sildenafil (Viagra®) or other PDE5 inhibitors.
The sexual function o f men as assessed by PR25 and the IIEF-5 2 years post HBXT or 
BXTC was not significantly different from baseline. This is almost certainly artefactual. 
The failure to demonstrate change in sexual function may be related to the small numbers 
of men reporting potency at baseline. High levels o f impotence resulted in a ‘floor effect’ 
where low questionnaire scores cannot decrease further as men are already affected by 
severe erectile problems. This is compounded by the PR25 having a sexual function 
scale where completion is conditional on being sexually active. Where completion rates 
are low at baseline, significant reductions in power can lead to a type II error in failing to 
demonstrate a real deterioration in potency. The effects o f baseline administration o f  
androgen deprivation also make the sexual function data difficult to interpret.
iv. General Cancer Distress (GCD) in men who have received treatment with 
brachytherapy and their partners
Men who underwent brachytherapy had significant levels o f GCD which at baseline were 
significantly (p=0.018) related to which type o f treatment they underwent (BXT/HBXT 
vs. BXTC). This may suggest that they had a good understanding o f their level o f risk 
from prostate cancer and increased risk was associated with greater anxiety. As
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hypothesized, the GCD improved significantly over time (p<0.01 in all groups by 3 
months post treatment) with a decrease in the percentage of men reporting morbid levels 
of GCD from 60-76% at baseline to 12-30% at 2 years. Levels o f GCD remained 
different when reported by treatment group, men treated with BXTC consistently 
reported the highest levels o f GCD. Levels of GCD improved in a similar manner in 
partners of men undergoing brachytherapy treatment although their anxiety/distress levels 
were worse than for the patients and unrelated to the type o f brachytherapy delivered.
Limitations of the assessment of brachytherapy in the Prostate Cancer Symptom 
Study
I. Non-random selection o f patients for treatment with BXT, HBXT or BXTC.
II. 10% dropout rate for baseline questionnaires.
III. 34.9% of men failed to fill out more than 4 o f the 8 questionnaires.
IV. Possible effect on baseline assessments from preimplant androgen deprivation.
V. Inadequate statistical power, particularly for assessment in the BXTC group.
These limitations are discussed below:
I. Whilst data on the toxicity o f any brachytherapy subtype versus no immediate 
treatment would have been better explored using a randomised trial these are expensive 
and patient recruitment is difficult to achieve. The difficulties o f recruiting to these types 
of randomised studies have been documented in chapter 2.4 and the levels o f resource to 
undertake a full scale implementation o f this design of study were unavailable. The 
PCSS has nevertheless produced valuable confirming the duration o f urinary symptoms 
and the nature o f symptoms still present two years post implant as well as the sexual 
toxicity of brachytherapy. In 2001 limited data were available detailing HRQOL 
outcomes after brachytherapy in longitudinal prospective studies and there are still few
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studies that have utilised optimum selection o f HRQOL questionnaires. 
Recommendations for design o f future studies are made in chapter 7.2, p261.
II-III Whilst reporting o f the completeness o f data is excellent in the PCSS compared 
with the published literature from studies o f HRQOL in prostate cancer in general (46% 
of randomised trails measuring HRQOL in prostate cancer report baseline compliance 
with questionnaires and only 54% have data on completeness o f follow up), our levels of  
missing data higher than one would wish. In a similar longitudinal study o f HRQOL 
using the EORTC QLQ C30 study in France, Buron et al reported rates o f questionnaire 
booklet return decreasing steadily over time from 8% missing baseline data to 42% 
missing at 2 years (194). The pattern o f missing data in that study was for increasingly 
poor data at longer follow up. This was not observed in our study with the worst 
completion rates at 9 and 12 months (when toxicity in those men who returned completed 
questionnaires was improving). The pattern o f continued symptom improvement 
continued in our study at 18-24 months when 76-77% of forms were returned.
It is possible that failure to complete and return questionnaires was more common in men 
who had severe deterioration in their symptoms, although we know that it was not related 
to biochemical recurrence (recorded in table 21, p i56) or death (which did not occur to 
date in the PCSS patients). However if  men with bad symptoms omitted more 
questionnaires, then we would expect that the highest questionnaire omission rates would 
be at the time o f maximum recorded symptoms (6 weeks post implant). Conversely men 
with better health outcomes might have less frequent contact with the hospital and thus 
complete fewer questionnaires than those men who are receiving ongoing treatment for 
symptoms. Unfortunately data on consultation rates were not collected in our study to 
further examine these possibilities. Comparisons o f baseline demographics including
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urinary and sexual symptoms between patients with different response rates and of 
response rates by treatment type did not reveal differences, which suggested that the level 
of response rate was not different due to differences in the patients at the start o f the 
study.
IV. The analysis o f pre-brachytherapy symptoms in men who underwent treatment 
involving androgen deprivation showed that there were significant (p<0.001) differences 
in baseline sexual function and treatment symptoms between groups. This suggests that 
at least some men in the AD exposed groups (HBXT and BXTC) might have returned 
their first questionnaire reporting symptoms after starting hormonal therapy but before 
receiving their brachytherapy implant (as the questionnaires were collected when the 
patients returned for their planning scan). Although patients were requested to fill out the 
questionnaires as soon as possible after they were seen and consented for the study some 
men sent their questionnaires in later and in addition a proportion of men were started on 
bicalutamide at the referring hospital. Future studies might be advised to include any 
prior hormonal therapy within the last 12 months as exclusion criteria. It might also be 
advisable for questionnaire front sheets (on paper or in electronic form) to check that 
patients understand that the questionnaire needs to be filled out before starting any 
hormonal therapy or completed during the clinic visit. Reducing the size o f the 
questionnaire packet and providing a dedicated clinic room might be useful in allowing 
men to complete questionnaires during a standard clinic visit.
V. We achieved inadequate power to answer questions on IPSS and sexual problems 
after BXTC at most points o f follow up (particularly since only 13 out o f 37 men in this 
group were free from moderate to severe erectile dysfunction at baseline). Future studies 
of the results o f BXTC (which is usually reserved for MSKCC high risk patients) would
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benefit from multi-centre design in order to achieve more rapid recruitment. Although 
we achieved MREC approval for the PCSS in 2002 we only recruited brachytherapy 
patients from one centre due to staffing limitations and a lack o f another available centre 
in the UK who were doing a large volume o f BXTC and were willing to cooperate. 
Brachytherapy is now available more widely in the UK and it might be possible to do a 
study of the HRQOL of combination brachytherapy as a boost following external beam 
radiotherapy with or without androgen deprivation in the future.
Impact of the prostate cancer symptom study
This project has delivered valuable new longitudinal data on quality o f life and symptoms 
after brachytherapy in the UK. When our project commenced, only a single longitudinal 
design study had been published describing toxicity after brachytherapy (192). This 
study used a suboptimal questionnaire for investigating urinary and sexual toxicity. 
Although since 2001 a number o f other studies have been published (table 12, p i07) 
comparing brachytherapy with other radical treatments, few have combined longitudinal 
designs and questionnaires without significant flaws in measuring urinary toxicity after 
brachytherapy (194, 214). Of the two studies using the best available instruments for 
measuring urinary toxicity, only the study by Buron et al from 2007 used a questionnaire 
which reports dysuria (PR25) and in this study, brachytherapy patients were not 
described according to level o f androgen exposure, which makes some o f the results 
difficult to interpret (194).
HRQOL results after brachytherapy in the UK have been published by Ash et al in 2007 
in a study that recruited a similar cohort o f men to those described in the PCSS (263). 
This study lacks the depth o f information presented here on potency and urinary function
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outcomes and makes little attempt to address the clinical significance o f its findings. The 
study by Ash et al is limited to brachytherapy patients with no plan to report outcomes in 
any alternative treatment group. It also suffers a similar flaw to our own study in that 
although patients treated with HBXT are identified there is bias in the baseline values for 
the sexual toxicity scores due to administration of AD prior to ‘baseline’ questionnaire 
assessment.
The strengths o f the PCSS are its longitudinal design and although we administered twice 
the questionnaire burden by administering the PR25 as well as IPSS and IIEF this gives 
our study a unique insight into the toxicity after brachytherapy as well as an ability to 
comment on the utility o f these questionnaires.
Critics o f the PCSS approach might suggest that to avoid a randomised design was to 
make comparison between subgroups impossible. However it is important that real- 
world studies describe outcomes in common referral groups as well as in the subgroups 
of patients who can be recruited to randomised controlled trials. The outcomes can be 
described in terms of time to return to baseline when the study is powered appropriately. 
Although regression to the mean and adjustment phenomena may partly explain the 
normalisation o f questionnaire responses, particularly in subjective wellness domains, 
they are unlikely to miss significant toxicity in the specific questions on sexual and 
urinary toxicity.
Chapter 6.2 - Predicting urinary symptoms after brachytherapy 
-  role of pre-operative investigations
Acute Urinary Retention (AUR) probably represents the most significant short term 
toxicity for brachytherapy patients and is an endpoint that can be measured easily in 
all patients after brachytherapy. This contrasts with the IPSS, which is meaningless in 
patients who are catheterised and o f questionable clinical relevance in patients who 
perform intermittent self catheterisation (ISC). Data on catheter use was available on 
all o f our patients and this is important as there is evidence from other cohorts with 
comprehensive follow-up in the post-hospital phase that only half o f catheterisation 
events happen in the first week post-implant (264). In our study less than half (43%) 
of all ISC events were due to AUR with the remaining patients using ISC to manage 
urinary symptoms from transient sub-acute retention of urine.
Postoperative catheter use in our population was closely linked to pre-implant IPSS, 
baseline prostate volume and urodynamic obstruction status. Although previous 
authors have correlated a number of factors including pre-implant IPSS (146), 
baseline prostate volume and use o f neoadjuvant androgen deprivation (158) with risk 
of urinary retention, other centres have not identified measures o f voiding function 
such as flow rate or urodynamic obstruction status as important in multivariate 
models. This may reflect the relative difficulty o f assessing bladder function using 
uroflowometry alone. Uroflowometry was not a significant predictor o f outcome in 
our series and good urinary flow rates may mask urodynamic obstruction in a bladder 
with good detrusor function but significant obstruction.
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Another important difference in our study group is that patients had been selected 
according to the EAU/ESTRO/EORTC guidelines, which recommended 
brachytherapy as most suitable for treating patients with lower IPSS. Since 
publication of the EAU guidelines we have not treated patients with IPSS >20, and 
the majority of our patients had an IPSS <17. Selection o f patients with fewer urinary 
symptoms may have allowed us to assess the importance o f other factors such as 
prostate volume and urodynamic status which had a more measurable effect in our 
population. In the study by Crook et al (158) patients were advised not to undergo 
brachytherapy if their pre-brachytherapy flow rate was less than lOml/s. Crook et al 
suggested IPSS was not a significant predictor o f AUR on multivariate analysis in 
their study because patients at the highest risk of bladder outflow obstruction (BOO) 
were excluded. In our study urodynamic assessment o f high-risk patients (IPSS>16, 
Prostate Volume >35cc) showed that patients who were obstructed before 
brachytherapy needed to use ISC post implant whereas unobstructed patients did not.
Recruitment to the study o f urodynamics in predicting outcome from brachytherapy 
was completed in November 2002 though data collection on men undergoing 
urodynamics as part o f their preparation for brachytherapy is ongoing. Figure 60. 
(p252) shows the updated data on 178 patients who have been assessed with 
urodynamics, TRUS volume study and IPSS scoring. This allows us to start to 
identify risk groups o f patients most suitable for brachytherapy treatment in terms o f  
risk of urinary retention post-implant. As this work and the work o f others has 
identified high IPSS score at presentation as predictive o f severe postoperative 
symptoms (265) these men should consider alternative treatment to brachytherapy if  
possible. Similarly in terms o f risk of urinary retention it is arguable that patients who
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have prostate volumes above 35cc and urodynamic evidence o f obstruction may also 
be poor candidates for brachytherapy.
Urethral dosimetry was found to be a significant predictor of urinary morbidity by 
Wallner et al (266) in 1995, who recommended central urethral doses be kept to less 
than 400 Gy (250% of prescription dose). Other measures such as DIO have not been 
found to correlate better with urinary morbidity than maximal urethral dose although 
they are perhaps more likely to represent the true extremes o f dose than a point dose 
on a single CT slice. Our limited data (n= 60 patients) did not reveal a relationship 
between DIO, D25 or D50 and either IPSS or rates o f AUR. This suggests that the 
current guidelines used (urethral dose 150-250% of prescription dose) limit dose to 
the extent that it had no measurable impact of urinary retention or the symptoms 
assessed by the IPSS. Further work using longer follow-up and larger sample sizes 
might reveal clinically important short and long term toxicity resulting from high 
doses to the urethra. The results from our series are in keeping with the modem 
American literature (267, 268).
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Chapter 6.3 - Effects of bicalutamide and goserelin on prostate 
volume
Short courses o f neo-adjuvant androgen suppression are commonly prescribed prior to 
radical external beam radiotherapy especially in locally advanced disease. This 
practice is supported by the result o f a randomised study showing an improvement in 
the biochemical-relapse-free survival after four months of combined androgen 
blockade starting two months prior to radiotherapy (115). It appears that this benefit 
is only found in moderately differentiated tumours, and that patients with high grade 
tumours only benefit from longer adjuvant treatment (269). One interpretation o f  
these results is that a few months o f androgen deprivation improves the local cell 
killing o f radiation but those tumours at high risk o f distant rather than local relapse 
require longer periods of systemic treatment. This interpretation may be supported by 
the fact that the only randomised trials showing significant benefit from using 
androgen deprivation after radical prostatectomy randomised patients with lymph- 
node positive disease to adjuvant AD or no treatment (270). Bicalutamide has proven 
efficacy compared with placebo as adjuvant treatment after external beam 
radiotherapy for locally advanced with a hazard ratio o f clinical disease progression o f
0.58 (95% Cl 0.41-0.84; P=0.003)(127).
It is not known with certainty how androgen suppression enhances the effect o f  
radiation. Two possible mechanisms for the effect o f short course hormones are 
either a radiation sensitisation effect on prostate cancer cells, or a reduction in the 
number o f clonogens to be eradicated.
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In vivo androgen deprivation (AD) experiments using the Shionogi tumour in nude 
mice by Zeitman et al (271) have shown that the greatest reduction in the radiation 
dose needed to kill 50% of the clonogen population occur when maximal reduction in 
tumour volume occurs prior to EBRT. Pilepich (272) found prostate tumour volume 
to be a significant determinant in local control rate and tumour size adversely effects 
local control after radical radiotherapy in other tumour sites such as cervical 
carcinoma (273). Zeitman (271) concluded that the efficacy of neoadjuvant androgen 
deprivation was unlikely to represent radio-sensitisation o f individual cells as in vitro 
experiments did not show a synergistic effect. However a reduction in the prostate 
tumour hypoxia, which has been demonstrated in vivo (274), or simply a reduction in 
number o f clonogens may lead to an improved radiation dose-response, which would 
not have been demonstrated by these in vitro studies.
Regardless o f the possible effects on tumour control, reducing prostate volume allows 
a smaller planned treatment volume. In EBRT this significantly reduces the amount 
of normal tissue included in the high dose region and hence reduces the long term 
morbidity (275). This suggests that the efficacy o f neoadjuvant AD in prostate 
volume reduction may determine its efficacy in terms o f both disease control and 
symptom reduction when used before EBRT.
To our knowledge the role o f bicalutamide 150mg monotherapy as a neoadjuvant 
treatment prior to radiotherapy has not been studied (although its role adjuvant to 
radiotherapy has been investigated (127, 276)). While our data suggest that LHRH 
analogues are superior in reducing the prostate volume when compared to 
bicalutamide, this finding must be viewed with a degree o f caution as this was not a
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randomised study and is therefore open to confounding by indication (where a 
difference is due to different population studied and not treatment efficacy). However 
placebo controlled studies of bicalutamide (131) and LHRH analogues (121) in 
benign disease have also shown that LHRH analogues have greater cytoreductive 
efficacy. In the absence o f randomised data to demonstrate equivalent volume 
reduction using bicalutamide monotherapy, LHRH analogues must remain the drug of 
choice either as monotherapy or as part o f a combined androgen blockade prior to 
radiotherapy. The use o f neoadjuvant bicalutamide prior to radiotherapy should be 
reserved for the clinical trial setting with appropriate power calculations and quality 
of life assessment to determine whether the possible reduction in side effects 
(particularly sexual toxicity) reported in studies o f AD as sole management o f prostate 
cancer apply to the neoadjuvant setting.
Chapter 7
Conclusions
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Chapter 7.0 - Conclusions from the prostate cancer symptom study
In the PCSS HRQOL was adversely affected by BXT but clinically significant change 
was limited to the first 12 months after treatment. Bias in baseline assessment of 
patients undergoing HBXT and BXTC means we can be less confident o f the duration 
of clinically significant deterioration in HRQOL after these treatments but, given our 
results and those o f other studies it is likely to be o f similar magnitude (<12 months).
Urinary function after brachytherapy deteriorated due to urinary urgency and 
frequency symptoms with a maximal deterioration at 6 weeks post implant. Marked 
urinary incontinence at 2 years was rare (fewer than 4% reported > ‘a little’ 
incontinence) as was significant bother from wearing an incontinence aid (<3%). In 
contrast to previous reports, patients in the PCSS who underwent HBXT or BXTC did 
not report longer durations o f deteriorated urinary function. Sexual function after 
BXT was adversely affected for the duration o f the study with about half o f men 
developing new moderate-severe erectile dysfunction during the first year after 
treatment. A small decrease in median scores occurred at later follow-up but no 
increase in the number o f men deemed impotent. 67% of previously potent men 
needed to use pharmacological therapy to improve erectile function compared with 
14% at baseline. The sexual toxicity of HBXT and BXTC were difficult to assess 
confidently due to baseline assessments that may have been affected by AD, however 
a subset of men who reported potency at baseline assessment before BXT and BXTC 
did not report worse potency outcomes than men undergoing BXT. General cancer 
distress as assessed by the Taunton questionnaire improved to levels better than 
baseline at all follow-up assessments after 3 months in both patients and their 
partners.
- 2 5 7 -
Chapter 7.1 - Improvements in the delivery of brachytherapy
Predicting urinary symptoms after prostate brachytherapy
Review o f previously published work and our own suggests that the current 
EAU/ESTRO/EORTC guidelines on patient selection for brachytherapy are not 
evidence based (152). Analysis of the data from this study suggests that, preimplant 
prostate volume, IPSS score and urodynamic evidence o f obstruction are likely to be 
useful in selecting patients at lowest risk from AUR after treatment with 
brachytherapy. This study was successful in producing an algorithm for selecting 
patients who should be considered for alternative treatment for prostate cancer due to 
high risk o f postoperative urinary retention. To my knowledge the identification of 
preoperative urinary obstruction as a predictor o f post-brachytherapy urinary retention 
was novel at the time o f publication (277). More recent studies have commented that 
urodynamic assessment is becoming routine in some centres in the USA in deciding 
whether men who have higher levels of urinary symptoms are suitable for 
brachytherapy (278).
Whilst the pathophysiology of the early changes in urinary symptoms is unknown, the 
finding that urodynamic obstruction led to AUR events stimulated investigations o f  
the options for reducing symptoms in men following brachytherapy further. The 
impact o f urethral stents was investigated in a small number o f men who experienced 
either severe urinary symptoms or urinary retention requiring intermittent self 
catheterisation after brachytherapy (279). The stents were poorly tolerated due to 
urethral pain although they improved flow and urodynamic parameters o f bladder 
emptying. This underlines the impression that although obstruction due to prostatic
- 2 5 8 -
Chapter 7.1
swelling is part o f the pathophysiology o f early symptoms after brachytherapy, it is 
not the complete answer and much o f the pain from urination present at significant 
levels in 12-20% of men 6-weeks post brachytherapy (see PCSS table 46, p i91) is 
probably due to radiation urethritis. The pathophysiology o f long term urgency 
symptoms is also unknown. We have shown that although improved over time post­
implant, they remain prevalent in 10-17% of men 2 years after brachytherapy. One 
possibility is that new detrusor overactivity, which is a common cause o f urgency 
symptoms, may be secondary to transient obstruction associated with prostatic 
swelling. Obstruction has been demonstrated as a cause o f detrusor overactivity in 
animal models and is thought to be important in some cases o f detrusor overactivity in 
man (280). Detrusor overactivity has been demonstrated in a high percentage o f men 
with severe urinary symptoms that do not resolve spontaneously after brachytherapy 
(278). It is possible that further studies might be able to determine whether avoidance 
of treating obstructed patients reduces the rate of severe urinary symptoms associated 
with detrusor overactivity.
Antiandrogens and cytoreduction
The role o f neoadjuvant AD prior to TIPB in improving oncological outcome is 
unproven although still commonly used (chapter 2.5, p71). Cytoreduction in 
brachytherapy is typically used to avoid pubic arch interference, which may be 
necessary in prostate glands above 50cc or where the pubic arch is narrow. It is clear 
that without evidence o f equivalence from randomised studies bicalutamide at the 
150mg dose cannot be considered equivalent to LHRH analogues for cytoreduction 
prior to brachytherapy. The publication o f the study reported in this thesis (281) was 
followed by further work by Merrick et al on oral agents for cytoreduction prior to
- 2 5 9 -
Chapter 7.1
brachytherapy. They reported results o f a further study describing the cytoreductive 
efficacy o f bicalutamide in combination with dutasteride in 2006 (282). This showed 
that the volume reduction of dual agent treatment was equivalent to LHRH analogues. 
Although the current costs of such a regimen are higher than standard treatment and 
the side effect profile is unknown, it is now possible to give effective cytoreduction 
before brachytherapy without central suppression o f testosterone secretion.
- 2 6 0 -
Chapter 7.2 - Future Studies
Having completed a period of research which investigated quality of life after 
brachytherapy and other radical treatments for EPC it is clear that there are a number of 
remaining questions relating to the efficacy and toxicity of LDR-brachytherapy compared 
to other radical treatments for EPC.
If I were given the opportunity of reinvestigating the outcome of EPC treatments 
including brachytherapy starting in 2007, I would identify the following research 
priorities as most likely to report clinically useful outcomes and focus my resources on a 
single project:
i. What is the biochemical relapse free, metastasis free and overall survival 
benefit associated with LDR-brachytherapy monotherapy (BXT) compared to 
radical prostatectomy (RP) in low-intermediate risk prostate cancer
ii. What are the quality of life outcomes of BXT in comparison to RP in low- 
intermediate risk prostate cancer
These are clearly not the only questions of interest, however the information being 
collected in the PIVOT randomised trial of RP vs. observation in screen detected prostate 
cancer and the published Bill-Axelson et al (46) trail of RP vs. watchful waiting (WW) in 
Scandinavian men give context of the benefit of radical prostatectomy vs. WW with 
androgen deprivation on progression. Furthermore two randomised studies investigating 
the impact of the addition of EBRT to LDR brachytherapy alone are being conducted 
(RTOG 0232 and NCT00241384) so commencing a further study in this area is less 
attractive. Although other study arms detailing the outcome of interventions other than
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BXT and RP would be of interest, the ProTeCT RCT will investigate the effects of EBRT 
compared with AM and RP and duplication of this difficult and expensive study would be 
hard to justify. Although I believe it would be ethical to propose a trial of AM vs. 
brachytherapy it might be more difficult to recruit to such a study and the variable level 
of intervention inherent in the active monitoring arm might make the results difficult to 
interpret.
The ideal design for the study of RP vs. BXT would be an experimental one using a 
randomised design. The failure of the SPIRIT trial (of RP vs. BXT) to recruit holds 
several useful lessons that would determine whether an RCT would be the appropriate 
design for a future study. The SPIRIT group found that all men who had already had 
information given to them before being approached for recruitment into the study were 
unwilling to consent to study entry (283) and that if they were approached in a 
multidisciplinary specialist clinic up to 13% consented. In addition to the practical 
problems of slow recruitment these men may not be representative of the general 
population of men with early prostate cancer. In contrast the ProTeCT study group have 
been able to randomise up to 43% of diagnosed patients to a study of EBRT vs. active 
monitoring vs. radical prostatectomy (284). This success has largely been attributed to 
their control of the recruitment process, including identification of men at high risk of 
prostate cancer in the healthy population invited to participate, biopsy of men with 
abnormal PSA or DRE and their subsequent recruitment into the study. The large levels 
of resource (ProTeCT budget in excess of 10 million pounds sterling, personal 
communication F.Hamdy, Professor of Urology, Sheffield University), time and
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manpower necessary to repeat this design would be impossible for a small research team 
to achieve in a 30 month timescale but might represent a gold standard for future work.
If this level of resource were unavailable then it might be possible to complete a 
randomised trial of radical prostatectomy vs. brachytherapy recruiting patients already 
diagnosed with prostate cancer but with patient access to an agreed set of information 
pointing out the uncertainties inherent in the treatments for prostate cancer and 
involvement of a multidisciplinary clinic as suggested by the SPIRIT group (283). To 
optimise recruitment patients would probably need to be identified very early in their 
diagnostic pathway and seen with information about the trial at the first meeting for 
results of their prostate biopsy in a similar clinic to that run by the hospitals that 
established that recruitment was possible in SPIRIT. This would also be a large and 
costly trial to complete even if  recruitment were possible.
A third option would be to repeat a patient choice study where patients selected their 
treatment (between brachytherapy and surgery). If such a study were to be repeated in 
2007 and add new information to the current literature it would need to improve on the 
design of the PCSS and I would suggest the following:
a. That the patients were comparable at baseline with similar low-intermediate risk 
cancer in all recruited patients (Gleason sum<7, PSA<15, TNM Stage <T3)
b. That the patients be suitable for either option (in terms of fitness for 2-3 hour 
surgery and with IPSS* score and prostate volume suitable for brachytherapy)
c. That a multi-centre design be adopted with standardisation of nerve sparing 
techniques and credentialing of surgeon experience/outcome in the surgical
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intervention and with exclusion of the use of androgen deprivation and 
credentialing of dosimetric outcomes in the brachytherapy arm
d. That appropriate questionnaires be selected; I would recommend those outlined in 
table 72 (page 266), selected from recommendations made in the paper 
reproduced in appendix VIII.
e. That a separate question should be added to record the level of dysuria (using the 
pain on urination question from PR25)
f. That the time points of interest for questionnaire assessment after a baseline 
assessment (which would be before any treatment and performed at a clinic 
appointment), be limited to describe early and long term toxicity. At discharge 
from hospital and 6 week post implant to describe early toxicity, at 3 month 
follow-up for assessment of resolution of early symptoms and at 1 and 5 years to 
assess resolving toxicity.
g. That appropriate resource is allocated to allow questionnaires to be filled in at a 
clinic visit when questionnaire return and timing of completion could be verified.
h. That use of medications should be recorded prospectively by both physician and 
patient to assess compliance. Drug classes o f particular interest would be the 
phosphodiesterase inhibitors (sildenafil, vardenafil and tadalafil), the alpha- 
antagonists (tamsulosin, alfuzosin etc), anticholinergic drugs (detrusitol, 
solifenicin, oxybutenin, trospium) and analgesics.
i. That rate of procedures to treat complications of local therapy (i.e. urethral 
dilation for urethral stricture) should be recorded separately by the physician.
- 26 4 -
Chapter 7.2
Of these options with the level of resource available at the outset of the PCSS I would 
not choose to repeat a patient choice study in 2007. With several longitudinal studies 
(outlined in table 12, p i07) and the PCSS having published or maturing results from 
patients selected or allocated to treatment in real world studies, the inherent lack of 
randomised controlled trial evidence of benefit from brachytherapy is the most 
pressing question. Assessing the benefit of BXT compared with other treatment 
options for EPC in terms of all cause or biochemical relapse free survival or of 
improved symptomatic outcome after brachytherapy will only be possible in a study 
with a randomised design.
The most valuable use of a 2-3 year research fellowship investigating quality of life in 
20007 would be to perform a limited, pilot, randomised study of outcome from 
radical prostatectomy vs. brachytherapy within a local cancer network. This would 
utilise the learning points (a-i above) from the PCSS and other studies of outcome 
from treatment of EPC. Although it would inevitably be underpowered for any 
meaningful survival analysis, it would have the potential to be expanded to a 
meaningful study which would answer some of the current questions about the place 
of brachytherapy in the treatment of prostate cancer and justify the estimated 9-12 
million pounds spent on such treatment by the UK government, health insurers, and 
patients.
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Appendix I:
Outline submission of project to 
University of Surrey for higher degree
Appendix I
Prostate Cancer and Brachytherapy- MD Outline 
Aims Of Project
The aim o f this project is to improve the management o f men with early stage prostate cancer using 
brachytherapy, (radioactive seeds implanted into the prostate). The development o f  this therapy 
will greatly reduce the morbidity o f  patients undergoing treatment for early stage prostate cancer, 
who previously were treated by radical surgery or conventional radiotherapy.
The quality o f life o f  patients will be expected to improve together with a shorter hospital length o f  
stay and a reduced overall healthcare costs. The specific objectives o f  this four-part research 
project are as follows:
1 To use genetic bio-markers to assess which types o f  prostate cancer will best respond to
brachytherapy so that only those patients most likely to have a good response may be 
offered this treatment in future.
2 To assess the effects o f treatment on the quality o f  life o f  patients using validated
questionnaires and to compare these to patients having conventional treatments o f  radical 
prostatectomy or external beam radiotherapy.
3 To identify patients likely to experience difficulty passing urine after treatment with
brachytherapy (a complication specific to this form o f  treatment) using video urodynamics 
and symptom score questionnaires to assess each patient before and after therapy.
4 To investigate the effects o f  radioactive iodine and palladium seeds using cell culture
models o f  prostate cancer as well as o f the urinary sphincter (muscle involved in urinary 
continence) in vitro. In particular the kill rate o f  each isotope on the different cells w ill be 
assessed
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1. Identification o f  prostate cancers ideally suitable for brachytherapy using genetic biomarkers.
Prospectively, the clinical results o f  patients treated with brachytherapy will be correlated with their 
genetic biomarker profile.
Assays will be performed on the biopsy samples from which the cancer was identified. The 
research pathology laboratories at the Royal Surrey County Hospital regularly run assays for p53, 
bcl-2 and Ki67 using established techniques.
Treatment failure will be assessed using PSA as a surrogate marker, measured at 6 monthly 
intervals after implantation. The ASTRO definition o f  3 sequential rises in PSA after nadir will be 
used to identify biochemical recurrence.
80 patients will be recruited into this prospective study over a 2 year period. These patients will 
remain under observation until there is evidence o f  PSA recurrence and or death either by prostate 
cancer or other causes. Such patients will be flagged through the cancer registry tables and follow  
up will be required for a number o f years.
2. Assessment o f  patients suitable for brachytherapy with respect o f their lower urinary tract 
symptoms
Patients urinary symptoms and voiding characteristics will be assessed prior to treatment.. The 
following parameters will be assessed for each patient
Prostate volume measure by transrectal ultrasound 
International Prostate Symptom Score, IPSS, questionnaire 
Urodynamic studies to assess for: 
detrusor instability 
urethral pressure profile 
maximum flow rate 
post void residual
bladder outlet obstruction (via Abrams Griffiths normogram)
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Prostate ultrasound scanning is part o f  the clinical assessment o f patients in outpatients. 
Urodynamic studies are regularly performed in the Urology Department o f  The Royal Surrey 
County Hospital.
The ability o f patients to void post implant will be correlated to the above parameters. The 
morbidity o f patients as assessed by the questionnaires in section will also be related to their initial 
voiding characteristics.
3.3.3 Quality of life assessment of patients treated with brachytherapy, external beam 
radiotherapy and radical prostatectomy
Quality o f  life outcomes after treatment will be compared between patients undergoing 
brachytherapy to those treated by either external beam radiotherapy or radical prostatectomy. 
Three validated questionnaires will be used to assess patients pre-treatment and following treatment 
at 1, 6, and 12 weeks then every 6 months for 2 years.
The questionnaires to be used are the UCLA prostate cancer index (PCI), which addresses the 
toxicity associated with local treatment o f  the prostate cancer and has been shown to be reliable and 
valid and provides a summary measure for statistical analysis. This instrument is composed o f  20 
items falling under 6 dimensions: sexual function, sexual bother, urinary function, urinary bother, 
bowel function, bowel bother. It was developed specifically to assess the impact o f  surgery or 
external beam therapy on the quality o f life o f  men with early prostate cancer. As it may not 
adequately capture symptoms related to urethral irritation or obstruction associated with 
brachytherapy the second questionnaire, the IPSS questionnaire will also be administered.
To address the overall impact o f  the disease and its treatment on the quality o f  life o f  patients the 
Short Form 36 (SF 36) questionnaire will also be u sed . This instrument has been selected since it is 
widely used in clinical trials in both well and chronic disease populations. It is recognised as 
reliable and valid and has been administered with a UCLA PCI.
Eighty patients will be recruited into each possible treatment arm, brachytherapy, external beam 
prostatectomy and radical prostatectomy. Sequential patients attending St Luke’s Cancer Centre for 
external beam radiotherapy will be invited to enter the study as will sequential patients undergoing 
radical prostatectomy at the Royal Surrey County, Frimley Park, and North Hampshire Hospitals. 
A commitment has been received from the urologists and oncologists working at these hospitals to 
enter patients and participate in this study.
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3.3.4 Development of a cell culture model for brachytherapy
Established cell culture lines for prostate cancer will be used to model the effects o f  I and Pd seeds. 
Cell cultures o f  the urinary sphincter muscle will be grown from cells harvested from human 
radical prostatectomy specimens, prior to their preservative in formalin. The parameters detailed 
below will be assessed on the tissue cultures for each isotope. Standardised techniques using 
cellular exclusion o f vital tissue markers, such as Trypan blue will be used to assess cell death.
A. The cell kill rate
B. The total number (volume) o f  cells killed
C. The effect o f  testosterone on the kill rate o f prostate cancer cells
D. The effect o f distance between seeds in terms o f  their kill rate and the effects o f  combining both 
palladium and iodine seeds.
This work will be carried out in the cell biology laboratories at the Institute o f  Urology, London, 
with Professor Fry who has much experience in working with tissue culture models. Informed 
consent to harvest tissues from the radical prostatectomy specimens o f patients will be gained.
Appendix II
Appendix II
Prostate cancer symptom study protocol submitted to the 
multi-centre research ethics committee
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PROTOCOL -  
“Treatment for prostate cancer- Symptoms Study” 
Background
Quality o f  life following contemporary curative treatments for prostate cancer is an essential factor 
in determining treatment for men who may present with few symptoms and survive for relatively 
long periods untreated.
Radical prostatectomy has an incidence o f  urinary incontinence o f  up to 34% in UK studies, with 
erectile dysfunction affecting up to 60% o f men potent preoperatively (290) and is known to affect 
quality o f  life(192). The incidence o f these complications and their impact on quality o f  life after 
laparoscopic radical prostatectomy has not been prospectively assessed. Brachytherapy has a 
incidence o f incontinence o f  <1% in selected patients (146) but difficulty with frequency, nocturia 
and poor urinary flow may be troublesome and result in a temporary decrease in quality o f  
life(192). Similarly external beam radiotherapy has been shown to decrease quality o f  life(291), 
though tiredness and bother from bowel frequency were reported as most bothersome in this group. 
Previous studies addressing these issues have either not been prospective or failed to include all o f  
the current options for men with early prostate cancer. Studies have also not assessed the effect o f  
treatment on a partner where psychosocial morbidity may be greater than that reported by the 
patient (247). The UK population where screen detection o f  prostate cancer is less common and 
specialist centres treat fewer patients may also produce a different outcome to that in studies from 
the USA.
Aims
We aim to assess the effects o f treatment on the quality o f  life using validated questionnaires in 
patients having one o f  the accepted treatments for early prostate cancer namely, radical 
prostatectomy (by the open or laparoscopic method), brachytherapy or conformal external beam 
radiotherapy. Symptoms such as urinary incontinence, urinary bother bowel and erectile 
dysfunction will be specifically addressed using validated questionnaires as well as the 
psychosocial effect o f treatment on the patient and partner.
Methods
Quality o f life outcomes after treatment will be compared between patients undergoing 
brachytherapy, external beam radiotherapy or radical prostatectomy (by either the open or 
laparoscopic route). Patients will have chosen/been allocated treatment prior to inclusion in the 
study. Validated questionnaires will be used to assess patients pre-treatment and following  
treatment at 6, and 12 weeks then every 6 months for 2 years. Clinical data will be recorded on 
patients at interview when they are recruited for the study and questionnaires will be self­
administered (postal).
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The questionnaires used include EORTC QLQ C30, which is a cancer-specific health index. This 
will be coupled with the EORTC PR25 module designed to assess prostate cancer related 
symptoms. As this may not adequately capture symptoms related to urethral irritation or 
obstruction associated with brachytherapy the IPSS questionnaire will also be administered.
The international index o f  erectile function (IIEF) will be used to measure change in erectile 
function and an erectile-function specific quality o f  life measure and patient and partner anxiety 
questionnaire included. All questionnaires have been validated in the setting o f  prostate cancer in 
the UK.
Sixty patients will be recruited into each treatment arm, brachytherapy, external beam 
prostatectomy and radical prostatectomy. Sequential patients attending St Luke’s Cancer Centre for 
conformal external beam radiotherapy will be invited to enter the study as will sequential patients 
undergoing radical prostatectomy at the StGeorges, Royal Surrey County, Frimley Park, and North 
Hampshire Hospitals. A  commitment has been received from the urologists and oncologists 
working at these hospitals to enter patients and participate in this study. The Bristol centre 
performing radical prostatectomy has agreed to recruit patients for the study.
Data protection will be assured as the study databases for contact details and address will be kept 
separately from the questionnaire responses on a portable computer. These will be password 
protected and only accessible to the research team (Research Registrar and nurse). Questionnaires 
will be identified by number and supplied with reply paid envelope. They can therefore be easily 
sent via the post without confidentiality being an issue. The QOL data-set will be available in 
anonymous form to the participating consultants. The written and verbal information given will 
specify state that we are asking for consent to store the information about address and contact 
details electronically for the duration o f  the study. That the details will be stored securely and not 
used for other purposes or kept without specific permission after the duration o f  the study.
Study Protocol -  Quality of Life after Treatment for Prostate Cancer
1. Patients will be recruited following decision to treat with curative intent for early prostate 
cancer (T 1-3, PSA<20, Negative MRI/Bone scan if  clinically indicated) and will already have 
selected or been allocated to treatment.
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2. Demographic data will be recorded on a standard form relating to stage and grade o f  cancer, 
use o f  hormone treatments and general health pre-treatment.
3. The treatment modalities assessed will be conformal external beam radiotherapy (EBRT) 
alone, brachytherapy (+/- EBRT), radical prostatectomy and laparoscopic radical prostatectomy.
4. Patients will be given written information in clinic or by post. A  contact number will allow  
patients to opt in to the study by deciding to arrange a recruitment interview.
5. Patients and their partners attending for interview will be asked to give written consent and 
demographic details will be gained from the notes to compare the populations studied. A sample 
questionnaire will be shown to patients to allow explanation o f  any unclear areas.
6. Postal questionnaires will be completed prior to treatment and at 6 and 12 weeks and then 
six monthly intervals for 2 years following treatment. Serum PSA levels will be recorded from the 
host institutions (recurrence o f  disease is known to affect QOL).
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Prostate cancer symptom study questionnaire bundle
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Symptoms Following Treatment For Prostate Cancer
Thank you very much for taking part in this study. The information that we gain 
from this study will make a great difference to future patients with prostate cancer.
Choosing one of the many treatments for prostate cancer may be a very difficult 
decision particularly as many men find it difficult to talk about loss of control of 
urinary function, problems when urinating or ability to have erections and/or make 
love. We will ask you to answer questions about these subjects which are very 
personal. We hope you will be able to answer them honestly, as the answers will be 
of great interest to both urologists and to future patients. As you will see from the 
questionnaires you are not identified by name anywhere on the booklet and only the 
research doctor and nurse will have access to the results. These questionnaires will 
not be stored in your notes and therefore none of the hospital or clinic staff other than 
the research team will see the questionnaires. This is to protect your privacy and 
allow you to answer all of the questions as honestly as possible.
This study will allow the doctors who advise future patients to give accurate figures 
for the likely side effects of treatment. We hope it will also give us an insight into 
your health and general wellbeing. This will help future patients to choose the best 
treatment for them. Some of the questions may be very similar or may not apply to 
your lifestyle but please answer them, if possible, as they have been shown (by other 
investigators) to be useful indicators of how much trouble people are having with 
their symptoms.
Please fill in the questions on the white paper first on pages 3-16. If you have had 
any problems with erections of the penis please fill in the questions in green on pages 
17-18. If you have a partner then please tear off the partner’s questionnaire (on the 
yellow paper) on pages 19-20 and ask them to complete it. The questionnaires may 
then be returned in the envelope provided. You may discuss the questions with your 
partner if you wish.
Thank you for your help and if you have any problem filling out the questionnaires or 
are unsure of what to do please contact us at the addresses below.
Mr Alastair Henderson, Brachytherapy Research Fellow,
Department of Urology, Royal Surrey County Hospital.
Telephone : 01483 571122 and ask switchboard to contact
Ms Devina Choolun, Brachytherapy Research Nurse,
Department of Urology, Royal Surrey County Hospital.
Telephone : 01483 571122 
Or Mobile: 07810 162325
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General Health Questionnaire (EORTC QLQ C30 v3)
We are interested in some things about you and your health. Please answer all of the 
questions yourself by circling the number that best applies to you. There are no "right" or 
"wrong" answers. The information that you provide will remain strictly confidential.
Please fill in your initials:
Today's date (Day, Month, Year): / /
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase?
2. Do you have any trouble taking a long walk?
3. Do you have any trouble taking a short walk outside 
of the house?
4. Do you need to stay in bed or a chair during the day?
5. Do you need help with eating, dressing, washing 
yourself or using the toilet?
Not at A Quite Very
All Little a Bit Much
During the past week:
6. Were you limited in doing either your work or other 
daily activities?
7. Were you limited in pursuing your hobbies or other 
leisure time activities?
8. Were you short of breath?
9. Have you had pain?
10. Did you need to rest?
11. Have you had trouble sleeping?
12. Have you felt weak?
13. Have you lacked appetite?
14. Have you felt nauseated?
15. Have you vomited?
Not at A Quite Very
All Little a Bit Much
Please go on to the next page 
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During the past week: Not at A Quite Very
All Little a Bit Much
16. Have you been constipated? 1 2
17. Have you had diarrhoea? 1 2
18. Were you tired? 1 2
19. Did pain interfere with your daily activities? 1 2
20. Have you had difficulty in concentrating on things,
like reading a newspaper or watching television? 1 2
21. Did you feel tense? 1 2
22. Did you worry? 1 2
23. Did you feel irritable? 1 2
24. Did you feel depressed? 1 2
25. Have you had difficulty remembering things? 1 2
26. Has your physical condition or medical treatment
interfered with your family life? 1 2
27. Has your physical condition or medical treatment
interfered with your social activities? 1 2
28. Has your physical condition or medical treatment
caused you financial difficulties? 1 2
For the following questions please circle the number between 1 and 7 that best applies to you
29. How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
3 0. How would you rate your overall quality of fife during the past week?
1 2 3 4 5 6 7
Very poor Excellent
© Copyright 1995 EORTC Study Group on Quality o f Life. All rights reserved. Version 3.0
- 2 9 8 -
Specific Sym ptom s Related To Prostate Problem s (EORTC q l q - p r 2 5 )
Patients sometimes report that they have the following symptoms or problems. 
Please indicate the extent to which you have experienced these symptoms or 
problems during the past week. Please answer by circling the number that best 
applies to you.
During the past week
Not 
at all
A little Quite a 
bit
Very
much
31. H ave vou had to  urinate frequently  during the day? 1 2 3 4
32. H ave vou  had  to urinate frequently  at night? 1 2 3 4
33. W hen you  felt the urge to  pass urine, d id  you  have 
to  hurry  to get to  the to ile t?
1 2 3 4
34. W as it d ifficu lt for you  to  get enough  sleep, because 
yo u  needed  to  get up frequently  at n igh t to  urinate?
1 2 3 4
35. H ave you  had d ifficu lty  go ing  out o f  the house 
because y o u  needed  to be close to  a to ilet?
1 2 3 4
36. H ave you  had any unin ten tional release (leakage) 
o f  u rine?
1 2 3 4
37. D id you  have pain  w hen  you  urinated? 1 2 3 4
Answer this question only if you wear an incontinence aid
38. Has wearing an incontinence aid been a problem 
for you?
1 2 3 4
39. H ave you r daily  activ ities been  lim ited  by your 
urinary  problem s?
1 2 3 4
40. H ave you r daily  activ ities been lim ited  by your 
bow el prob lem s?
1 2 3 4
41. H ave you  had any unin ten tional release (leakage) 
o f  stoo ls?
1 2 3 4
42. H ave you  had blood in your stools? 1 2 3 4
43. D id you  have a  b loated  feeling  in y o u r abdom en? 1 2 3 4
44. D id you  have hot flushes? 1 2 3 4
45. H ave you  had sore or en larged nipples o r b reasts? 1 2 3 4
46. H ave you  had sw elling  in your legs or ankles? 1 2 3 4
Please go to the  next page 
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During the last 4 w eeks...
Not at 
all
A little Quite a 
bit
Very
much
47. H as w eigh t loss been  a  prob lem  for you? 1 2 3 4
48. H as w eigh t gain been  a  p roblem  fo r you? 1 2 3 4
49. H ave you felt less m asculine as a  resu lt o f  your 
illness or trea tm en t?
1 2 3 4
50. T o w hat ex ten t w ere yo u  interested  
in sex?
1 2 3 4
51. To w hat ex ten t w ere yo u  sexually  active (w ith  or 
w ithou t in tercourse)?
1 2 3 4
PLEASE ANSWER THE NEXT FOUR QUESTIONS ONLY IF YOU HAVE BEEN 
SEXUALLY ACTIVE OVER THE LAST 4 WEEKS
52. To w hat ex ten t w as sex  en joyab le  for you? 1 2 3 4
53. D id you  have d ifficulty  getting  o r m ain ta in ing  an 
erection?
■ : , - . . .
54. D id yo u  have e jacu la tion  p roblem s (eg  dry 
e jacu la tion )?
1
,
2
2
3
3
4
4
55. H ave y o u  felt uncom fortab le abou t being  sexually  
in tim ate?
; S : i: 
1
:: y t a s C E :':
2 3 4
Copyright 1999 EORTC Study Group on Quality o f  Life. All rights reserved.
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International Index o f Erectile Function
These questions ask about the effects your erection problems have had on your sex life over 
the past 4 weeks. Please answer the following questions as honestly and clearly as possible. In 
answering these questions, the following definitions apply:
Sexual activity includes intercourse, caressing, foreplay and masturbation
Sexual intercourse is defined as vaginal penetration o f  the partner 
(you entered your partner)
Sexual stimulation includes situations like foreplay with a partner, looking at pictures, etc 
Ejaculate: the ejection o f  semen from the penis (or the feeling o f this)
1. Over the past 4 weeks, how often were you able to get an erection during sexual activity?
Please tick one box only
□  No sexual activity 0
□  Almost always or always 5
□  Most Times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A  few times (much less than half the time) 2
□  Almost never or never 1
2. Over the past 4 weeks, when you had erections with sexual stimulation, how often were
your erections hard enough for penetration?
Please tick one box only
□  N o sexual stimulation 0
□  Almost always or always 5
□  Most Times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A  few times (much less than half the time) 2
□  Almost never or never 1
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The next three questions will ask about the erections you may have had during sexual intercourse.
3. Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to 
penetrate (enter) your partner?
□  Did not attempt intercourse 0 Please tick one box only
□  Almost always or always
□  Most times (much more than half the time)
□  Some times (about half the time)
□  A  few times (much less than half the time)
□  Almost never or never
5
4
3
2
1
4. Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your 
erection after you had penetrated (entered) your partner?
□  Did not attempt intercourse 0 Please tick one box only
□ Almost always or always 5
□ Most times (much more than half the time) 4
□ Sometimes (about half the time) 3
□ A few  times (much less than half the time) 2
□ Almost never or never 1
5. Over the past 4 weeks, during sexual intercourse, how difficult was it to maintain your 
erection to completion o f  intercourse?
□  Did not attempt intercourse 0 Please tick one box only
□ Extremely difficult 1
□ Very difficult 2
□ Difficult 3
□ Slightly difficult 4
□ Not difficult 5
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6. Over the past 4 weeks how many times have you attempted sexual intercourse?
□  N o attempts 0 Please tick one box only
□ 1-2 attempts 1
□ 3-4 attempts 2
□ 5-6 attempts 3
□ 7-10 attempts 4
□ 11+ attempts 5
7. Over the past 4 weeks, when you attempted sexual intercourse how often was it 
satisfactory for you?
□  Did not attempt intercourse 0 Please tick one box only
□ Almost always or always 5
□ Most times (much more than half the time) 4
□ Sometimes (about half the time) 3
□ A few times (much less than half the time) 2
□ Almost never or never 1
Over the past 4 weeks, how much have you enjoyed sexual intercourse?
□  N o intercourse 0 Please tick one box only
□  Very highly enjoyable 5
□  Highly enjoyable 4
□  Fairly enjoyable 3
□  Not very enjoyable 2
□  No enjoyment 1
9. Over the past 4 weeks, when you had sexual stimulation or intercourse how often did you 
ejaculate?
□  N o sexual stimulation/intercourse 0 Please tick one box only
□  Almost always or always 5
□  Most times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A few times (much less than half the time) 2
□  Almost never or never 1
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10. Over the past 4 weeks, when you had sexual stimulation or intercourse how often did you 
have the feeling o f  orgasm (with or without ejaculation)?
□  N o sexual stimulation/intercourse 0 Please tick one box only
□  Almost always or always 5
□  Most times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A  few times (much less than half the time) 2
□  Almost never or never 1
The next two questions ask about sexual desire. Let’s define sexual desire as a feeling that may 
include wanting to have a sexual experience (for example masturbation or intercourse), thinking 
about having sex, or feeling frustrated due to lack o f  sex.
11. Over the past 4 weeks how often have you felt sexual desire?
□  Almost always or always 5 Please tick one box only
□  Most times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A  few times (much less than half the time) 2
□  Almost never or never 1
12. Over the past 4 weeks how would you rate your level o f sexual desire?
□  Very high 5 Please tick one box only
□  High 4
□  Moderate 3
□  Low 2
□  Very low or none at all 1
13. Over the past 4 weeks how satisfied have you been with your overall sex life?
□  Very satisfied 5 Please tick one box only
□  Moderately satisfied 4
□  About equally satisfied and dissatisfied 3
□  Moderately dissatisfied 2
□  Very dissatisfied 1
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14. Over the past 4 weeks how satisfied have you been with your sexual relationship with your 
partner?
□  Very satisfied 5 Please tick one box only
□  Moderately satisfied 4
□  About equally satisfied and dissatisfied 3
□  Moderately dissatisfied 2
□  Very dissatisfied 1
15. Over the past. 4 weeks how do you rate your confidence that you can get and keep your 
erection?
Please tick one box only□ Very High 5
□ High 4
□ Moderate 3
□ Low 2
□ Very low 1
Thank you for completing this questionnaire.
Supplementary Questionnaire
We need to know to what extent your treatment affects the amount o f  time and help you require 
from the local health services and from your family or friends.
The questions below should be answered in relation to those services you have required since the 
last questionnaire and are to do with all those services which relate to the treatment you are having 
within this study. If you have not previously completed a questionnaire then please complete this 
section for the past 3-months.
Since the last assessment
l. Have you been to your own doctor for any reason? 
times
Y esD  N oD
Number o f
2. Has your own doctor visited you at home for any reason? 
YesD N oD
Number o f  times
3. Have you visited your nurse or surgery/health clinic for any reason?
YesD  N oD
Number o f  times
4. Has the nurse visited you at home for any reason? 
Y esD  N oD
Number o f  times
5. Have you required any help from social services/any voluntary group?
YesD N oD
Number o f  times
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Please complete this form which you may have seen previously in clinic, it relates to your current ease of 
urination. Please ring the closest answer to how you have felt over the last month. Thank you.
Date:
Less Less About More 
Not at than 1 than Half than half Almost Your 
all time in half the the time the time always score 
5 time
1 Incomplete emptying
Over the past month, how often 
have you had a sensation of not 
emptying your bladder completely 
after you finish urinating?
0 1 2 3 4 5
2 Frequency
Over the past month, how often 
have you had to urinate again 
less than two hours after you 
finished urinating?
0 1 2 3 4 5
3 Intermittency
Over the past month, how often 
have you found you had stopped 
and started again several times 
when you urinated?
0 1 2 3 4 5
4 Urgency
Over the past month, how often 
have you found it difficult to 
postpone urination?
0 1 2 3 4 5
5 Weak Stream
Over the past month, how often 
have you had a weak urinary 
stream?
0 1 2 3 4 5
6 Straining
Over the past month, how often 
have you had to push or strain to 
begin urination?
0 1 2 3 4 5
5 Times
None 1 Time 2 Times 3 Times 4 Times or more
7 Nocturia
Over the past month, how many 
times did you most typically get 
up to urinate from the time you 
went to bed at night until the time 
you got up in the morning?
0 l 2 3 4 5
Total I-PSS Score
■ - “ “ “
M ixed
Quality of Life due to Urinary Delighted Pleased Mostly Equally Mostly Unhapp Terribl
Symptoms satisfied satisfied & dksatkfi v e
J * dissatisfied aissatlsn y
ed
If you were to spend the rest of 0 1 2 3 4 5 6
your life with your urinary
condition just the way it is now,
how would you feel about that?
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Patient’s Questionnaire
These questions attempt to measure some of the effects of your prostate cancer upon 
you. We will ask your partner to complete a similar questionnaire (if you have one). 
Please read each question carefully and answer by ticking the appropriate box. 
Answer according to how you are feeling at the moment.
* Are you worried or concerned about the fact that you have cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Are you worried or concerned about what might happen in the future?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Are you having any difficulty in coping with your feelings or emotions resulting 
from your cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Your day to day activities might include chores around the house, going shopping or your  
job. Do you find yourself restricted in these sort o f activities, because o f  your cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Your social life might include seeing friends, going for day trips and your  
hobbies. Has your social life become restricted, for whatever reason, as a result 
o f your cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
From now on, first answer YES or NO, then answer the second part o f the question only if asked to do
so.
•  Are you receiving any treatment for your cancer?
Yes No
IF YOU ANSW ERED YES, how much does the treatment worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
IF YOU ANSW ERED NO, how much does this worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
•  Do you have any pain?
Yes No
IF YOU ANSW ERED YES, how much does this pain worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
•  Do you have any urinary problems?
Yes No
IF YOU ANSW ERED YES, how much does these problems worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
•  Do you have difficulty doing the things that you used to be able to do, as a result o f your  
cancer?
□ Yes □ No
IF YOU ANSW ERED YES, how much does this worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
•  Has your sex life been changed by your cancer diagnosis or treatment?
□ Yes □ No
IF YOU ANSW ERED YES, how much does this worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
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QUALITY OF LIFE QUESTIONNAIRE
This questionnaire only applies to men who have problems getting an erection. If  you never have 
problems getting an erection DO NOT complete this questionnaire.
This questionnaire asks for your views about your erectile problem. Please read each item and place 
a tick in the box opposite the reply which comes closest to how you feel.
Not 
at all
A
little Somewhat
Quite a 
lot
A great deal
1. As a result o f  your erectile 
difficulties, do you blame yourself for 
being unable to satisfy your partner ?
□ o
Not at 
all
□ i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
2.Does your inability to produce an 
erection with your partner make you feel 
guilty ?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
3.Do you feel less desirable as a 
result o f your erectile difficulties?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
4.Do you feel hurt by your partner’s 
response to your erectile difficulties?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
5. Does the fact that you are unable to 
produce an erection make you feel less 
o f  a man?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
6.Do you feel angry or bitter that you 
cannot produce an erection?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
7.Do you feel a failure because o f  
your erectile difficulties?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
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Please read each item and place a tick in the box opposite the reply which comes closest to how you 
feel.
Not 
at all
A
little Somewhat
Quite a 
lot
A great deal
8 . Does your partner feel let down by 
your inability to produce an erection?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
9 . Are you worried that your erectile 
problems have affected the closeness 
between you and your partner?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
lO.Does your erectile failure make you 
worry about how your life will 
develop in the future?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
11 .Is your sense o f identity altered by 
your lack o f erectile function?
□ o
Not at 
all
□ i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
12. Are you preoccupied by your 
erection problems?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
13.Do you feel sad or tearful as a result 
o f your erectile difficulties?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
14.Do you feel that other people are 
happier than you are because they 
are sexually fulfilled?
□ o
Not at 
all
□ i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
15. Is your self esteem damaged by your 
erectile problems?
□ o
Not at 
all
□  i
A little
□ 2
Somewhat
□ 3
Quite a 
lot
□ 4
A great deal
© 1998 Taunton and Somerset NHS Trust
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P A R T N E R ’S Q U E S T IO N N A IR E
These questions attempt to m easure som e o f  the effects o f  your partner’s prostate cancer 
upon you. Please read each question carefully and answer by ticking the appropriate box  
and answer according to h ow  you  are feeling  a t th e  m om ent.
•  A re  you  w orried  or con cern ed  ab ou t the fact th at y o u r  p artn er  has cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Are you worried or concerned about what might happen in the future?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Are you having any difficulty in coping with your feelings or emotions resulting 
from your partner’s cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Your day to day activities might include chores around the house, going shopping 
or your job. Do you find yourself restricted in these sort of activities, because of 
your partner’s cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
* Your social life might include seeing friends, going for day trips and your 
hobbies. Has your social life become restricted, for whatever reason, as a result 
of your partner’s cancer?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
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From now on, first answer Y ES or N O , then answer the second part o f  the question only if
asked to do so.
• Is your partner receiving any treatment for his cancer?
Yes No
IF YOU ANSW ERED YES, how much does the treatment worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
IF YOU ANSWERED NO, how much does this worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
• Does your partner have any pain?
Yes No
IF YOU ANSW ERED YES, how much does this pain worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
• Does your partner have any urinary problems?
Yes No
IF YOU ANSW ERED YES, how much do these problems worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
• Does your partner have difficulty doing the things that he used to be able to do, 
as a result of his cancer?
Yes No
IF YOU ANSW ERED YES, how much does this worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
• Has your sex life been changed by your partner’s cancer diagnosis or treatment?
Yes No
IF YOU ANSW ERED YES, how much does this worry you?
□ Not at all (0) □ A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A  great deal (4)
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Appendix IV
Prostate cancer symptom study questionnaire bundle and
patient information
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Appendix IV
Patient Information Sheet
Study Title : Treatment For Prostate Cancer -  Symptoms 
Study
You are being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends/relatives and your GP if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical research and 
you’. This leaflet gives more information about medical research and looks at some questions 
you may want to ask. A copy may be obtained from CERES, PO Box 1365, London N16 OBW.
What is the purpose of this study ?
The purpose of this study is to examine the side effects, in terms of urinary symptoms and 
general quality of life issues, of patients being treated for localized prostate cancer with either 
brachytherapy, external beam radiotherapy or radical surgery (radical prostatectomy). Patients 
in the study may be having surgery by either the open or laparoscopic (keyhole) method. In 
addition, the particular type of prostate cancer present, in those patients being treated by 
brachytherapy, will be compared to the long-term success of this treatment.
Why have I been chosen ?
All patients who are undergoing prostate brachytherapy are being invited to enter this study. 
Similarly patients who are having conventional radiotherapy at St Luke’s Cancer centre, or 
radical prostatectomy at the Royal Surrey County Hospital, Frimley Park or Basingstoke (North 
Hampshire Hospital) will be invited to participate in this study.
Do I have to take part ?
It is up to you to decide whether or not to take part. If you do decide to take part you will he 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. This will not affect 
the standard of care you receive in any way.
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What will happen to me if I take part?
If you agree to take part in this study you will be asked to complete a series of questionnaires. 
The first time that you are asked to fill in a questionnaire a research doctor or nurse will be 
present to explain any questions if necessary. It will not require any additional visits to the 
hospital and the questionnaire take approximately 20 minutes to complete.
Information already in your Hospital notes relating to your current and past medical 
history and the results of your urodynamic studies if you have had them will also be 
collected in this study. All such information will be stored anonymously and only 
viewed by the doctors/nurses involved in this research study. Your privacy and 
anonymity will be maintained at all times. As part of the study your name and 
address will be stored securely on a computer in order that we may follow up your 
progress over the next 2 years. When the study is over we will not store this data 
unless we have your permission to do so.
Patients who are being treated by Brachytherapy will have their prostate biopsy tissue, from 
which the diagnosis of prostate cancer was made, further analyzed in the Pathology 
Department of the Royal Surrey County Hospital to define the exact type that is present. Such 
detailed analysis is not routinely performed by hospitals, as it is not necessary for diagnosing 
cancer. However, there are a number of different molecular markers that can be used to help 
characterize your cancer more closely. This information may be useful in identifying which 
cancer respond best to brachytherapy.
There is no control or dummy arm to this study nor has your treatment being selected by 
random. Your planned treatment will be unaffected by this study. The only additional role that 
will be asked of you is to complete the urinary symptom and quality of life questionnaires 
around the time that you attend for follow up appointments. These appointments are usually at 
6 weeks, 3, 6, 9,12,18 and 24 months post treatment. The questionnaire may be sent in the 
post to you and then either returned by post or to the clinic if you agree to this. Questionnaires 
are identified by a number and not your name.
What are the possible benefits of taking part?
There may be no immediate benefits to you during the study, although the questionnaires may 
help to remind you of issues or concerns that you wish to ask your consultant. However, the 
information gained from this study may help us the better treat patients with prostate cancer in 
the future. Sometimes, during the course of a research project new information becomes 
available about the treatment, and if so the information will be discussed with you.
What happens when the research study stops?
After the study period you will still continue to be followed up by your consultant in the standard 
fashion, usually every 6 months for at least 5 years.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the study will be kept strictly 
confidential. Any information about you that leaves the hospital will have you name and 
address removed so that you cannot be recognised from it.
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What will happen to the results of this study?
The results of this study will be presented widely at medical meetings both in the UK and 
abroad and the results will be published in international medical journals.
Who is funding the research?
The study is being funded by an independept national medical charity, called PPP Healthcare 
Trust, Neither the consultants, research doctors nor nurses are being paid for including you in 
this study.
Who has reviewed the study?
The South West Surrey, North West Surrey and North Hampshire Local Research Ethics 
Committees have reviewed this study.
Contact for Further Information
The following Research Nurse or Doctor may be contacted at any stage.
Mr Alastair Henderson MRCS, Brachytherapy Research Registar.
Royal Surrey County Hospital,
Egerton Road,
Guildford,
Surrey,
GU2 5XX Telephone: 01483 571122 Bleep : 4945
Ms Devina Choolun RGN, Brachytherapy Research Nurse.
Royal Surrey County Hospital,
Egerton Road,
Guildford,
Surrey,
GU2 5XX Telephone: 01483 571122 Ext: 20581 Bleep :4897
Thank you for your valuable help in taking part in this study.
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The Royal Surrey County Hospital
NHS Trust
Patient Identification Number for this Trial:
CONSENT FORM
Title of Project: Treatment for prostate cancer -  symptoms study 
Name of Researcher: Alastair Henderson
2 .
I confirm that I have read and understood the information sheet □
dated 18/10/2001 for the above study
and have had the opportunity to ask questions.
I understand that my participation is voluntary and that I am free to
Please initial box
□
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.
I understand that sections of any of my medical notes may be looked□
at by responsible individuals from regulatory authorities where it is 
relevant to my taking part in research. I give permission for these 
individuals to have access to may records.
I agree to take part in the above study□
Name of Patient Date Signature
Name of Person taking consent 
(if different from researcher)
Date Signature
Researcher Date
1 for patient; 1 for researcher; 1 to be kept with hospital notes
Signature
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Appendix V
Recommendations from the EORTC on processing PR25 
data and scheme for processing data from current PCSS
database
Appendix V
Reccomendations from the EORTC on processing PR25 data
Items 1 through 9 address urinary symptoms and problems. It is hypothesized that 
these items, excluding item 8, will form a multi-item scale. Item 8 is conditional on 
the use o f  incontinence aids, and thus is not o f relevance to all patients. Thus it should 
be treated as a separate item. The individual items and the multi-item scale should be 
scored such that higher scores represent more symptoms/problems (i.e., higher score = 
worse).
Items 10-13 are hypothesized to form a scale assessing bowel symptoms/function.
The individual items and the multi-item scale should be scored such that higher scores 
represent more symptoms/problems (i.e., higher score = worse).
Items 14-19 are hypothesized to form a scale assessing treatment-related symptoms. 
The individual items and the multi-item scale should be scored such that higher scores 
represent more symptoms/problems (i.e., higher score = worse).
Items 20-25 are related to sexuality.
Items 20 and 21 can be completed by all patients, and are hypothesized to form a 
scale. The individual items and the multi-item scale should be scored such that higher 
scores represent higher levels o f  sexual functioning (i.e., higher = better). Note: this 
will require recoding the response categories o f  questions 20 and 21.
Items 22-25 are conditional on being sexually active, and thus will only be completed 
by a subgroup o f  patients. They are hypothesized to form a scale. The individual items 
and the multi-item scale should be scored such that higher scores represent higher 
levels o f sexual functioning (i.e., higher = better). Note: this will require recoding the 
response categories o f questions 23 through 25.
If reporting scale level data, it is highly recommended that some basic psychometric 
analyses be carried out. Minimally, one would want to look at the internal consistency 
o f  the scales (using the reliability program o f  SPSS or a similar software package that 
calculates a Cronbach's alpha coefficient). That coefficient should preferably be above 
0.70 for any given multi-item scale (for purposes o f  group comparisons). You do not 
need to recode the items to perform the reliability analysis.
If forming a scale appears to be justified, then the same algorithm can be used as is 
presented in the scoring manual for the QLQ-C30 for linearly converting items and/or 
scales to 0-100 scales).
The module items can also be reported individually. If this is done, it may be more 
useful to report the percentage o f patients endorsing each o f  the response categories, 
rather than mean scores. It may even be useful to recode the response categories to 
yield a dichotomous outcome per item (e.g., “not at all” and “a little” vs. “quite a bit” 
and “very much”). This allows one, for example, to report the percentage o f  patients 
with moderate to severe symptoms or problems. If item mean scores are being 
presented, the items should first be linearly converted to a 0 to 100 scale.
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Additional Instructions for converting QLQ-C30 and PR25 questionnaire 
answers to scale data
These are additional instructions which are designed to be used as an aide memoire 
for future users o f  the research database at the RSCH in conjunction with the 
instructions to users outlined in the EORTC QLQ-C30 user manual(248).
QLQ-c30
Insert additional 15 columns after qlqc30.
Paste titles in bar (Rename qlqc30 ql-30).
Copy q l-30  to new sheet.
Rename worksheet for ID.
Save the worksheet and close the new sheet.
Open the new sheet in SPSS.
Ensure data is numeric and nominal in variable view.
Open qlqc30 code program (reproduced in Ch 5.7) and type
qlqscal 3.
Execute.
Then type run
Save output as excel file 
Replace #null with blanks 
Paste Data Into Master DB
Appendix V
PR25
Ensure extra six (5 new) columns are inserted after PR25 
Paste in title bar (rename PR 1-25)
Recode 23-25 (so that higher scores represent more problems)
Replace 1 with d
Then 2 with c
Then 3 with 2
Then 4 with 1
Then c with 3
Then d with 4
Delete Zeros and dots from columns 22-25
(When processing sexual function don’t forget that as zeros represent no sex then this 
could be considered worse than 4 ’s (i.e. 100% trouble)).
Copy prl-25 to new sheet (include relabelled header bar)
Rename worksheet for ID.
Save the worksheet and close the new sheet.
Open the new sheet in SPSS.
Ensure data is numeric and nominal in variable view
Open qlqc30 code program (reproduced in Ch 5.7) and type
prscal 3.
Execute.
Then type run
Save as excel file 
Replace #null with blanks 
Paste Data Into Master DB
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* .* S P S S  C O M M A N D S  to generate Q LQ  scales.* = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = .*
.* S P S S  version 7 .5  .
/*  P eter Fayers, 30  August, 1998  */
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
/*  This code is provided as is without w arranty of any kind, either */
/*  expressed or implied. It is not guaranteed to be error free, and in */
/*  no event will w e  accept liability for any dam ages arising out of the */
/*  use o f this code.
* / /* = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
define qlqsub ( IP O S IT IO N A L  !T O K E N S (1)
/IP O S IT IO N A L  !T O K E N S (1)
/IP O S IT IO N A L  !T O K E N S (1)
/IP O S IT IO N A L  !T O K E N S (1)
/IP O S IT IO N A L  lENCLOSECC,')')
/IP O S IT IO N A L  IC M D E N D ). 
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/*  qlqsub is the utility routine called by the S P S S  programs that * /
/*  calculate scores for the Q L Q -C 3 0  and its modules. * /
/ *  * /
/*  A R G U M E N T S  */
/*  N am e o f scale ISC A LE */
/*  Description of scale ISC A LN A M  */
/*  Num ber of items in scale IN IT E M S  */
/*  R ange of each item in the scale IIR A N G E  */
/*  List of items in the scale (IQ L Q V A R S ) */
/*  (O ptional) string FS C A LE  - indicates function scales (highscore=good) */
/*  (Optional) string X M IS S  - to stop missing values being imputed *1 
I* *1
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
ILET ISCALE =11.
ILET ISC A LN A M  = !2.
ILE T  IN IT E M S  = !3.
ILET IIR A N G E  = !4
ILET IQ LQ V A R S  = !5.
C O M P U T E  #S M E A N  = M E A N  ( IQ L Q V A R S  ) .
C O M P U T E  # S N U M R  = N V A LID  ( IQ LQ V A R S  ) .
ILET IFS C A LE  = (!IN D E X (!6 ,F S C A L E )> 0).
ILET IX M IS S  = (!IN D E X (!6 ,X M IS S )> 0 ).
IF (# S N U M R  G E  IN IT E M S /2 ) ISC A LE = ((# S M E A N -1 .0 )/(!IR A N G E ))*1 00 .
IF (IFS C A L E  EQ  1) ISC A LE = 100.0  -  ISCALE .
IF (IX M IS S  EQ  1 A N D  # S N U M R  LT IN IT E M S ) ISCALE = $ S Y S M IS  .
V A R IA B LE  LABEL ISCALE IS C A LN A M  . 
len d d e fin e .
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/ *  * /
/*  Program  for the Q L Q -C 3 0  (all versions) * /
/ *  * /  
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
define qlqscal ( IP O S IT IO N A L  !T O K E N S (1)
/IP O S IT IO N A L  IC M D E N D ).
ILET IQLQ  = 11.
ILET IU S E R O P  = !2.
IIF (IQ LQ  = 3) ITH E N .
- 3 2 4 -
Appendix VI
M IS S IN G  V A L U E S  q1, q2, q3, q4, q5, q6, q7, q8, q9, 
q 1 0 fq 11 ,q 12 Iq 1 3 lq 1 4 Iq 1 5 Iq 1 6 lq 1 7 Iq 1 8 lq 1 9 f 
q 2 0 Iq 21 lq 22 ,q 23 Iq 24 ,q 25 lq 26 ,q 27 ,q 28  (0 ,5  thru H IG H E S T ). 
M IS S IN G  V A L U E S  q29,q 30  (0 ,8  thru H IG H E S T ), 
qlqsub Q L2 'Global health status/QoL' 2  6  (q29 ,q 30) IU S E R O P .
qlqsub P F 2 'Physical Function' 
qlqsub R F2 'Role Function' 
qlqsub E F  'Emotional Function' 
qlqsub C F  'Cognitive Function' 
qlqsub S F  'Social Function' 
qlqsub FA 'Fatigue' 
qlqsub N V  'N ausea /  vomiting' 
qlqsub
5 3 (q1,q2 ,q3,q4,q5) FS C A LE  IU S E R O P .
2  3 (q6,q7) FS C A LE  IU S E R O P .
4  3 (q 21 ,q 22 ,q 23 ,q 24 ) F S C A L E  IU S E R O P . 
2 3 (q 20 ,q 25) FS C A LE  IU S E R O P .
2  3 (q 26 ,q 27) FS C A LE  IU S E R O P .
3 3 (q 10 ,q 12 ,q 18 ) IU S E R O P .
2 3 (q14 ,q 15) IU S E R O P .
PA 'Pain' 2  3 (q 9 ,q 1 9 ) IU S E R O P .
qlqsub D Y  'Dyspnoea' 1 3 (q8) IU S E R O P .
qlqsub SL 'Insomnia' 1 3 (q 11) IU S E R O P .
qlqsub A P  'Appetite loss' 1 3 ( q 1 3 )  IU S E R O P .
qlqsub C O  'Constipation' 1 3 ( q 1 6 )  IU S E R O P .
qlqsub Dl 'Diarrhoea' 1 3 ( q 1 7 )  IU S E R O P .
qlqsub FI 'Financial problems' 1 3 (q28).
IIFEN D .
IIF (IQ LQ  = 2 ) ITH E N  .
M IS S IN G  V A L U E S  q1, q2, q3, q4, q5 (0 ,3  thru H IG H E S T ).
M IS S IN G  V A L U E S  q6, q7, q8, q9,
q 10 ,q 11 ,q 12 ,q 13 ,q14 ,q15 ,q 16 ,q 17 ,q 18 ,q 19 , 
q 20,q 21 ,q 22 ,q 23 ,q 24 ,q 25 ,q 26 ,q 27 ,q 28  (0 ,5  thru H IG H E S T ). 
M IS S IN G  V A L U E S  q 29,q30 (0 ,8  thru H IG H E S T ), 
qlqsub Q L2 'Global health status/QoL' 2  6  (q29 ,q 30) IU S E R O P .
qlqsub
qlqsub
qlqsub
qlqsub
qlqsub
qlqsub
qlqsub
qlqsub
qlqsub
qlqsub
P F  'Physical Function' 
R F 2 'Role Function'
EF 'Emotional Function' 
C F  'Cognitive Function' 
S F  'Social Function'
FA 'Fatigue'
N V  'N ausea /  vomiting'
5 1 (q 1 ,q2 ,q3,q4,q5) FS C A LE  IU S E R O P .
2 3 (q6,q7) FS C A LE  IU S E R O P .
4  3 (q 21 ,q 22 ,q 23 ,q 24) FS C A LE  IU S E R O P . 
2 3 (q 20 ,q 25) F S C A L E  IU S E R O P .
2 3 (q26 ,q 27) FS C A L E  IU S E R O P .
3 3 (q 10 ,q 12 ,q 18) IU S E R O P .
2 3 (q14,q15) IU S E R O P .
PA 'Pain' 2  3 (q 9 ,q 1 9 ) IU S E R O P .
D Y  'Dyspnoea' 1 3 (q8) IU S E R O P .
SL 'Insomnia' 1 3 ( q 1 1 )  IU S E R O P .
qlqsub A P  'Appetite loss' 1 3 ( q 1 3 )  IU S E R O P .
qlqsub C O  'Constipation' 1 3 (q16) IU S E R O P .
qlqsub Dl 'Diarrhoea' 1 3 ( q 1 7 )  IU S E R O P .
qlqsub FI 'Financial problems' 1 3 (q28) IU S E R O P .
IIFEN D .
IIF  (IQ LQ  = 303) ITH E N  .
M IS S IN G  V A L U E S  q1, q2, q3, q4, q5, q6, q7 (0 ,3  thru H IG H E S T ). 
M IS S IN G  V A L U E S  q8, q9,
q 10 ,q 11 ,q 12 ,q 13 ,q14 ,q15 ,q 16 ,q 17 ,q 18 ,q 19 , 
q 20,q 21 ,q 22 ,q 23 ,q24 ,q25 ,q 26 ,q 27 ,q 28 , q29, q30  
(0 ,5  thru H IG H E S T ).
M IS S IN G  V A L U E S  q 31,q 32 ,q 33  (0 ,8  thru H IG H E S T ).
qlqsub Q L2 'Global health status/QoL' 2  6  (q32,q33) IU S E R O P .
qlqsub Q L 'Global health status/QoL' 2  6 (q 3 1 ,q 3 3 ) IU S E R O P .
qlqsub PF  'Physical Function' 
qlqsub R F2 'Role Function' 
qlqsub R F 'Role Function' 
qlqsub EF  'Emotional Function' 
qlqsub C F  'Cognitive Function' 
qlqsub S F  'Social Function'
qlqsub FA 'Fatigue'
5 1 (q1,q2 ,q3,q4,q5) FS C A L E  IU S E R O P .
2 3 (q26,q27) FS C A LE  IU S E R O P .
2 1 (q6,q7) FS C A LE  IU S E R O P .
4  3 (q 21 ,q 22 ,q 23 ,q 24) F S C A L E  IU S E R O P . 
2  3  (q20,q25) F S C A L E  IU S E R O P .
2 3 (q28,q29) FS C A L E  IU S E R O P .
3 3 (q10 ,q 12 ,q 18) IU S E R O P .
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qlqsub N V  'N au se a /vo m itin g ' 2  3 (q 1 4 ,q 1 5 ) IU S E R O P . 
qlqsub PA  'Pain' 2  3 (q 9 ,q 1 9 ) IU S E R O P .
qlqsub D Y  'Dyspnoea' 1 3 (q8) IU S E R O P .
qlqsub SL  'Insomnia' 1 3 ( q 1 1 )  IU S E R O P .
qlqsub A P  'Appetite loss' 1 3 ( q 1 3 )  IU S E R O P .
qlqsub C O  'Constipation' 1 3 (q16) IU S E R O P .
qlqsub Dl 'D iarrhoea' 1 3 (q17) IU S E R O P .
qlqsub FI 'Financial problems' 1 3 (q30) IU S E R O P .
IIFEN D .
IIF (IQ L Q  = 1) ITH E N  .
M IS S IN G  V A L U E S  q1, q2, q3, q4, q5, q6, q7 (0 ,3  thru H IG H E S T ). 
M IS S IN G  V A L U E S  q8, q9,
q 10 ,q 11 ,q 12 ,q 13 ,q 1 4 ,q 1 5 ,q 16 Iq 17 )q 18 ,q 19 ) 
q20,q21 ,q 22 ,q23 ,q 24 ,q 25 ,q 26 ,q 27 ,q28  (0 ,5  thru H IG H E S T ). 
M IS S IN G  V A L U E S  q29,q 30  (0 ,8  thru H IG H E S T ), 
qlqsub Q L 'Global health status/QoL' 2  6  (q 29 ,q 30) IU S E R O P .
qlqsub PF  'Physical Function' 
qlqsub R F  'Role Function' 
qlqsub EF 'Emotional Function' 
qlqsub C F  'Cognitive Function' 
qlqsub S F  'Social Function' 
qlqsub FA 'Fatigue'
5 1 (q 1,q2 ,q3,q4,q5 ) FS C A LE  IU S E R O P .
2 1 (q6,q7) FS C A L E  IU S E R O P .
4  3 (q 21 ,q 22 ,q 23 ,q 24 ) FS C A LE  IU S E R O P . 
2 3 (q 20 ,q 25) F S C A L E  IU S E R O P .
2  3 (q 26 ,q 27) FS C A LE  IU S E R O P .
3 3 (q 10 ,q 12 ,q 18) IU S E R O P .
2 3 (q14,q15) IU S E R O P .qlqsub N V  'N ausea /  vomiting' 
qlqsub PA 'Pain' 2  3 (q 9 ,q 1 9 ) IU S E R O P .
qlqsub D Y  'Dyspnoea' 1 3 (q8) IU S E R O P .
qlqsub SL 'Insomnia' 1 3 (q 1 1) IU S E R O P .
qlqsub A P  'Appetite loss' 1 3 ( q 1 3 )  IU S E R O P .
qlqsub C O  'Constipation' 1 3 ( q 1 6 )  IU S E R O P .
qlqsub Dl 'D iarrhoea' 1 3 ( q 1 7 )  IU S E R O P .
qlqsub FI 'Financial problems' 1 3 (q28) IU S E R O P .
IIFE N D . 
execute, 
len d d e fin e .
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/ *  * /
/*  Program  for the Breast cancer module, Q L Q -B R 23 */
/ *  * /
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
define brscal (IP O S IT IO N A L  IC M D E N D ).
ILET IU S E R O P  = 11.
M IS S IN G  V A L U E S  br1, br2, br3, br4, br5, br6, br7, br8, br9, 
br10 ,br11,br12 ,br13,br14,br15,br16,br17,br18,br19 , 
br20,br21 ,br22,br23 (0 ,5  thru H IG H E S T ).
*Function scales.
qlqsub BRBI 'Body image' 4  3 (br9,br10,br11,br12) F S C A L E  IU S E R O P .
qlqsub B R S E F  'Sexual functioning’ 2  3 (br14,br15) IU S E R O P .
if (br15=1 or br15= $S Y S M IS  ) br16 = $S Y S M IS  .
qlqsub B R S E E 'S e x u a l enjoyment' 1 3 (br16) IU S E R O P .
qlqsub B R FU  'Future perspective' 1 3 (br13) F S C A L E  IU S E R O P .
*Sym ptom  scales.
qlqsub B R C T  'Systemic therapy' 7  3 (br1,br2,br3,br4,br6,br7,br8) IU S E R O P . 
qlqsub B R R T  'Breast symptoms' 4  3 (b r20 ,br21,br22 ,br23) IU S E R O P . 
qlqsub B R S Y  'Arm symptom s’ 3 3 (b r17,br18,br19) IU S E R O P . 
qlqsub B R HL 'Hair loss' 1 3 (br5) IU S E R O P .
if (b r4=1) B R H L = 0 . 
execute.
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len d d e fin e .
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/ *  * /
/*  Program  for the Head & N eck cancer module, Q L Q -H & N 35  * /
/* */
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
define hnscal (IP O S IT IO N A L  IC M D E N D ).
ILET IU S E R O P  = 11.
M IS S IN G  V A L U E S  hn1, hn2, hn3, hn4, hn5, hn6, hn7, hn8, hn9, 
hn10,hn11,hn12,hn13,hn14,hn15,hn16,hn17,hn18,hn19, 
hn20)h n21,hn 22 ,hn 23 ,h n 24,h n25Ihn26,hn27,hn28,hn29, 
hn30 (0 ,5  thru H IG H E S T ).
M IS S IN G  V A L U E S  hn31,hn32,hn33,hn34,hn35 (0 ,3  thru H IG H E S T ).
*Function scales.
* none.
*Sym ptom  scales.
qlqsub H N P A  'HN Pain' 4  3 (hn1 ,hn2,hn3,hn4) IU S E R O P .
qlqsub H N S W  'HN Swallowing' 4  3 (hn5,hn6,hn7,hn8) IU S E R O P . 
qlqsub H N S E 'H N  Senses' 2  3 (hn13,hn14) IU S E R O P .
qlqsub H N S P 'H N  Speech' 3 3 (hn16,hn23,hn24) IU S E R O P . 
qlqsub H N S O  'HN Social eating' 4  3 (hn19,hn20,hn21 ,hn22) IU S E R O P . 
qlqsub H N S C  'HN Social contact' 5  3  (h n18,hn25,hn26,hn27,hn28) IU S E R O P .
qlqsub H N S X  'HN Sexuality' 2  3 (hn29,hn30) 
qlqsub H N TE  'HN Teeth ' 1 3 (hn9)
qlqsub H N O M  'HN Opening mouth' 1 3 (hn10) 
qlqsub H N D R  ’HN Dry mouth' 1 3 (h n 11)
qlqsub H N S S  'H N  Sticky saliva' 1 3 (hn12) 
qlqsub H N C O  'HN Coughed' 1 3 (hn15)
qlqsub H N FI 'HN Felt ill' 1 3 (hn17) 
qlqsub H N P K  'HN Pain killers' 1 1 (hn31) 
qlqsub H N N U  'HN Nutritional supp.' 1 1 (hn32) 
qlqsub H N FE  'HN Feeding tube' 1 1 (hn33)
qlqsub H N W L  'H N  W eight loss' 1 1 (hn34)
qlqsub H N W G  'HN W eight gain' 1 1 (hn35) 
execute, 
len d d e fin e .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
/* = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/ *  * /
/*  Program  for the Lung cancer module, Q LQ -L C 13 7
/* 7
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
define Icscal (IP O S IT IO N A L  IC M D E N D ).
ILET IU S E R O P  = 11.
3 3 (Ic3,lc4,lc5) X M IS S  IU S E R O P .
M IS S IN G  V A L U E S  Ic1, Ic2, Ic3, Ic4, Ic5, Ic6, Ic7, Ic8, Ic9, 
Ic10,lc11,lc12,lc13 (0 ,5  thru H IG H E S T ). 
*Function scales.
* none.
*Sym ptom  scales, 
qlqsub LC D Y  'LC Dyspnoea' 
qlqsub LC C O  'LC Coughing' 
qlqsub LCHA 'LC Haem optysis' 
qlqsub LCSM  'LC Sore mouth' 
qlqsub LC D S 'LC Dysphagia' 
qlqsub LC P N  'LC Periph. neuropathy' 1 3 (Ic8) 
qlqsub LC H R  'LC Alopecia' 1 3 (Ic9) 
qlqsub LC PC  'LC Pain in chest' 1 3 (Ic IO )
1 3 (Ic1)
1 3 (Ic2) 
1 3 (Ic6) 
1 3 (Ic7)
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
IU S E R O P .
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qlqsub LC P A  'LC Pain in arm' 1 3 (Ic11) IU S E R O P .
qlqsub L C P O 'L C  Pain other' 1 3  ( I d 2) IU S E R O P .
execute, 
lenddefine.
/* = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/ *  / *
/ ‘ Program for the Prostate Module, Q L Q -P R 2 5  /*
/ *  /*
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
define prscal (IP O S IT IO N A L  IC M D E N D ).
ILE T IU S E R O P  = 11.
M IS S IN G  V A L U E S  pr1, pr2, pr3, pr4, pr5, pr6, pr7, pr8, pr9, 
p r10 ,pr11 ,pr12,pr13,pr14,pr15,pr16,pr17,pr18,pr19, 
pr20,pr21 ,pr22,pr23,pr24,pr25 (0 ,5  thru H IG H E S T ).
‘ Function scales.
qlqsub P R U R  'Urinary Problems' 8 3 (pr2,pr3,pr4,pr5,pr6,pr7,pr9) IU S E R O P .
qlqsub PR U I 'Urinary Incontinence' 1 3  (pr8) IU S E R O P .
qlqsub PR B S  'Bowel Sym ptoms' 4  3 (p r10 ,p r11 ,pr12,pr13) IU S E R O P .
qlqsub P R T S  'Treatm ent Sym ptoms' 6  3 (pr14,pr15,pr16,pr17,pr18,pr19) IU S E R O P .
qlqsub P R S A  'Sexual Activity’ 2  3 (pr20,pr21) IU S E R O P .
qlqsub P R S F  'Sexual Functioning' 4  3(pr22,pr23 ,pr24,pr25) IU S E R O P .
execute.
lenddefine.
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * /
/ *  * /
/*  For Q L Q -C 3 0 (V 3 ) enter "qlqscal 3 ."  */
/*  For Q L Q -C 3 0 (V 2 ) enter "qlqscal 2 ."  */
/*  For Q L Q -C 3 0 (V 1 ) enter "qlqscal 1 ."  */
/*  For Q L Q -C 3 0 (+ 3 ) enter "qlqscal 3 0 3 ."  * /
/*  For Q LQ -B R 23 enter "b rsca l." * /
/*  For Q L Q -H & N 35 enter "h nsca l." */
/*  F o rQ L Q -L C 1 3  enter " Icscal." * /
/*  F o rQ L Q -P R 2 5  enter "prscal." */
/ *  * /
/*  Usually, if less than half the scale items are missing, imputation is */
/*  used; the method is described in the Scoring M anual. * /
/ ‘ To cause missing values to result in the scale score being missing, */
/*  enter X M IS S  after the com m and. For exam ple, "qlqscal 1 X M IS S ." */
/ *  * /
/ * = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = * / .
prscal.
execute.
- 32 8 -
Appendix VII 
List of published papers related to thesis
Appendix VII
Review articles on prostate cancer in peer reviewed journals
Henderson A, Andreyev AJ, Stephens R, Deamaley D.
Patient and Physician Reporting o f  Symptoms and Health Related Quality o f  Life in 
Trials o f Treatment for Early Prostate Cancer: Considerations for Future Studies 
Clinical Oncology 2006; 18: 735-743
Henderson A, Laing RW, Langley SEM.
Quality o f Life Following Treatment for Early Prostate Cancer: Does Low Dose-Rate 
(LDR) Brachytherapy Offer a Better Outcome? A  Review  
European Urology 2004; 45(2): 134-141
Publications on prostate cancer in peer reviewed journals
Bott SRJ, Henderson A, Halls JE, Montgomery BSI, Laing RW, Langley SEM. 
Transperineal template biopsies o f the prostate -  the technique and results 
Urology 2006: 68(5); 1037-1041
Khaksar SJ, Laing RW, Henderson A, Sooriakumaran P, Lovell D, Langley SEM 
PSA relapse-free survival and toxicity following 1-125 LDR Prostate Brachytherapy- the 
Guildford experience
British Journal of Urology International 2006: 98(4); 1210-1215
Guedea F, Aguilo F, Polo A, Langley A, Laing R, Henderson A, Aaltomaa S, Kataja V, 
Palmgren J, Bladou F, Salem N, Serment G, Nava L, Losa A, Guazzoni G.
Initial biochemical outcomes following permanent interstitial brachytherapy as 
monotherapy in 1043 patients with clinical T1-T2 prostate cancer.
Radiotherapy and Oncology 2006; 80: 57-61
Sooriakumaran P, Lovell D, Henderson A, Laing R, Langley SEM.
Gleason scoring varies among pathologists and this affects clinical risk in prostate cancer 
patients. Clinical Oncology 2005; 17(8): 655-658
Langley SEM, Laing RWL, Henderson A, Aaltomaa S, Kataja V, Palmgren J-E, 
Bladou F, Salem N, Serment G, Nava L, Losa A, Guazzoni G, Guedea F, Aguilo 
F, Suarez JF. European Collaborative Group on Prostate Brachytherapy:
Preliminary Report in 1175 Patients. European Urology 2004; 46(5): 565-570
Henderson A, Ismail A, Cunningham M, Aldridge S, Loverock L, Langley SEM, 
Laing RW. Toxicity and early biochemical outcomes from 125Iodine prostate 
brachytherapy: a prospective study. Clinical Oncology 2004; 16(2) 95-104
Henderson A, Laing RW, Langley SEM.
Intraoperative identification o f pubic arch interference in prostate brachytherapy: 
simplifying the transrectal ultrasound technique. Brachytherapy 2003; 2(4) 240-245
- 3 3 0 -
Appendix VII
Publications on prostate cancer in peer reviewed journals
Bott S, Henderson A, Laing RW, Parkinson C, Langley SEM.
Setting up a prostate cancer database: how to get out more than you put in.
British Journal of Urology International 2003; 92: 665-666
Henderson A, Langley SEM, Laing RW.
Is Bicalutamide equivalent to goserelin for prostate volume reduction prior to prostate 
brachytherapy? Clinical Oncology 2003; 15: 318-321
Henderson A, Laing RW, Langley SEM.
A  spanner in the works; the use o f a new temporaiy urethral stent to relieve bladder 
outflow obstruction following prostate brachytherapy. Brachytherapy 2003; 1(4) 211- 
218
Henderson A, Cahill D, Laing RW, Langley SEM.
Iodine 125 Prostate Brachytherapy: Outcome from the first 100 consecutive patients & 
selection strategies incorporating urodynamics.
British Journal of Urology International 2002; 90: 567-572
Published letters
Simon R.J. Bott, Alastair Henderson, Robert W. Laing, Bruce S.I. Montgomery, Stephen 
E.M. Langley. Technical considerations when obtaining and interpreting prostatic 
biopsies from men with a suspicion o f early prostate cancer.
British Journal of Urology International 2005: 96(4); 686
Henderson A, Sooikumaran P, Langley SEM, Laing RW
Brachytherapy: The Surgeon’s Perspective
British Journal of Urology International 2004; 93(7):1118
Henderson A, Bott SRJ, Sooikumaran P, Laing RW, Langley SEM 
Urinary Morbidity After 125Iodine Brachytherapy o f the Prostate 
British Journal of Urology International. 2004; 93(6): 890
Henderson A, Laing RW, Langley SEM
Improvement in urinary symptoms after radical prostatectomy: a prospective
evaluation o f  flow rates and symptom scores
British Journal of Urology International 2004; 93 (1), 180
Book chapters
Henderson A, Sooikumaran P, Laing RW, Langley SEM.
Oncological and Quality o f Life Outcomes o f  Brachytherapy and other treatments for 
EPC. Prostate Cancer Research 2004 Vol I, Novascience NYNY
-331 -
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
